TO: NQF Members

FR: NQF Staff

RE: Voting Draft Report Perinatal and Reproductive Healthcare Endorsement Maintenance, 2011

DA: February 13, 2012

# BACKGROUND

NQF has previously endorsed consensus standards to evaluate the quality of care for perinatal and reproductive healthcare. This project seeks to identify and endorse measures for accountability and quality improvement addressing reproductive health, pregnancy, childbirth and post-partum care, and newborn care. An evaluation of all NQF-endorsed perinatal and reproductive health measures and consideration of new measures will ensure the currency of NQF's portfolio of voluntary consensus standards.

This report recommends continued endorsement of 12 measures and endorsement of 2 newly submitted measures. A <u>27-member Steering Committee</u> representing a range of stakeholder perspectives was appointed to evaluate 3 new measures (including one composite measure with ten components) and 19 previously endorsed measures for maintenance review. The draft document, *National Voluntary Consensus Standards: Perinatal and Reproductive Healthcare Endorsement Maintenance, 2011: A Consensus Report* is posted on the NQF website along with the measure submission forms. On January 19, 2012, the 30-day comment period concluded for the 14 measures recommended in the draft report.

# **Comments and Revised Voting Report**

NQF received 149 comments from a variety of stakeholders, including 19 member organizations and 53 organizations and private citizens who did are not NQF members:

| Consumers – 3                     | Professionals – 4             |
|-----------------------------------|-------------------------------|
| Purchasers – 2                    | Health Plans – 3              |
| Providers – 1                     | QMRI – 2                      |
| Supplier and Industry – 0         | Public & Community Health – 1 |
| Non-NQF member organizations – 28 | Individuals – 23              |

A table of complete comments submitted during the comment period, with the responses to each comment and the actions taken by the Steering Committee, is posted to the <u>Perinatal and</u> <u>Reproductive Health Endorsement Maintenance project page</u> on the NQF website, along with the measure submission forms.

The Steering Committee reviewed and responded to all comments received. Revisions to the draft report and the accompanying measure specifications are identified as red-lined changes. (Note: Typographical errors and grammatical changes have not been red-lined, to assist in reading.)

# COMMENTS AND THEIR DISPOSITION

The Steering Committee reviewed the comments and focused its discussion on specific measures or topic areas with the most significant and recurring issues. Comments about specific measure specifications and rationale were forwarded to the measure developers, who were invited to respond.

# **GENERAL COMMENTS**

# Additional areas for measure development

Many comments were submitted suggesting areas for additional measure development or echoed the areas identified in the draft report.

*ACTION TAKEN*: After review by the Committee, the report was updated to include many of these suggestions.

# **Electronic Health Records**

An EHR vendor submitted comments on all of the measures regarding the feasibility of each measure for a typical hospital or medical practice using an advanced EHR and the typical clinical users who will be recording the required information. They did not submit comments on the appropriateness, accuracy, or importance of the measures. They noted concerns or suggested minor modifications to the specifications for the following measures to improve the usability in EHRs.

ACTION TAKEN: Currently, none of the measures under consideration are specified for use in EHRs; thus, the issues raised have been provided to the developers for their consideration as they move toward an electronic environment. NQF intends to require EHR specifications for all measure in the near future; additional details and guidance on those requirements are under consideration by the Consensus Standards Approval Committee.

# Level of analysis

Several commenters requested additional level of analysis for three measures:

• 0469: PC-01 Elective Delivery (requesting clinician, clinician group, ACO, health plan)

- o Currently facility and population (national) level
- 0470: Incidence of Episiotomy (requesting clinician, clinician group, ACO, health plan)
   Ourrently facility level
- 0471: PC-02 Cesarean Section (requesting clinician, clinician group, ACO, health plan)
  - o Currently facility and population (national) level

**ACTION TAKEN:** The Committee noted that it is difficult to "just bring measures down to the clinician level" and that methodologic challenges (small sample size and attribution) result in unstable results at the clinician level. These measures would need testing at the clinician-level prior to specifying that level of analysis. The developers have responded that clinician- level measures are not the focus of their measure development program.

# Mandatory hospital reporting

Several comments noted the low numbers of participants by hospitals for the Joint Commission (TJC) core set and urged mandatory reporting be required to provide stakeholders more information about the quality of maternity care.

**ACTION TAKEN:** Reporting on and implementation of measures are not within the purview of the NQF endorsement process. However, the NQF-convened National Priorities Partnership Maternity Action Team is seeking mandatory reporting as a priority action for 2012. The Committee also noted that LeapFrog is also encouraging public reporting.

# **Target values**

A commenter noted that it is hard to know how to interpret a hospital's episiotomy rates (#0470) or NTSV cesarean section rates (#0471). The interpretation of these measures and the manner in which they are used can greatly affect their validity for accountability and/or quality improvement purposes. For example, if a low risk woman arrives in labor with a herpetic lesion she should have a cesarean section. Regions with higher rates of babies with macrosomia might also have more cesarean sections. Additionally, "routine" episiotomies should be avoided, but clinically indicated cases (albeit not in large numbers) are necessary.

**ACTION TAKEN:** The Committee stated that "de-contextualized, arbitrary targets are problematic" and that target rates are very context-driven. Committee members agreed that current rates are too high in many institutions on these measures and that until more data is available to fully describe current performance and relationships to outcomes and identify what improvement is possible, specific targets are not feasible. They noted that trends, or comparisons with other institutions, are a more useful measurement than a specific target value. The Committee requested that the developers consider developing

benchmarks based on data collected from using the measure, and presenting that when the measures undergo maintenance review.

### **MEASURE SPECIFIC COMMENTS**

#### 0480: Exclusive Breast Milk Feeding

### Measure evaluation form

This measure received 18 comments. While ten commenters acknowledged the health benefits of breastfeeding, they were primarily concerned with "mandated breastfeeding" and suggested that it was a woman's right to choose whether or not to breastfeed, and the measure would prevent women who chose not to breastfeed from receiving proper education and information on alternatives. However, eight commenters supported the measure, stating that the health reasons for breastfeeding are well documented, that the measure would not mandate breastfeeding for all babies, and that performance for this measure is not expected to be at 100%.

**ACTION TAKEN:** The Committee underscored the significant health benefits for newborns (reduction in otitis media, respiratory tract infections, atopic dermatitis, gastroenteritis, type 2 diabetes, sudden infant death syndrome, and obesity) and mother (decreased risk for type 2 diabetes, ovarian cancer, and breast cancer) conferred by breastfeeding and support all efforts to optimize maternal education, encouragement, and support to enable women to make the healthiest choices for herself and her child. The Committee agreed that improving support for mothers who wish to breastfeed does not equal removing a choice. The Committee acknowledged that the target for this measure is not 100% and that the potential unintended consequences of "inappropriate coercion" should be monitored.

The Committee noted that current performance is quite low at 40% with much room for improvement. Both the Committee and the developer agreed that the purpose of the measure is to eliminate impediments to breastfeeding. According to the CDC, (http://www.cdc.gov/breastfeeding/data/reportcard.htm) "less than 5% of U.S. infants are born in Baby-Friendly hospitals, a global designation that indicates best practices in maternity care to support breastfeeding mothers. The hospital period is critical for mothers and babies to learn to breastfeed, and hospitals need to do more to support them. Birth facility policies and practices significantly impact whether a woman chooses to start breastfeeding and how long she continues to breastfeed." The Committee recommends additional process measures to assist facilities in improving support for breastfeeding. The Committee agreed to maintain their recommendation of the measure.

# Health care acquired infection measures

- 0304: Late sepsis or meningitis in Very Low Birth Weight (VLBW) neonates (risk-adjusted) <u>Measure evaluation form</u>
- 0478: Neonatal Blood Stream Infection Rate (NQI #3) Measure evaluation form
- 1731: Health Care-Associated Bloodstream Infections in Newborns <u>Measure</u> evaluation form

Three commenters raised concerns about having three separate measures on hospital acquired/late onset infections and requested that the measures be harmonized. While some of the comments agreed that the measures use different reporting streams, they suggested having three separate measures would cause confusion. One commenter agreed that there was a need for three separate measures and supported all three. A commenter noted that measures 0478 and 1731 would identify infants with late-onset sepsis, and that the population of infants that develop late onset meningitis is unique and general measures would not be efficacious for this population. Additionally, all three measures received comments and questions on the specifications, which were sent to the developers.

*ACTION TAKEN:* The Committee agreed that measure 304 was a related HAI measure but is quite distinct in that it 1) focuses on a very-high risk population—VLBW infants with a infection rate of 15% (VLBW represents only 1.5% of all births); 2) the measure only applies to hospitals with NICUs (approximately 800-900 hospitals in the US); and uses clinical data for the Vermont Oxford Network registry that captures 80% of VLBW infants in the US.

Measure 1731 was created by TJC when it selected five NQF-endorsed measures, including measure 478, for its Perinatal Core Set. <u>Measures 478 and 1731 are fully</u> <u>harmonized measures</u> within the limits of their data sources and measure 1731 is also harmonized with the other four measures in TJC Perinatal Core Set (0469 Elective Delivery < 39 weeks; 0471 Cesarean section; 0476 Antenatal Steroids; and 0480 Exclusive Breast Milk Feeding) for use in TJC's performance measurement programs. Measures 478 and 1731 differ from related measure 304 in that they also capture larger babies who experience in-hospital death; operating room procedure; mechanical ventilation; or transfers in less than 2 days of age. Measure 478 is based on administrative data and is collected in the HCUP State Inpatient Databases that are widely used by states.

The Committee understands the concerns about multiple related measures, but in the absence of head-to-head comparisons of the measures the Committee cannot make any judgments as to differences in reliability and validity. All three measures are widely used and each is useful to different user groups. After reviewing and discussing the comments, the Committee did not change its recommendation of all three measures.

# 0470: Incidence of Episiotomy

### Measure evaluation form

A commenter suggested additional exclusions for shortening the second stage of labor; the developer responded that the suggested exclusions did not align with ACOG guidelines and that it would be too complicated to captured using current data collection methods. Two comments were submitted in support of this measure.

**ACTION TAKEN:** The developer responded that "the ACOG technical bulletin (number 71, 2006) states that "(e)ven the presumption that episiotomy shortens the second stage of labor has not been conclusively shown." Regardless, the goal of this measure is to reduce (not eliminate) the routine use of episiotomy at the facility level. We anticipate that there may be clinical scenarios wherein a provider may choose to perform an episiotomy. These indications and the one cited above are too complex to be captured using current methods of data capture and therefore cannot and should not be included in this measure." The Committee agreed with the developer response and did not change their recommendation.

# 0475: Hepatitis B Vaccine Coverage Among All Live Newborn Infants Prior to Hospital or Birthing Facility Discharge

### Measure evaluation form

This measure received three supportive comments and one comment noting concern with the exclusion of parental refusals, and requested that refusals be measured separately as a component of the numerator, consistent with NQF-endorsed immunization measures for influenza and pneumonia.

*ACTION TAKEN*: The developer replied that the original proposal for this measure encouraged such an approach—intending parental/guardian exclusions to be an optional adjustment to the denominator. Data obtained during field testing of the measure indicated that hospitals were not yet fully able to compute the amount of vaccination refusals. As use of ICD-10 codes is adopted (effective October 1, 2013), training hospital staff to appropriately document vaccinations refusals will occur and the measure will become more accurate. The Committee noted that coding for parental refusals will be standardized with ICD-10 and that should be incorporated into the next annual update. The Committee did not change their recommendation.

# 0476: Appropriate Use of Antenatal Steroids

## Measure evaluation form

A comment was submitted that supported the measure, but suggested that the specifications be altered to bring them in line with the new ACOG Committee Opinion (Feb 2011); the developer agreed that these specifications should be updated and responded that:

"the denominator for this measure has been changed in the Specifications Manual for Joint Commission National Quality Measures (V2012B) to be published February 2012 to read: "Patients delivering live preterm newborns with >=24 and <32 weeks gestation completed".

The notes for abstraction for the data element Gestational Age have been changed to: Gestational age should be rounded off to the nearest completed week, not the following week. For example, an infant born on the 5th day of the 36th week (35 weeks and 5/7 days) is at a gestational age of 35 weeks, not 36 weeks."

A second comment requested clarification on the list of reasons for the exclusion criteria "documented reason for not administering antenatal steroid," noting that without a specified list, there will be inconsistency in measurement with facilities, who will provide their own coding reasons. This comment was forwarded to the developer for review.

*ACTION TAKEN:* The Committee agreed with the updated specifications. The developer explained that the data analysis is done by trained abstractors who are able to assess whether or not the documented reasons meet the specifications. The Committee did not change their recommendation.

# 0477: Under 1500g infant Not Delivered at Appropriate Level of Care

### Measure evaluation form

This measure received two comments requesting expansion of the exclusion criteria to include reasons outside of the health care system's control for failure to transport to a hospital with appropriate levels of care services (e.g., very late presentation in active labor, lack of safe transportation, distance to NICU in rural areas). The comments were forwarded to the developer for a response.

**ACTION TAKEN:** The developer noted that in their use of this measure, urban hospitals were less likely to perform well on this measure than rural ones and also noted that the performance on this measure is not intended to be zero. The measure data is collected from simple administrative data and does not require chart review. After review of the comments and developer response, the Committee did not change their recommendation on the measure.

# 0483: Proportion of infants 22 to 29 weeks gestation screened for retinopathy of prematurity.

# Measure evaluation form

A commenter raised concerns noting that their internal data (submitted for publication) does not support the burden of reporting this measure. Another commenter requested clarification on the exclusion criteria, stating that the exclusions "Outborn infants admitted to the reporting hospital more than 28 days after birth" and "Outborn infants who have been home prior to admission" do not appear aligned. This comment has been sent to the developer for a response.

ACTION TAKEN: The Committee agreed the data mentioned by the commenter should be reviewed after it is published, and that it should be taken into consideration during annual updates or maintenance review. The Committee also noted that some highperforming hospitals may have very little room for improvement but the Vermont Oxford Network (VON) data indicates that more than 23% percent of infants at 29 weeks gestation are not screened before hospital discharge. The developer clarified the exclusions, explaining that they pertain to VON's data collection criteria. The Committee did not change their recommendation of the measure.

# 1746: Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (GBS)

### Measure evaluation form

Commenters submitted questions on the details of the specifications, and on the ability of EHRs to manage the many different data elements required to calculate this measure. The comments were sent to the developer for a response.

**ACTION TAKEN:** The developer responded that they kept the scope of the measure confined to the essentials for delivering care, and that they expect data collection will be easier as electronic systems are standardized. After reviewing the developer's response, the Committee had no additional comments and did not change their recommendation.

# **MEASURES NOT RECOMMENDED**

Three measures not recommended by the Committee received comments in support of the measures:

# 0479: Birth dose of hepatitis B vaccine and hepatitis B immune globulin for newborns of hepatitis B surface antigen (HBsAg) positive mothers

# Measure evaluation form

The measure developer, supported by 31 comments from a range of stakeholders, requested reconsideration of measure 0479. Commenters raised concerns about the disparities in care for babies born to HBsAg positive mothers and the long-term implications of not measuring

Hepatitis B immune globulin (HBIG) administration to prevent Hepatitis B infection (HBV). The Immunization Action Coalition submitted data noting that of the 24,000 infants born to mothers who are chronically infected, this measure could prevent an estimated 9,100 infants from developing chronic HBV, including preventing an estimated 2,300 from dying of liver failure or liver cancer as adults. Other commenters noted that the CDC estimates that 1,000 newborns a year are infected with the HBV. Multiple comments noted that this measure would help achieve one of the primary goals of the DHHS "Action Plan for the Prevention, Care and Treatment of Viral Hepatitis".

ACTION TAKEN: The Committee noted that this is a very regional issue, and with measure 0475: Hep B vaccine coverage among all live newborn infants prior to hospital or birthing facility discharge in place, the additional impact of this measure would be small and highly variable among states. This measure addresses only babies born to HBsAg positive mothers. In 2009 in California, the state with the largest number of maternal cases 2077 of 2138 infants, (97.1%) received the first dose of the hepatitis B vaccine and the HBIG within 24 hours of birth. The developer argued that since HBV is a preventable disease every effort should be made to reach 100% compliance. The Committee agreed with the importance of the issue but suggested that with a small gap in current performance a national quality measure may not be the right approach to capture the few babies that are being missed. The Committee pointed to CDC's funded state, local, and territorial <u>Perinatal Hepatitis B Prevention Coordinators</u> that focus on preventing perinatal transmission of HBV. After reviewing the comments and listening to the measure developer, the Committee voted not to change their recommendation against endorsement of the measure.

### 0502: Pregnancy test for female abdominal pain patients

### Measure evaluation form

The developer requested that the Committee review and reconsider its recommendation against this measure, as it passed all of the four NQF evaluation criteria.

**ACTION TAKEN:** The Committee acknowledged some inconsistency but pointed to the number of medium to low ratings on the sub-criteria. The Committee agreed to re-evaluate the measure after review of the transcript of the original Steering Committee and workgroup discussions. On re-evaluation, the Committee again decided not to recommend the measure. Although the Committee determined the measure passed the Importance criteria, members voiced concerns over lack of data on ectopic disease burden; little data on current performance and gap; and specifically, no data on how many ectopic pregnancies are identified by routine urine pregnancy testing in the ER and impact on outcomes. Committee members noted that the ratings on reliability and

validity and feasibility again had substantial numbers of medium or low votes citing concerns with the conflicting information presented on reliability and validity, and burden of data collection particularly for the exclusions.

# 0747: Admission to Neonatal Intensive Care Unit at Term

## Measure evaluation form

Two comments were submitted suggesting that this component of the composite Adverse Outcomes Index measure is an important measure and that it be endorsed on its own as a measure. Supporters voiced concerns with potential overuse of NICU facilities and the need for a measure to monitor the quality and appropriateness of NICU admissions. These comments were forwarded to the developer.

ACTION TAKEN: The developer is willing to support a stand-alone measure. The developer clarified that the measure captures only the highest NICU acuity, i.e., uniform billing code 174 Level IV, newborn intensive care. Committee members noted that staffing and utilization patterns for NICUs is highly variable and speculated that overuse might be more likely at lower levels of acuity, e.g., observation for possible sepsis or hypothermia or hypoglycemia. Committee members would want to review the literature and evidence for overutilization as part of the evaluation for a stand-alone measure. Committee members asked how an NICU admission measure would relate to endorsed measure 0716 <u>Healthy Term Newborn</u> and noted that it would need to be harmonized if it was not directly competing. The Committee agreed the developer should pursue further development and testing, and bring the measure back to NQF for review in the future.

# VOTING

Information for electronic voting has been sent to NQF Member organization primary contacts. Accompanying comments must be submitted via the online voting tool.

Please note that voting concludes on February 27, 2012, at 6:00 pm ET—no exceptions.

### PERINATAL AND REPRODUCTIVE HEALTH ENDORSEMENT MAINTENANCE, 2011

### DRAFT TECHNICAL REPORT FOR VOTING

February 13, 2012

# TABLE OF CONTENTS

| Introduction  | 3   |
|---|-----|
| Measure Evaluation                                      | 3   |
| Overarching Issues                                      | 4   |
| Recommendations for Future Measure Development          | 5   |
| Measures Recommended                                    | 6   |
| Measures Not Recommended                                | 6   |
| Measure Evaluation Tables                               | 8   |
| Measures Withdrawn from Consideration                   |     |
| Appendix A - MEASURE SPECIFICATIONS                     | A-1 |
| Appendix B –STEERING COMMITTEE                          | B-1 |
| APPENDIX C – PERINATAL AND REPRODUCTIVE HEALTH MEASURES |     |
| ENDORSED SINCE JUNE 2009                                | C-1 |
|   |     |

## PERINATAL AND REPRODUCTIVE HEALTH ENDORSEMENT MAINTENANCE, 2011 Draft Technical Report

## **INTRODUCTION**

Research suggests that morbidity and mortality associated with pregnancy and childbirth are to a large extent preventable through adherence to existing evidence-based guidelines. Poor-quality care during pregnancy, labor and delivery, and the postpartum period can translate into unnecessary maternal and newborn complications, prolonged lengths of stay, costly neonatal intensive care unit (NICU) admissions, and anxiety and suffering for patients and families. Moreover, numerous studies have documented persistent racial, ethnic, and socioeconomic disparities in maternal morbidity and mortality, preterm births, low birth weight infants, and other adverse outcomes.

This endorsement maintenance project evaluated measures for public reporting/accountability and quality improvement that specifically address reproductive health; pregnancy care; childbirth; and newborn care. Perinatal and reproductive health-related consensus standards that were endorsed by NQF before June 2009 were evaluated under the maintenance process. Endorsement maintenance provides the opportunity to harmonize specifications and to ensure that an endorsed measure represents the best in class. Composite and outcome measures and measures sensitive to the needs of vulnerable populations, including racial/ethnic minorities and Medicaid populations were a priority.

### **MEASURE EVALUATION**

On November 29-30, 2011 the Perinatal and Reproductive Health Steering Committee evaluated three new measures and 19 measures undergoing maintenance review against NQF's standard evaluation criteria. To facilitate the evaluation, the committee and candidate standards were divided into four workgroups for preliminary review of the measures against the evaluation sub-criteria prior to consideration by the entire Steering Committee. The Committee's discussion and ratings of the criteria are summarized in the evaluation tables beginning on page 8.

|                                     | JUNINARI                     |                |       |
|-------------------------------------|------------------------------|----------------|-------|
|                                     | MAINTENANCE                  | NEW            | TOTAL |
| Measures under consideration        | 28                           | 3*             | 31    |
| Withdrawn from consideration        | 10                           |                |       |
| Recommended                         | 12                           | 2              | 14    |
| Not recommended                     | 6                            | 1              | 7     |
| <b>Reasons for Not Recommending</b> | Importance – 3               | Importance - 1 |       |
|                                     | Scientific Acceptability - 1 |                |       |
|                                     | Overall - 1                  |                |       |
|                                     | Competing measure – 1        |                |       |

# PERINATAL AND REPRODUCTIVE HEALTH ENDORSMENT MAINTENANCE SUMMARY

\*Includes one composite measure with 10 components.

### **Overarching Issues**

During the Steering Committee's discussion of the measures, several overarching issues emerged that were factored into the Committee's ratings and recommendations for multiple measures and are not repeated in detail with each individual measure:

### Long-term outcomes

Several measures assessed use of medications have been shown to benefit the infant (steroids, Group B Strep prophylaxis) or the mother (prophylactic antibiotics for Cesarean section) without evidence of adverse outcomes in the short term. However, emerging data raise concerns regarding potential changes in neonatal gut flora with C-section and antibiotics use. Data on long-term outcomes are not available though questions remain. The Committee suggested that population-health level measures that can follow children for many years may provide valuable information on potential long-term risks.

### Population-level companion measures

The Committee noted that several measures have significant regional and cultural influences, such as breast feeding rates. Companion population-level measures may be useful in changing the attitudes and values of a community for overall improved care for women and infants.

### Composite measures

The Committee generally supported the concept of composite measures for various aspects of prenatal, intra-partum, postpartum, and neonatal care. Although the Committee did not recommend the one safety-related composite measure submitted for consideration, they urged the developers to continue their work and offered suggestions to improve the measure. There were also multiple Committee suggestions for new composite measure development.

# Use of vital statistics as a data source

Committee members noted that vital statistics data are underutilized for performance measurement. Many stakeholders such as states and Medicaid agencies do not have access to medical record data. Birth certificate data can provide additional clinical information not available in billing records. Measures that combine claims data and vital records data can be useful in the absence of chart data.

# **Related and competing measures**

The Committee evaluated four similar measures for health-care acquired neonatal infections and agreed it would prefer to recommend a single measure rather than multiple, overlapping measures. While the measure specifications are similar, the data sources for three of the four measures, however, are very different. One is built from hospital billing data, a second is based on voluntary individual hospital submissions to The Joint Commission, and two are developed from data submitted to the Vermont Oxford Network by its member hospitals. Thus the variation and benchmark information each could generate is potentially quite different, and the various current users understandably do not

want to lose that capacity. However, states and private purchasers do not readily have access to the registry-base measures. In the absence of head-to-head comparisons of the measures the Committee cannot make any judgments as to differences in reliability and validity. Given these issues, the Committee recommended retaining three of the measures for the present time.

# Harmonization

Harmonization was not a significant issue in this project. One new measure was submitted fully harmonized with an endorsed measure. It is anticipated that clinician-level measures in development will be harmonized with these facility-level measures.

# **RECOMMENDATIONS FOR FUTURE MEASURE DEVELOPMENT**

During their discussions the Committee identified numerous areas where additional measure development is needed:

- Preconception care reproductive health planning and optimized health status at onset of pregnancy including HIV screening, obesity screening; assessment of medication use; screening for tobacco, drugs and alcohol use; and coordination with clinicians caring for medical conditions such as diabetes and hypertension.
- Prenatal care the many important care processes lend themselves to a composite that might include: HIV screening, tuberculosis screening, Hepatitis B screening, screening for tobacco, drugs and alcohol use; screening for domestic violence; screening for STDs; screening for congenital anomalies; accurate dating; weight management; and flu vaccination.
- Disparities-sensitive measures in prenatal care such as anemia.
- Management of obesity and weight gain during pregnancy.
- The common, consequential, and treatable circumstances of smoking in pregnancy.
- Postpartum depression and treatment.
- Access to and adequacy of genetic counseling and patient assessment of the counseling.
- Quality of obstetrical ultrasound, i.e., potentially diagnosable conditions that were missed.
- Diabetes management including appropriate screening, management, glucose control and postpartum follow-up.
- Spontaneous labor and birth and lack of unwarranted intervention measure in low-risk women.
- Vaginal Birth After C section (VBAC) counseling all women; availability of VBAC and VBAC success rates.
- Appropriateness/efficiency measures (in addition to episiotomy and C-section) for induction of labor, ultrasound use, prenatal testing.
- Measures that are specific to care that nurses provide
- "Ideal" or "Optimal" birth outcome measure mom and baby go home together without complications; a measure could build on the NQF-endorsed *Healthy Term Newborn* measure (#716).
- A composite measure that addresses the quality of care during labor and birth.
- Breastfeeding
  - measures to support hospitals using measure *Exclusive Breast Milk Feeding (#480)*,
     e.g., prenatal education on benefits of breastfeeding, skin to skin contact during the first hour of life, timing of breastfeeding initiation; and elements of WHO Baby Friendly

Hospital Initiative and CDC Maternity Practices in Infant Nutrition and Care (mPINC) survey;

- o rates of exclusive breastfeeding stratified by maternal intention to breastfeed;
- rates of breastfeeding for infants cared for in NICUs stratified by weight groups and gestational age.
- Postpartum follow-up expand beyond NQF endorsed measure Prenatal and Postpartum Care (#1517) to include important care at the postpartum visit such as contraception counseling/reproductive health planning, diabetes follow-up, weight management, breastfeeding support.
- Care of VLBW infants (<1500 grams and >24 weeks) such as any human milk at discharge; chronic lung disease (oxygen required at 36 weeks); pneumothorax rate; growth velocity; and in hospital mortality after 12 hours of life.
- Prematurity rates and Late Preterm Infants (70% of Preterm Infants born in the United States), e.g., number of infants born, location of care, intervention rates, use of progesterone in appropriate patients; stratified by race/ethnicity
- Adverse outcome measures for mother and infant including mortality and near misses and complications, such as from instrumented deliveries.
- Care coordination and care transitions in maternity care.
- Family-centered care/family empowerment and shared decision making.
- Adaptation of the CAHPS provider, facility and health plan surveys tailored to the experience of care of childbearing woman and infants that include the full range of care providers, settings and complex issues such as pain relief
- Patient reported outcomes of the childbirth experience captured around six weeks postpartum.

The Committee and stakeholders identified numerous areas where additional measure development is needed in this topic area:

**Reproductive Health** 

- Primary care for reproductive age women;
- Pregnancy planning and prevention;
- Preconception care –optimized health status at onset of pregnancy including HIV screening, obesity screening; assessment of medication use; screening for tobacco, drugs and alcohol use; and coordination with clinicians caring for medical conditions such as diabetes and hypertension;

Pregnancy care

- Measures across the full episode of pregnancy care;
- Disparities-sensitive measures in pregnancy care;

Prenatal care:

- Prenatal care the many important care processes lend themselves to a composite that might include: HIV screening, tuberculosis screening, Hepatitis B screening, screening for tobacco, drugs and alcohol use; screening for domestic violence; screening for STDs; screening for congenital anomalies; accurate dating; weight management; and flu vaccination;
- Access to and adequacy of genetic counseling and patient assessment of the counseling;

- Quality of obstetrical ultrasound, i.e., potentially diagnosable conditions that were missed;
- Appropriateness/efficiency measures for ultrasound use and prenatal testing;
- Management of obesity and weight gain during pregnancy;
- Management of the drug dependant expectant mother;
- The common, consequential, and treatable circumstances of smoking in pregnancy;
- Diabetes management including appropriate screening, management, glucose control and postpartum follow-up;

Labor and delivery:

- Spontaneous labor and birth and lack of unwarranted intervention measure in low-risk women;
- "Ideal" or "Optimal" birth outcome measure mom and baby go home together without complications; a measure could build on the NQF-endorsed 0716 Healthy Term Newborn measure;
- Vaginal Birth After C-section (VBAC) counseling; availability of VBAC and VBAC success rates;
- Appropriateness/efficiency measures (in addition to episiotomy and C-section) for induction of labor;
- A composite measure that addresses the quality of care during labor and birth;

Post-partum care:

- Breastfeeding
  - measures to support hospitals using measure 0480 Exclusive Breast Milk Feeding e.g., prenatal education on benefits of breastfeeding, skin-to-skin contact during the first hour of life, timing of breastfeeding initiation; and elements of WHO Baby Friendly Hospital Initiative and CDC Maternity Practices in Infant Nutrition and Care (mPINC) survey;
  - o rates of exclusive breastfeeding stratified by maternal intention to breastfeed;
  - rates of breastfeeding for infants cared for in NICUs stratified by weight groups and gestational age.
- Postpartum follow-up expand beyond NQF-endorsed measure *1517 Prenatal and Postpartum Care* to include important care at the postpartum visit such as contraception counseling/reproductive health planning, diabetes follow-up, weight management, breastfeeding support.
- Continued DVT prophylaxis;
- Postpartum depression screening and treatment;

Newborn care:

- Care of VLBW infants (<1500 grams and >24 weeks) such as any human milk at discharge; chronic lung disease (oxygen required at 36 weeks); pneumothorax rate; growth velocity; and in-hospital mortality after 12 hours of life;
- Prematurity rates and Late Preterm Infants (70% of Preterm Infants born in the United States), e.g., number of infants born, location of care, intervention rates, use of progesterone in appropriate patients; stratified by race/ethnicity;
- Composite measures for care of VLBW infants;

Cross-cutting measures:

- Measures that are specific to care that nurses provide;
- Adverse outcome measures for mother and infant including near misses and complications, such as from instrumented deliveries;
- Care coordination and care transitions in maternity care;
- Family-centered care/family empowerment and shared decision-making;
- Adaptation of the CAHPS provider, facility and health plan surveys tailored to the experience of care of childbearing woman and infants that include the full range of care providers, settings and complex issues such as pain relief;
- Patient reported outcomes of the pregnancy and childbirth experience captured around six weeks postpartum.
- Harmonized measures for other levels of care such as clinicians, clinician groups, accountable care organizations and health plans,

### MEASURES RECOMMENDED

| 0469 PC-01 Elective Delivery  | 10 |
|---|----|
| 0470 Incidence of Episiotomy  | 12 |
| 0471 PC-02 Cesarean Section   | 14 |
| 0472 Appropriate Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision- Cesarean Section    | 16 |
| 0473 Appropriate DVT Prophylaxis in Women Undergoing Cesarean Delivery  | 18 |
| 0475 Hepatitis B Vaccine Coverage Among All Live Newborn Infants Prior to Hospital or Birthing Facility Discharge | 20 |
| 0476 PC-03 Antenatal Steroids   | 22 |
| 1746 Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (GBS)   | 24 |
| 0477 Under 1500g infant Not Delivered at Appropriate Level of Care  | 26 |
| 0478 Neonatal Blood Stream Infection Rate (NQI #3)  | 28 |
| 1731 Health Care-Associated Bloodstream Infections in Newborns  | 31 |
| 0304 Late Sepsis or Meningitis in Very Low Birth Weight (VLBW) Neonates (risk-adjusted)                           | 34 |
| 0480 PC-05 Exclusive Breast Milk Feeding  | 37 |
| 0483 Proportion of Infants 22 to 29 Weeks Gestation Screened for Retinopathy of Prematurity.                      | 40 |

### MEASURES NOT RECOMMENDED

| 0479 Birth Dose of Hepatitis B Vaccine and Hepatitis B Immune Globulin for Newborns of Hepatitis B Surface Antigen (HBsA) Positive Mothers |    |
|--|----|
| 0481 First Temperature Measured Within One Hour of Admission to the NICU.  | 44 |
| 0482 First NICU Temperature < 36 degrees Centigrade  | 45 |
| 0303 Late Sepsis or Meningitis in Neonates (risk-adjusted)   | 46 |
| 0502 Pregnancy Test for Female Abdominal Pain Patients.  | 49 |
| 0582 Diabetes and Pregnancy: Avoidance of Oral Hypoglycemic Agents   | 51 |
| 1769 Adverse Outcome Index   | 52 |
| 0741 Five Minute APGAR Less Than 7<br>NQF REVIEW DRAFT—DO NOT CITE OR QUOTE<br>NQF Member Votes Due by February 27, 2012 by 6:00 PM ET     | 52 |

| 0742 Birth Trauma                                      | 53 |
|--|----|
| 0743 In-hospital Maternal Deaths                       | 53 |
| 0744 Uterine Rupture During Labor                      | 54 |
| 0745 Unplanned maternal admission to the ICU           | 54 |
| 0746 In-hospital Neonatal Death                        | 55 |
| 0747 Admission to Neonatal Intensive Care Unit at Term | 55 |
| 0748 Third or Fourth Degree Perineal Laceration        | 56 |
| 0749 Unanticipated Operative Procedure                 | 56 |
| 0750 Maternal blood transfusion                        | 57 |
|  |    |

#### MEASURE EVALUATION SUMMARY TABLES

### MEASURES RECOMMENDED

3b. QI: H-4; M-3; L-0; I-1

| 0469 PC-01 Elective Delivery   |
|--|
| Maintenance Measure (previously time-limited endorsement)<br>Description: This measure assesses patients with elective vaginal deliveries or elective cesarean sections at >= 37 and < 39 weeks of<br>gestation completed. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-02:<br>Cesarean Section, PC-03: Antenatal Steroids, PC-04: Health Care-Associated Bloodstream Infections in Newborns, PC-05: Exclusive<br>Preset Milk Fooding)  |
| Breast Milk Feeding)<br><b>Numerator Statement:</b> Patients with elective deliveries with ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes<br>for one or more of the following:  |
| <ul> <li>Medical induction of labor as defined in Appendix A, Table 11.05 available at: <u>http://manual.jointcommission.org</u></li> <li>Cesarean section as defined in Appendix A, Table 11.06 while not in Active Labor or experiencing Spontaneous Rupture of Membranes available at: <u>http://manual.jointcommission.org</u></li> </ul>  |
| <b>Denominator Statement</b> : Patients delivering newborns with >= 37 and < 39 weeks of gestation completed <b>Exclusions</b> :   |
| <ul> <li>ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for conditions possibly justifying elective delivery prior to 39 weeks gestation as defined in Appendix A, Table 11.07</li> <li>Less than 8 years of age</li> </ul>   |
| <ul> <li>Greater than or equal to 65 years of age</li> <li>Length of Stay &gt;120 days</li> <li>Enrolled in clinical trials</li> </ul>   |
| Adjustment/Stratification: No risk adjustment or risk stratification Not Applicable Not Applicable<br>Level of Analysis: Facility, Population : National<br>Type of Measure: Process<br>Data Source: Administrative claims, Electronic Clinical Data, Paper Records<br>Measure Steward: The Joint Commission   |
| <ul> <li>STEERING COMMITTEE MEETING 11/29-30/2011</li> <li>Importance to Measure and Report: Y-25; N-0 (1a. High Impact: 1b. Performance Gap, 1c. Evidence)</li> <li>1a. Impact: H-7; M-0; L-1; I-0; 1b. Performance Gap: H-8; M-0; L-0; I-0</li> <li>1c. Evidence Quantity: H-7; M-1; L-0; I-0; Quality: H-3; M-4; L-1; I-0; Consistency: H-7; M-0; L-1; I-0</li> <li>Rationale: <ul> <li>Significant opportunity for improvement – Joint Commission data indicates current performance at 18%.</li> <li>Evidence is strong that elective delivery prior to 39 weeks impacts newborn adversely.</li> <li>The goal is not 0% because of unusual circumstances that will not be captured by the measure.</li> </ul> </li> </ul> |
| <ol> <li>Scientific Acceptability of Measure Properties: Y-24; N-1<br/>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>Reliability: H-5; M-2; L-0; I-1 2b. Validity: H-4; M-4; L-0; I-0<br/><u>Rationale</u>:</li> </ol>   |
| <ul> <li>Measure has generous exclusions, but two significant exclusions are left out – prior Classical C-section and myomectomy – developer acknowledges that they are hearing this feedback repeatedly and are considering including, though the number of Classical C-sections and myomectomies is quite small.</li> <li>Some coding issues – "active labor" not easily coded; ICD-10 has greater specificity but Classical C-section and myomectomy are not in the first iteration.</li> <li>Exclusions are generous but some "diagnosis creep" may be seen with increased use of allowable exclusions</li> </ul>  |
| 3. Usability: H-9; M-15; L-1; I-0<br>( <i>Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement</i> )<br>3a. Public Reporting: H-4; M-3; L-0; I-1   |

#### 0469 PC-01 Elective Delivery

#### Rationale:

- Some limitations for use with Medicaid not all elements are readily captured in billing codes.
- Some chart review is needed after use of the codes.
- Adopted by the March of Dimes as a major campaign.

#### 4. Feasibility: H-3; M-21; L-1; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-7; M-0; L-1; I-0

4b. Electronic data sources: H-4; M-4; L-0; I-0

4c. Suscep inaccuracies, consequences: H-2; M-4; L-1; I-1

4d. Data collection strategy: H-6; M-2; L-0; I-0

Rationale:

• Data intense but feasible.

• Possibility for overuse of "soft" exclusion criteria.

#### Steering Committee Recommendation for Endorsement: Y-25; N-0

**Rationale**: Since endorsement in 2008 this measure has been adopted by many providers and the March of Dimes has launched a major campaign to prevent unnecessary prematurity. Data indicates significant opportunity for improvement and the evidence is strong that newborns are adversely affected by unnecessary early birth. The developers indicate a willingness to include two important exclusions – Classical C-section and myomectomy.

RECOMMENDATION: Strongly recommend additional exclusions for prior Classical C/S and myomectomy

#### Public & Member Comment Comments included:

• Comments suggested that this be reported at the clinician level.

Developer response: provider level measures are not the focus of their measure development program.

**Committee Response:** The Committee noted that it is difficult to "just bring measures down to the clinician level" and that methodologic challenges (small sample size and attribution) result in unstable results at the clinician level. These measures would need testing at the clinician-level prior to specifying that level of analysis.

| 0470 Incidence of Episiotomy  |  |
|---|--|
|   |  |
| Maintenance Measure (previously time-limited endorsement)   |  |
| Description: Percentage of vaginal deliveries (excluding those coded with shoulder dystocia) during which an episiotomy is performed.               |  |
| Numerator Statement: Number of episiotomy procedures (ICD-9 code 72.1, 72.21, 72.31, 72.71, 73.6; ICD-10  |  |
| PCS:0W8NXZZ,0WQNXZZ,10D07Z3,10D07Z4,10D07Z5,10D07Z6) performed on women undergoing a vaginal delivery (excluding                                    |  |
| those with shoulder dystocia) during the analytic period- monthly, quarterly, yearly etc.   |  |
| Denominator Statement: All vaginal deliveries during the analytic period- monthly, quarterly, yearly etc. excluding those coded with a              |  |
| shoulder dystocia.  |  |
| Exclusions: Women who have a coded complication of shoulder dystocia. In the case of shoulder dystocia, an episiotomy is performed                  |  |
| to free the shoulder and prevent/mitigate birth injury to the infant.   |  |
| Adjustment/Stratification: No risk adjustment or risk stratification NA NA  |  |
| Level of Analysis: Facility   |  |
|   |  |
| Type of Measure: Outcome, Process   |  |
| Data Source: Administrative claims, Paper Records   |  |
| Measure Steward: Christiana Care Health System  |  |
|   |  |
| STEERING COMMITTEE MEETING 11/29-30/2011  |  |
| Importance to Measure and Report: Y-19; N-0   |  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)  |  |
| 1a. Impact: H-5; M-4; L-0; I-0; 1b. Performance Gap: H-6; M-3; L-0; I-0   |  |
| 1c. Evidence Quantity: H-6; M-2; L-0; I-1; Quality: H-4; M-4; L-0; I-1; Consistency: H-6; M-1; L-0; I-1   |  |
| Rationale:  |  |
|   |  |
| • Significant literature against episiotomy; evidence for increased risk of 3 <sup>rd</sup> and 4 <sup>th</sup> degree lacerations with episiotomy. |  |
| <ul> <li>ACOG supports restricted use of episiotomy.</li> </ul>   |  |
| <ul> <li>Wide variation in provider performance: in 2010 the National Perinatal Information Center reported a national rate of 16.2%</li> </ul>     |  |
| with tremendous inter center variation (4.3% to 34.6%).   |  |
| <ul> <li>Committee members report that when this measure is implemented, rapid improvement is seen.</li> </ul>                                      |  |
|   |  |
| 2. Scientific Acceptability of Measure Properties: Y-19; N-0  |  |
| (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)  |  |
| <b>2a</b> . Reliability: H-8; M-1; L-0; I-0 2b. Validity: H-4; M-5; L-0; I-0  |  |
|   |  |
| Rationale:  |  |
| <ul> <li>Uses administrative data; CPT procedure codes are usually coded reliably.</li> </ul>   |  |
| <ul> <li>Developers' comparison with charts: some mismatch but random whether over coding or under coding.</li> </ul>                               |  |
| <ul> <li>Only exclusion is shoulder dystocia – an appropriate indication for episiotomy.</li> </ul>   |  |
| Level of analysis at the facility level produces a stable result. Confidence intervals for individual clinicians is very unstable.                  |  |
|   |  |
| 3. Usability: H-14; M-4; L-1; I-0   |  |
| (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)              |  |
| 3a. Public Reporting: H-5; H-1; L-3; I-0  |  |
|   |  |
| 3b. Ql: H-5; M-4; L-0; I-0  |  |
| Rationale:  |  |
| Easily understood by multiple audiences.  |  |
| NPIC data shows wide variation in episiotomy incidence.   |  |
| Where measure has been used, rates of episiotomy are dropping.  |  |
| ······································  |  |
| 4. Feasibility: H-15; M-5; L-0; I-0   |  |
| (4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences              |  |
|   |  |
| identified 4d. Data collection strategy can be implemented)   |  |
| 4a. Byproduct of Care Processes: H-8; M-1; L-0; I-0   |  |
| 4b. Electronic data sources: H-8; M-1; L-0; I-0   |  |
| 4c. Suscep inaccuracies, consequences: H-8; M-0; L-1; I-0   |  |
| 4d. Data collection strategy: H-9; M-0; L-0; I-0  |  |
| Rationale:  |  |

High fidelity in coding.

#### 0470 Incidence of Episiotomy

• Measures is easy to collect and useful for comparisons

### Steering Committee Recommendation for Endorsement: Y-19; N-1

**Rationale:** Current data indicates overuse of episiotomy and wide variation in performance. Evidence and ACOG guidelines support restricted use of episiotomy. When this measure is implemented, rapid performance improvement has been observed.

#### Public & Member Comment

#### Comments included:

- Additional exclusions for shortening the second stage of labor;
- Report at the clinician level

#### **Developer response:**

- Suggested exclusions did not align with ACOG guidelines and it would be too complicated to capture using current data collection methods.
- Clinician level measures are not the focus of their measure development program.

**Committee Response:** The Committee agreed with the developer about the exclusions and noted that it is difficult to "just bring measures down to the clinician level" and that methodologic challenges (small sample size and attribution) result in unstable results at the clinician level. These measures would need testing at the clinician-level prior to specifying that level of analysis.

# 0471 PC-02 Cesarean Section

| 04/1 PC-02 Cesarean Section  |  |  |
|--|--|--|
| Maintenance Measure  |  |  |
|  | ber of nulliparous women with a term, singleton baby in a vertex position delivered by   |  |
| cesarean section. This measure is part of a se   | t of five nationally implemented measures that address perinatal care (PC-01: Elective   |  |
| Delivery, PC-03: Antenatal Steroids, PC-04: Health Care-Associated Bloodstream Infections in Newborns, PC-05: Exclusive Breast Milk            |  |  |
| Feeding).  |  |  |
|  | n sections with ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes  |  |
| for cesarean section as defined in Appendix A,   | Table 11.06 available at:  |  |
| http://manual.jointcommission.org  |  |  |
|  | delivered of a live term singleton newborn in vertex presentation  |  |
|  | osis Code or ICD-9-CM Other Diagnosis Codes for contraindications to vaginal delivery as   |  |
| defined in Appendix A, Table 11.09   |  |  |
| Less than 8 years of age   |  |  |
| Greater than or equal to 65 years of   | age  |  |
| Length of Stay >120 days   |  |  |
| Enrolled in clinical trials  | standardization to the distribution of the 2004 LIC nonulation of nullinoraus hitthe. See  |  |
|  | standardization to the distribution of the 2006 US population of nulliparous births. See   |  |
|  | e direct standardization. Not Applicable The Stratification Table used for direct  |  |
|  | ified By, and the Age Stratum (Allowable Value). The Age Stratum refers to Patient Age sion Date minus the data element Birthdate. Each case will be stratified according to the |  |
|  | .g., numerator, denominator, not in measure population) are completed and the overall  |  |
| rate is calculated.  | .g., numerator, denominator, not in measure population, are completed and the overall  |  |
| Set Number Stratified By Age St  | ratum  |  |
|  | ue exists for the overall rate. It includes all patients greater than or equal to 8 years and  |  |
| less than 65 years.  | de exists for the overall rate. It includes all patients greater than of equal to o years and  |  |
|  | ent Age (Admission Date minus Birthdate) greater than or equal to 8 years and less than  |  |
| 15 years.  | shi Aye (Aumission Date minus Dintituate) greater than or equal to o years and less than   |  |
| PC-02c Age 15 years through 19 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 15 years and   |  |
| less than 20 years.  | A ration Aye (Admission bate minus birthdate) greater than of equal to 15 years and  |  |
| PC-02d Age 20 years through 24 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 20 years and   |  |
| less than 25 years.  |  |  |
| PC-02e Age 25 years through 29 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 25 years and   |  |
| less than 30 years.  |  |  |
| PC-02f Age 30 years through 34 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 30 years and   |  |
| less than 35 years.  | 5 . , , , , , , , , , , , , , , , , , ,  |  |
| PC-02g Age 35 years through 40 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 35 years and   |  |
| less than 40 years.  |  |  |
| PC-02h Age 40 years through 44 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 40 years and   |  |
| less than 45 years.  |  |  |
| PC-02i Age 45 years through 64 years   | A Patient Age (Admission Date minus Birthdate) greater than or equal to 45 years and   |  |
| less than 65 years.  |  |  |
| Level of Analysis: Facility, Population : Nation   | nal  |  |
| Type of Measure: Outcome   |  |  |
| Data Source: Administrative claims, Paper Records  |  |  |
| Measure Steward: The Joint Commision   |  |  |
|  |  |  |
| STEERING COMMITTEE MEETING 11/29-30  |  |  |
| Importance to Measure and Report: Y-25; N-0  |  |  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)   |  |  |
| 1a. Impact: H-7; M-0; L-0; I-0; Ib. Performance Gap: H-7; M-0; L-0; I-0  |  |  |
| 1c. Evidence Quantity: H-6; M-0; L-0; I-0; Quality: H-4; M-2; L-0; I-0; Consistency: H-5; M-1; L-0; I-0  |  |  |
| Rationale:   |  |  |
| • ACOG says this is the "optimal measure" for Cesarean section because it focuses on the first-time, uncomplicated pregnancy.                  |  |  |
| Current performance 27.7% nationwide; rates are stable, not increasing.  |  |  |
| Measure looks at the outcome of the management of labor.   |  |  |
| <ul> <li>The low-risk population is responsible for the large overall increase in C-section rates and shows the greatest variation.</li> </ul> |  |  |

# NATIONAL OUALITY FORD

| <ul> <li>0471 PC-02 Cesarean Section <ul> <li>Large regional variations are observed.</li> <li>Measure results are related to induction rates; also parallels regional hysterectomy patterns.</li> </ul> </li> <li>2. Scientific Acceptability of Measure Properties: Y-25; N-0 <ul> <li>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> </ul> </li> <li>2a. Reliability: H-6; M-1; L-0; I-0 2b. Validity: H-4; M-3; L-0; I-0 <ul> <li>Rationale:</li> <li>Easily extractable from vital records.</li> <li>Good definitions.</li> <li>Stratification by age adjustment reflects linear rise in C/S rates from age 18 through 40 years (correlation coefficient = 98%).</li> </ul> </li> <li>3. Usability: H-23; M-2; L-0; I-0 <ul> <li>(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)</li> <li>3a. Public Reporting: H-6; M-1; L-0; I-0</li> </ul> </li> </ul> |  |
|--|--|
| <ul> <li>Measure results are related to induction rates; also parallels regional hysterectomy patterns.</li> <li>2. Scientific Acceptability of Measure Properties: Y-25; N-0         <ul> <li>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-6; M-1; L-0; I-0 2b. Validity: H-4; M-3; L-0; I-0             </li> <li>Rationale:                 <ul> <li>Easily extractable from vital records.</li> <li>Good definitions.</li> <li>Stratification by age adjustment reflects linear rise in C/S rates from age 18 through 40 years (correlation coefficient = 98%).</li> </ul></li> <li>Usability: H-23; M-2; L-0; I-0</li></ul></li></ul>   |  |
| <ul> <li>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-6; M-1; L-0; I-0 2b. Validity: H-4; M-3; L-0; I-0</li> <li><u>Rationale</u>: <ul> <li>Easily extractable from vital records.</li> <li>Good definitions.</li> <li>Stratification by age adjustment reflects linear rise in C/S rates from age 18 through 40 years (correlation coefficient = 98%).</li> </ul> </li> <li>3. Usability: H-23; M-2; L-0; I-0 <ul> <li>(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)</li> </ul> </li> </ul>  |  |
| (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)   |  |
| <b>3b.</b> QI: <b>H-5</b> ; <b>M-2</b> ; <b>L-0</b> ; <b>I-0</b><br>Rationale:   |  |
| <ul> <li>Medicaid program core measure</li> <li>Greater incentives may be needed to see greater impact on results.</li> <li>Systems issues need to be addressed</li> <li>Initially a poorly understood measure – significant learning curve as measure is more widely adopted.</li> <li>Improved performance on elective delivery &lt; 39 weeks measure may reduce the C/S rate</li> <li>Another good measure for population assessment – vital records are readily available</li> </ul>   |  |
| <ul> <li>4. Feasibility: H-16; M-9; L-0; I-0 (4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)</li> <li>4a. Byproduct of Care Processes: H-5; M-2; L-0; I-0</li> <li>4b. Electronic data sources: H-7; M-0; L-0; I-0</li> <li>4c. Suscep inaccuracies, consequences: H-4; M-3; L-0; I-0</li> <li>4d. Data collection strategy: H-7; M-0; L-0; I-0</li> <li>Fationale: <ul> <li>States, Medicaid agencies and purchasers can do this measure.</li> <li>Vital records as an alternative data source.</li> </ul> </li> </ul>   |  |
| Steering Committee Recommendation for Endorsement: Y-25; N-0<br>Rationale: This is considered to be the "optimal measure" for primary Cesarean section. The measure assesses the outcome of the<br>management of labor. Large regional variations are seen. The measure is readily constructed from several data sources.  |  |
| Public & Member Comment         Comments included:         • Comments suggested that this be reported at the clinician level.         Developer response: Clinician level measures are not the focus of their measure development program.   |  |

**Committee Response:** The Committee noted that it is difficult to "just bring measures down to the clinician level" and that methodologic challenges (small sample size and attribution) result in unstable results at the clinician level. These measures would need testing at the clinician-level prior to specifying that level of analysis.

#### 0472 Appropriate Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision– Cesarean Section. Maintenance Measure

**Description:** Percentage of patients undergoing cesarean section who receive appropriate prophylactic antibiotics within 60 minutes of the start of the cesarean delivery, unless the patient is already receiving appropriate antibiotics

**Numerator Statement:** Percentage of women who receive recommended antibiotics within one hour before the start of cesarean section. This requires that (a) the antibiotic selection is consistent with current evidence and practice guidelines, and (b) that the antibiotics are given within an hour before delivery.

If the patient is already receiving appropriate antibiotics, for example for chorioamnionitis, additonal dosing is not necessary. **Denominator Statement:** All patients undergoing cesarean section without evidence of prior infection or already receiving prophylactic antibiotics for other reasons. Patients with significant allergies to penicillin and/or cephalosporins AND allegies to gentamicin and/or clindamycin are also excluded.

**Exclusions:** Women with evidence of prior infection or already receiving prophylactic antibiotics for other reasons; or with significant allergies to penicillin and/or cephalosporins AND allegies to gentamicin and/or clindamycin.

We do not exclude patients having emergency cesarean deliveries. We recognize that while in the case of most urgent and emergent cesarean deliveries administering timely antibiotic prophylaxis will be possible, very rarely clinical circumstances may not permit administration of antibiotic prophylaxis before skin incisions. Specifying these unusual circumstances, especially from readily abstracted medical record data, is not possible/feasible. Allowing a self-defined exclusion risks inappropriate definition. Instead we recognize that ideal performance on this measure may not be 100% given the small number of unusual emergencies and/or other circumstances. Providers/facilities should however target a 100% goal by, among other efforts, considering how antibiotic prophylaxis will be appropriately delivered even in the case of emergencies

Adjustment/Stratification: No risk adjustment or risk stratification n/a The measure may electively be stratified by race, ethnicity, or other variables of interest. These additional variables would be identified and supplied by users according to local needs and interests. Level of Analysis: Facility, Population : State

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper Records Measure Steward: Massachusetts General Hospital/Partners Health Care System

# STEERING COMMITTEE MEETING 11/29-30/2011

Importance to Measure and Report: Y-26; N-0

(1a. High Impact: 1b. Performance Gap, 1c. Evidence)

1a. Impact: H-7; M-1; L-0; I-0; 1b. Performance Gap: H-5; M-2; L-1; I-0

1c. Evidence Quantity: H-8; M-0; L-0; I-0; Quality: H-6; M-2; L-0; I-0; Consistency: H-8; M-0; L-0; I-0 Rationale:

- More than 1 million C-sections every year; high rates of surgical site infection.
- Clear evidence than antibiotic prophylaxis reduces surgical site infection.
- The measure is in use in the MassHealth pay for performance program --, state-wide rates of compliance with the overall measure (timing and selection) were 61% in FY 2008, 75% in RY 2009, and 77% in FY 2010.
- Uncertain impact of antibiotic exposure to fetus; early data indicating change in fetal gut flora with C-section and antibiotic exposure; recent studies show changes in microbiological environment but not yet associated with health outcomes need longer-term studies to follow babies.

2. Scientific Acceptability of Measure Properties: Y-26; N-0 (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-5; M-3; L-0; I-0 2b. Validity: H-6; M-2; L-0; I-0 Rationale:

• Good specifications.

• Well-tested; includes both timing and antibiotic selection.

### 3. Usability: H-24; M-2; L-0; I-0

(*Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement*) **3a.** Public Reporting: **H-7**; **M-1**; **L-0**; **I-0** 

3b. QI: H-8; M-0; L-0; I-0

Rationale:

- Used in Massachusetts with steady improvement in past three years.
- Hospitals already collect data for SCIP this is an additional surgical procedure .

#### 0472 Appropriate Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision- Cesarean Section.

• Harmonized with SCIP measures.

#### 4. Feasibility: H-19; M-7; L-0; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-7; M-0; L-1; I-0

4b. Electronic data sources: H-2; M-4; L-2; I-0

4c. Suscep inaccuracies, consequences: H-6; M-2; L-0; I-0

4d. Data collection strategy: H-7; M-1; L-0; I-0

Rationale:

• Can't do routine electronic data collection on all systems, but some do have the capability.

### Steering Committee Recommendation for Endorsement: Y-26; N-0

**Rationale:** This measure is harmonized with the SCIP measures, but covers a surgery that is excluded in the SCIP measures. Cesarean section is a high-frequency procedure with significant risk of surgical site infection. Current use in Massachusetts identifies opportunity for improvement and improvement over time when implemented.

**Public & Member Comment** 

Comments included:

• A commenter raised concerns on the ability of EHRs to handle the exclusion criteria.

**Developer response:** We have worked to use standard data elements as far as possible. We expect that, as with any process of care guideline, there will be individual cases with unusual circumstances. We are hopeful that most of the data collection can be done using common electronic data elements, and that over a period of time important additional factors can be incorporated into the systems.

**NQF response**: Currently, none of the measures under consideration are specified for use in EHRs; thus, the issues raised have been provided to the developers for their consideration as they move toward an electronic environment. NQF intends to require EHR specifications for all measure in the near future; additional details and guidance on those requirements are under consideration by the Consensus Standards Approval Committee.

Committee Response: The Committee appreciated the comments but agreed it was beyond the scope of their work at this time.

#### 0473 Appropriate DVT Prophylaxis in Women Undergoing Cesarean Delivery

Maintenance measure (previously time-limited endorsement)

**Description**: Measure adherance to current ACOG, SMFM recommendations for use of DVT prophylaxis in women undergoing cesarean delivery. Current ACOG and SMFM recommendations call for the use of pneumatic compression devices in all women undergoing cesarean delivery who are not already receiving medical VTE prophylaxis. Numerator: Number of women undergoing cesarean delivery receiving either pneumatic compression device or medical prophylaxis prior to cesarean delivery. Denominator: All women undergoing cesarean delivery.

Numerator Statement: Number of women undergoing cesarean delivery who receive either fractionated or unfractionated heparin or heparinoid, or pneumatic compression devices prior to surgery

Denominator Statement: All women undergoing cesarean delivery.

Exclusions: Not receiving medical anticoagulation

Adjustment/Stratification: No risk adjustment or risk stratification N/A N/A

Level of Analysis: Facility

Type of Measure: Process

**Data Source:** Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records **Measure Steward:** Hospital Corporation of America

### STEERING COMMITTEE MEETING 11/29-30/2011

Importance to Measure and Report: Y-20; N-3

(1a. High Impact: 1b. Performance Gap, 1c. Evidence)

1a. Impact: H-3; M-4; L-1; I-0; 1b. Performance Gap: H-1; M-4; L-3; I-0

1c. Evidence Quantity: H-1; M-4; L-3; I-0; Quality: H-1; M-4; L-3; I-0; Consistency: H-3; M-2; L-2; I-0

Rationale:

- Process to prevent an uncommon but catastrophic event pulmonary embolism accounts for 10% maternal deaths in US.
- VTE is the number 1 preventable cause of maternal death.
- Limited data on current performance as it is not in widespread use.
- Recent ACOG practice bulletin (September 2011) recommends DVT prophylaxis. Society of Maternal Fetal Medicine has similar guideline.
- Limited evidence in pregnant patients except for recent study from HCA; extrapolated from experience in other surgical patients. Data from HCA reported a reduction in fatal PE rate from 1.5/100,000 to 0.5/100,000 with use of prophylaxis.
- Cost-effectiveness data suggests low cost/easy to use.
- Does not address antepartum or post-partum DVT- intraoperative use only.
- 3/1000 incidence of DVT in pregnancy though some ascertainment issues; five-fold increase in DVT with C-section.

### 2. Scientific Acceptability of Measure Properties: Y-24; N-1

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity) 2a. Reliability: H-3; M-2; L-2; I-0 2b. Validity: H-3; M-4; L-0; I-0 Rationale:

• Data elements are straightforward

• Single exclusion of being on pharmacologic prophylaxis (small number of patients) eases data collection.

### 3. Usability: H-18; M-6; L-1; I-0

(*Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)* **3a.** Public Reporting: H-3; M-4; L-0; I-0

3b. QI: H-4; M-2; L-1; I-0

Rationale:

- Easy to understand
- Easy to drive practice change
- However, does not deal with the problem of continuing compliance through to hospital discharge and longer period of elevated risk.

### 4. Feasibility: H-13; M-11; L-1; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

#### 0473 Appropriate DVT Prophylaxis in Women Undergoing Cesarean Delivery

- 4a. Byproduct of Care Processes: H-6; M-1; L-1; I-0
- 4b. Electronic data sources: H-5; M-2; L-1; I-0
- 4c. Suscep inaccuracies, consequences: H-2; M-4; L-2; I-0
- 4d. Data collection strategy: H-6; M-2; L-0; I-0

Rationale:

- Data field in some electronic records already
- Easy to document

#### Steering Committee Recommendation for Endorsement: Y-21; N-2

• **Rationale:** Existing measures of VTE prophylaxis exclude pregnant women/C-section despite being at risk for catastrophic event (PE or death). Preventive measures have been shown to reduce mortality but are not widely used.

#### Public & Member Comment Comments included:

- mments included:
- Supportive comments.
- One commenter suggested that the developer create and test a paired measure for continued DVT prophylaxis, which may increase the benefit.

Steering Committee: The Committee agreed to add the suggested measure to the recommendations for future measure development.

| 0475 Hepatitis B Vaccine Coverage Among All Live Newborn Infants Prior to Hospital or Birthing Facility Discharge  |
|--|
| Maintenance Measure (previously time-limited endorsement)  |
| Description: Percent of live newborn infants that receive hepatitis B vaccination before discharge at each single hospital/birthing facility   |
| during given time period (one year).   |
| Numerator Statement: The number of live newborn infants administered hepatitis B vaccine prior to discharge from the hospital/birthing   |
| facility ("birth dose" of hepatitis B vaccine).  |
| Denominator Statement: The number of live newborn infants born at the hospital/birthing facility during the reporting window (one  |
| calendar year)   |
| <b>Exclusions:</b> a. Optional recommended adjusted MEASURE denominator: determine number of live newborn infants born at the hospital/birthing facility whose parent/guardian refused hepatitis B birth dose and exclude from the denominator. ICD-10 code for this |
| information might include the following (link: http://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z28/Z28-/#Z28):  |
| i. Z28.03 Immunization not carried out because of immune compromised state of patient  |
| ii. Z28.04 Immunization not carried out because of patient allergy to vaccine or component   |
| iii. Z28.1 Immunization not carried out because of patient decision for reasons of belief or group pressure  |
| iv. Z28.20 Immunization not carried out because of patient decision for unspecified reason   |
| v. Z28.21 Immunization not carried out because of patient refusal  |
| vi. Z28.29 Immunization not carried out because of patient decision for other reason   |
| vii. Z28.82 Immunization not carried out because of caregiver refusal  |
| The results of this measure should be reported as a separate MEASURE identifying that the coverage excludes infants whose  |
| parent(s)/guardian(s) refused hepatitis B vaccine for their infant before hospital or facility discharge (or by 1 month of age if during a   |
| prolonged stay).   |
| Adjustment/Stratification: No risk adjustment or risk stratification N/A N/A   |
| Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Facility, Health Plan   |
| Type of Measure: Process   |
| Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data  |
| : Pharmacy, Electronic Clinical Data : Registry  |
| Measure Steward: Centers for Disease Control and Prevention  |
| STEERING COMMITTEE MEETING 11/29-30/2011   |
| Importance to Measure and Report: Y-22; N-2  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)   |
| 1a. Impact: H-3; M-2; L-0; I-0; 1b. Performance Gap: H-3; M-2; L-0; I-0  |
| 1c. Evidence Quantity: H-3; M-2; L-0; I-0; Quality: H-1; M-4; L-0; I-0; Consistency: H-4; M-1; L-0; I-0  |
| Rationale:   |
| <ul> <li>Increasing number of pregnant women are found to be Hepatitis B Surface Antigen (HBsAg) positive (approximately 25,000/year)</li> </ul>   |
| The 2010 National Immunization Study demonstrated that for 50 states and the District of Columbia, the calculated results for  |
| birth dose coverage were: median 66.7%; mean 65.7%; minimum 21.4%; maximum 83.3%. There is an APIC   |
| recommendation for neonatal immunization,  |
| <ul> <li>Captures initial immunization in the series of three Hepatitis B vaccinations.</li> </ul>   |
| Immunization prevents development of chronic hepatitis infection.  |
|  |
| 2. Scientific Acceptability of Measure Properties: Y-11; N-13 as written with optional exclusion for parent refusal;   |
| If exclusions are mandatory Y=22; N=3  |
| (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)<br>2a. Reliability: H-3; M-2; L-0; I-0 2b. Validity: H-3; M-2; L-0; I-0   |
| Za. Reliability: H-3; M-2; L-0; I-0 Zb. Validity: H-3; M-2; L-0; I-0<br>Rationale:   |
| Optional exclusions affect standardization and reduce comparability. Developer reports that exclusions are included if hospitals   |
| can collect the data.  |
| <ul> <li>Including refusals is important for validity as a performance measure – different perspective than for a public health</li> </ul>   |
| surveillance measure.  |

- Developers report <3% refusal rate overall; some areas of 10-12% refusal. ICD-10 codes for parent refusal (none in ICD-9). ٠
- •

#### NATIONAL QUALITY FORUM 0475 Hepatitis B Vaccine Coverage Among All Live Newborn Infants Prior to Hospital or Birthing Facility Discharge 3. Usability: H-4; M-14 L-6; I-0 (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement) 3a. Public Reporting: H-1; M-3; L-1; I-0 3b. QI: H-1; M-3; L-1; I-0 Rationale: Not in use in public reporting ٠ Difficult to capture refusals until ICD-10 4. Feasibility: H-3; M-19; L-3; I-0 (4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented) 4a. Byproduct of Care Processes: H-2; M-2; L-1; I-0 4b. Electronic data sources: H-1: M-3: L-1: I-0 4c. Suscep inaccuracies, consequences: H-0; M-3; L-1; I-1 4d. Data collection strategy: H-0; M-2; L-3; I-0 Rationale: Costly to review charts for refusals though numbers are small ٠ There is cost for initial programming for EHRs, but thereafter an advantage. • Steering Committee Recommendation for Endorsement: Y-22; N-3 with mandatory exclusion for parent refusal Rationale: This measure conforms to APIC recommendations for neonatal immunization and national rates demonstrate wide variation and opportunity for improvement. The developer agreed to remove the "optional" aspect of exclusions for parental refusal. Public & Member Comment Comments included: Three supportive comments Concerns with the exclusion of parental refusals, including a request that they be measured separately as a component of the • numerator, as would be consistent with other NQF-endorsed immunization measures; and a concern that it may be difficult to capture reasons for refusal in EHRs. **Developer response:** CDC agrees that ideally both measures (birth dose coverage including and excluding parent refusals) would be reported. A coverage assessment that includes parent refusals would be the most consistent with all other immunization coverage measures. As the ICD-10 codes are adopted and additional technology becomes available, accounting for parent refusals could add more granular way to evaluate coverage. From a health perspective, hospitals are perceived to have a joint responsibility with providers to educate families (even those • wishing to refuse vaccination) on the importance of all childhood vaccinations, as well as on the hepatitis B vaccine as a means for preventing perinatal and household transmission of hepatitis B acquired from persons who may not even know they are infected. Failure to account for refusals would underestimate the true success of each hospital's compliance with the quality measure. Steering Committee: The Committee noted that coding for parental refusals will be standardized with ICD-10 and that should be incorporated into annual updates. The Committee did not change their recommendation.

| 0476 PC-03 Antenatal Steroids   |
|---|
| 0476 PC-03 Antenatal Steroids         Maintenance Measure (previously time-limited endorsement)         Description: This measure assesses patients at risk of preterm delivery at 24 0/7-32 0/7 weeks gestation receiving antenatal steroids prior to delivering preterm newborns. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-01: Elective Delivery, PC-02: Cesarean Section, PC-04: Health Care-Associated Bloodstream Infections in Newborns, PC-05: Exclusive Breast Milk Feeding).         Numerator Statement: Patients with a full course of antenatal steroids completed prior to delivering preterm newborns (refer to Appendix B, Table 11.0, antenatal steroid medications available at: <a href="http://manual.jointcommission.org">http://manual.jointcommission.org</a> )         Denominator Statement: Patients delivering live preterm newborns with 24 0/7-32 0/7 weeks gestation completed Exclusions:         •       Less than 8 years of age         •       Less than 8 years of age         •       Length of Stay >120 days         •       Enrolled in clinical trials         •       Documented Reason for Not Administering Antenatal Steroid         •       ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for fetal demise as defined in Appendix A, Table         11.09.1 available at: <a href="http://manual.jointcommission.org&lt;/a">         Adjustment/Stratification: No risk adjustment or risk stratification Not Applicable Not applicable, the measure is not stratified.         Level of Analysis: Facility, Population : National</a> |
|   |
| <ul> <li>STEERING COMMITTEE MEETING 11/29-30/2011</li> <li>Importance to Measure and Report: Y-24; N-0 (1a. High Impact: 1b. Performance Gap, 1c. Evidence) 1a. Impact: H-5; M-0; L-0; I-0; 1b. Performance Gap: H-5; M-0; L-0; I-0 1c. Evidence Quantity: H-5; M-0; L-0; I-0; Quality: H-5; M-0; L-0; I-0; Consistency: H-5; M-0; L-0; I-0 <u>Rationale</u>: <ul> <li>Strong data demonstrating the benefit of steroid use; NIH and ACOG recommend use of steroids.</li> <li>Change from the original endorsed measure: <ul> <li>Requires full course of treatment; (if no time for full course to be administered, patient is excluded)</li> <li>32-34 weeks with Premature Rupture of Membranes (PROM) not included</li> </ul> </li> <li>There is no evidence or guidance for &lt; 24 weeks</li> <li>From 2005-2007, data covering more than 90% of deliveries in California found that 23% of the more than 15,000 eligible infants did not receive antenatal steroids. Current Joint Commission data report 64.9% performance.</li> <li>Room for improvement; some improvement has been seen</li> <li>Another quality question might be whether steroids are overused in some patients. Need more information on the long-term impact of multiple steroid courses on the baby.</li> </ul> </li> </ul>  |
| <ul> <li>2. Scientific Acceptability of Measure Properties: Y-24; N-1 (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-4; M-1; L-0; I-0 2b. Validity: H-5; M-0; L-0; I-0 <u>Rationale:</u> <ul> <li>Testing indicates high reliability and moderate-high validity.</li> <li>The exclusion for patients who do not receive a complete course due to rapid delivery results in lack of credit to the provider for appropriate steroid therapy.</li> </ul> </li> </ul>   |
| <ul> <li>3. Usability: H-16; M-8; L-0; I-0<br/>(<i>Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement</i>)</li> <li>3a. Public Reporting: H-5; M-0; L-0; I-0</li> <li>3b. Ql: H-5; M-0; L-0; I-0<br/><u>Rationale</u>: <ul> <li>This measure is on the recommended list of Medicaid core measures.</li> </ul> </li> </ul>   |

### 0476 PC-03 Antenatal Steroids

4. Feasibility: H-6; M-16; L-2; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-3; M-2; L-0; I-0

4b. Electronic data sources: H-1; M-3; L-1; I-0

4c. Suscep inaccuracies, consequences: H-4; M-1; L-0; I-0

4d. Data collection strategy: H-4; M-0; L-1; I-0

Rationale:

• Some chart review is needed

#### Steering Committee Recommendation for Endorsement: Y-25; N-0

**Rationale:** There is significant room for improvement in performance for this evidence-based process of care that improves outcomes for premature infants. The measure is well-specified and demonstrates good reliability and validity.

### Public & Member Comment

Comments included:

- Suggestion that specs be updated to bring them in line with the new ACOG Committee Opinion (Feb 2011)
- Clarification on the list of reasons for the exclusion criteria "documented reason for not administering antenatal steroid," noting that without a specified list, there will be inconsistency in measurement with facilities, who will provide their own coding reasons.

#### Developer response:

- Agreed to update specs.
- Data analysis is done by trained abstractors who are able to assess whether or not the documented reasons meet the specifications

Steering Committee: The Committee agreed with the updated specifications and did not change their recommendation.

#### 1746 Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (GBS)

#### New Measure

**Description**: Percentage of pregnant women who are eligible for and receive appropriate intrapartum antibiotic prophylaxis (IAP) for Group B Streptococcus (GBS)

Numerator Statement: All eligible patients who receive intrapartum antibiotic prophylaxis for GBS.

Denominator Statement: All women delivering live infants, except certain classes (described in response to 2a1.9 below) who are specifically deemed not to be at risk of vertical transmission of GBS.

Exclusions: Women not included in the denominator defined above, with specific exclusions as described below.

Adjustment/Stratification: No risk adjustment or risk stratification

Level of Analysis: Facility, Integrated Delivery System, Population : State

Type of Measure: Process

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper Records **Measure Steward:** Massachusetts General Hospital

### STEERING COMMITTEE MEETING 11/29-30/2011

Importance to Measure and Report: Y-26; N-0

(1a. High Impact: 1b. Performance Gap, 1c. Evidence)

1a. Impact: H-5; M-0; L-0; I-0; 1b. Performance Gap: H-2; M-3; L-0; I-0

1c. Evidence Quantity: H-3; M-2; L-0; I-0; Quality: H-3; M-2; L-0; I-0; Consistency: H-2; M-3; L-0; I-0 Rationale:

- New data from Massachusetts suggests more opportunity for improvement that previously thought.
- In use in Massachusetts improved 71 to 87% over 3 years.
- CDC guidelines recommend prophylaxis for Group B Strep since it prevents lethal infection in newborns.

#### 2. Scientific Acceptability of Measure Properties: Y-24; N-2

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity) 2a. Reliability: H-3; M-1; L-0; I-0 2b. Validity: H-3; M-1; L-0; I-0 <u>Rationale</u>:

- Intended to align with CDC guidelines; developer will clarify specifications especially for pre-term screening.
- Reliability and validity rated moderate-high.

### 3. Usability: H-14; M-11; L-1; I-0

(*Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement*) 3a. Public Reporting: H-3; M-1; L-0; I-0 3b. QI: H-3; M-1; L-0; I-0

Rationale:

- In use in Massachusetts Medicaid program
- Unclear potential for unintended consequences: No data on long-term impact on children of exposure to antibiotics-. Though there is a not a clear relationship, gram negative infections have increased while GBS has declined.

#### 4. Feasibility: H-6; M-19; L-1; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-4; M-0; L-0; I-0

4b. Electronic data sources: H-2; M-2; L-0; I-0

- 4c. Suscep inaccuracies, consequences: H-1; M-3; L-0; I-0
- 4d. Data collection strategy: H-3; M-1; L-0; I-0

Rationale:

• Requires manual chart abstraction

#### Steering Committee Recommendation for Endorsement: Y-26; N-0

**Rationale:** A measure of GBS prophylaxis was not recommended in the 2008 Perinatal project because data at that time indicated high performance. Newer data indicates that performance is not as high as previously thought. This measure aligns with evidence-based guidelines from CDC.

1746 Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (GBS)

Public & Member Comment Comments included:

• Questions on details of the specifications and ability of EHRs to manage the many different data elements required to calculate the measure.

**Developer response:** The developer clarified the details for the commenters.

Steering Committee: The Committee had no additional comments and did not wish to change their recommendation.

#### 0477 Under 1500g infant Not Delivered at Appropriate Level of Care

#### Maintenance Measure

**Description:** The number per 1,000 livebirths of <1500g infants delivered at hospitals not appropriate for that size infant.

Numerator Statement: Liveborn infants (<1500gms but over 24 weeks gestation) born at the given birth hospital

**Denominator Statement:** All live births over 24 weeks gestation at the given birth hospital. NICU Level III status is defined by the State Department of Health or similar body typically using American Academy of Pediatrics Criteria.

Exclusions: Stillbirths and livebirths <24weeks gestation.

Adjustment/Stratification: No risk adjustment or risk stratification n.a. none

Level of Analysis: Facility, Health Plan, Population : County or City, Population : National, Population : Regional, Population : State Type of Measure: Outcome

Data Source: Electronic Clinical Data : Registry, Other

Measure Steward: California Maternal Quality Care Collaborative

# STEERING COMMITTEE MEETING 11/29-30/2011

Importance to Measure and Report: Y-25; N-0

(1a. High Impact: 1b. Performance Gap, 1c. Evidence)

1a. Impact: H-5; M-0; L-0; I-0; 1b. Performance Gap: H-5; M-0; L-0; I-0

1c. Evidence Quantity: H-3; M-1; L-0; I-0; Quality: H-3; M-1; L-0; I-0; Consistency: H-4; M-0; L-0; I-0

Rationale:

- 2010 meta-analysis by CDC demonstrated a significant survival benefit for VLBW infants in Level 3 NICU (60% increase in mortality outside Level 3 NICU)
- Measure has been used at state-level for many years regionalization of care ongoing for 30+ years but lately seeing deregionalization due to economic factors
- In California (2008) the range of VLBW births in non-level III facilities was 0 to 15 per thousand with a mean of 4.8. The distribution is not evenly distributed.
- In California, developers found that failure to transfer is not common among rural hospitals but more frequent among urban hospitals where a Level 3 NICU is close by likely economic factors rather than medical factors determine transfer.
- All states have networks for transfers.

### 2. Scientific Acceptability of Measure Properties: Y-25; N-0

(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity) 2a. Reliability: H-5; M-0; L-0; I-0 2b. Validity: H-4; M-1; L-0; I-0

Rationale:

- This measure uses AAP definition of Level 3 NICU. States use various definitions.
- Specifications are precise
- Standard reporting under state vital statistics
- Excludes hospital with <50 deliveries a single event distorts the results

# 3. Usability: H-17; M-8; L-0; I-0

(*Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement*) **3a.** Public Reporting: H-1; M-3; L-1; I-0

3b. QI: H-2; M-2; L-1; I-0

Rationale:

- EMTALA law concerns misinterpreted requires evaluation but does not preclude indicated transfer.
- This measure addresses system and administrative accountability for coordinating maternal transport.
- Need to involve EMS in quality improvement as transfer protocols typically require transport to nearest hospital rather than most appropriate hospital.
- Public reporting of this information likely to have big impact on local community and hospital trustees.

### 4. Feasibility: H-23; M-2; L-0; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-5; M-0; L-0; I-0

4b. Electronic data sources: H-3; M-2; L-0; I-0
#### 0477 Under 1500g infant Not Delivered at Appropriate Level of Care

4c. Suscep inaccuracies, consequences: H-4; M-1; L-0; I-0 4d. Data collection strategy: H-5; M-0; L-0; I-0

Rationale:

- Easy to report
- Collected in state birth data
- <1% missing data</li>

### Steering Committee Recommendation for Endorsement: Y-25; N-0

**Rationale:** This measure assesses appropriate transfer of VLBW babies to hospitals that greatly improve their chance of survival. In recent years, previously established regional transfer networks have been breaking down and transfer is not occurring, possibly due to economic rather than medical reasons. Current use of the measure in California indicates a large opportunity for improvement.

### **Public & Member Comment**

#### Comments included:

• Request to expand the exclusion criteria to include reasons outside of the health care system's control for failure to transport to a hospital with appropriate levels of care services (e.g. very late presentation in active labor, lack of safe transportation, distance to NICU in rural areas).

#### Developer response:

• There are some cases in which it is out of the hospital/doctor's control that the mother delivers a baby at a lower level location. This is well understood and recognized by the developer. For this reason, the measure does not expect a zero rate, just a low rate not different from the normal distribution. When California hospitals were examined, a small group of hospitals with very high rates stood out from their peers. Interestingly these were not in distant rural areas but in urban areas where referral centers were close but the practice pattern was to transfer the baby after birth rather than the mother before birth. Currently this measure can easily be calculated using administrative data and setting up exclusions (requiring chart review for every case) would significantly increase the collection burden.

Steering Committee: The Committee did not change their recommendation on the measure.

| 0478 Neonatal Blood Stream Infection Rate (NQI #3)  |      |
|---|------|
| Maintenance Measure (previously time-limited endorsement)   |      |
|   |      |
| <b>Description:</b> Percentage of high-risk newborn discharges with an ICD-9-CM diagnosis code of bloodstream infection                     | ada  |
| Numerator Statement: Discharges among cases meeting the inclusion and exclusion rules for the denominator with an ICD-9-CM co               | Jue  |
| for bloodstream infection in any secondary diagnosis field  |      |
| Denominator Statement: All newborns and outborns with   |      |
| 1) Birth weight 500 to 1499g OR   |      |
| 2) Gestational age between 24 and 30 weeks OR   |      |
| 3) Birth weight greater than or equal to 1500g AND  |      |
| - in-hospital death OR  |      |
| - operating room procedure OR   |      |
| - mechanical ventilation OR   |      |
| - age in days less than 2 AND transferred from another health care facility   |      |
| Exclusions: Exclude cases:  |      |
| with principal diagnosis code of sepsis or secondary diagnosis code present on admission  |      |
| with birth weight less than 500 grams   |      |
| • with length of stay less than 2 days  |      |
| • with missing data for (SEX=missing), age (AGE=missing), quarter (DQTR=missing), year (YEAR=missing) or principal diagnosis                |      |
| (DX1=missing)   |      |
| See Pediatric Quality Indicators Appendices:  |      |
| Appendix L – Low Birth Weight Categories  |      |
| http://qualityindicators.ahrq.gov/Downloads/Software/SAS/V43/TechnicalSpecifications/PDI%20Appendices.pdf                                   |      |
| Adjustment/Stratification: Statistical risk model The predicted value for each case is computed using a hierarchical model (logistic        |      |
| regression with hospital random effect) and covariates for gender, birthweight (500g groups), modified CMS DRG, congenital anomol           |      |
| transfer-in status and the availability of point of origin. The specific covariates retained in the model for this measure are listed below |      |
| The reference population used in the regression is the universe of discharges for states that participate in the HCUP State Inpatient [     | )ata |
| (SID) for the years 2008, a database consisting of 43 states and approximately 6 million pediatric discharges. The expected rate is         |      |
| computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (i.e.,         |      |
| hospital). The risk adjusted rate is computed using indirect standardization as the observed rate divided by the expected rate, multiple    | ied  |
| by the reference population rate.   |      |
| Specific covariates used for this measure:  |      |
| Birth Weight 1000 to 2499   |      |
| Birth Weight 750 to 999   |      |
| Birth Weight <500 to 749  |      |
| Modified DRG 1501 Neonates, died or transferred to another acute care   |      |
| facility  |      |
| Congenital anomalies category 1 Gastrointestinal  |      |
| Congenital anomalies category 5 Cardiovascular  |      |
| Congenital anomalies category 8 Other   |      |
| TRNSFER Transfer-in   |      |
| NOPOUB04 UB-04 Point-of-Origin Data Not Available Not applicable  |      |
| Level of Analysis: Facility   |      |
| Type of Measure: Outcome  |      |
| Data Source: Administrative claims  |      |
| Measure Steward: Agency for Healthcare Research and Quality   |      |
|   |      |
| STEERING COMMITTEE MEETING 11/29-30/2011  |      |
| Importance to Measure and Report: Y-25; N-0   |      |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)  |      |
| 1a. Impact: H-5; M-0; L-0; I-0; 1b. Performance Gap: H-4; M-1; L-0; I-0   |      |
| 1c. Evidence Quantity: H-4; M-1; L-0; I-0; Quality: H-2; M-3; L-0; I-0; Consistency: H-2; M-2; L-0; I-1                                     |      |
| Rationale:  |      |
|   |      |
|   |      |
| Increased incidence of infection in VLBW bables   |      |
| 2 Scientific Accentability of Maccure Dranartice, V 22, N 2   |      |
| 2. Scientific Acceptability of Measure Properties: Y-23; N-2  |      |

| ~   |
|---|
| 0478 Neonatal Blood Stream Infection Rate (NQI #3)         (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)         2a. Reliability: H-2; M-3; L-0; I-0 2b. Validity: H-1; M-4; L-0; I-0         Rationale:   |
| <ul> <li>Uses discharge billing data</li> <li>No chart based validation; user feedback assessed.</li> <li>Risk model includes transfers into hospital. Some recent changes to the measure due to harmonization efforts – AHRQ estimates has very little impact on mean rates or distribution</li> <li>Exclusions for specific bacteria only if present on admission</li> <li>ICD-9 to ICD-10 conversion in draft; ICD-10 has more specific codes for certain bacteria</li> <li>Includes larger babies who have certain characteristics as proxy for " likely to have been in NICU"</li> <li>Developer notes coding for mechanical ventilation is generally good as it is justification for longer length of stay</li> </ul> |
| <ul> <li>3. Usability: H-13; M-11; L-0; I-0</li> <li>(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)</li> <li>3a. Public Reporting: H-2; M-3; L-0; I-0</li> <li>3b. Ql: H-3; M-2; L-0; I-0</li> <li>Rationale: <ul> <li>Harmonized with new Joint Commission measure</li> <li>Transfers not a huge impact</li> </ul> </li> </ul>   |
| Transfers not a huge impact <b>4.</b> Feasibility: H-18; M-7; L-0; I-0      (a. Clinical data generated during one delivery the Electronic courses) to Support killing to incompare the delivery of the Electronic courses.   |
| <ul> <li>(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)</li> <li>4a. Byproduct of Care Processes: H-4; M-1; L-0; I-0</li> <li>4b. Electronic data sources: H-4; M-1; L-0; I-0</li> <li>4c. Suscep inaccuracies, consequences: H-2; M-3; L-0; I-0</li> <li>4d. Data collection strategy: H-4; M-1; L-0; I-0</li> <li>4d. Data collection strategy: H-4; M-1; L-0; I-0</li> <li>Based on administrative data.</li> </ul>   |
| Preliminary Assessment of Criteria Met/Suitable for Endorsement: Y-25; N-0<br>(All criteria met, but final recommendation pending further information and/or evaluation of related and competing measures)<br><u>Comments</u> :<br>• Uses discharge billing data  |
| Important patient safety-related outcome measure.   |
| 5. Related and Competing Measures ( <i>5a. Harmonization; 5b. Superior to competing measures</i> )<br>1731 Healthcare-associated bloodstream infections in newborns (Joint Commission)<br>303 Late sepsis or meningitis in neonates (risk-adjusted) (VON)<br>304 Late sepsis or meningitis in VLBW neonates (risk-adjusted) (VON)   |
| <u>Comments</u> :<br>The different data streams are important for different users: states, Medicaid, and purchasers do not have access to chart data and rely<br>on administrative data; Registry measures provide more clinical detail for the feedback/quality improvement program. The combined<br>coding and chart review of the Joint Commission is important for accreditation purposes.  |
| Steering Committee Recommendation for Endorsement: Y-10; N-8 to recommend both 478 and 1731 as harmonized measures with different data streams<br>Steering Committee members acknowledged the added burden of multiple measures on hospitals and struggled with evaluating competing measures for hospital-acquired infections. The Committee noted that the variety of users with different data capabilities justify multiple, harmonized measures at this time.  |
| Public & Member Comment<br>Comments included:   |

### 0478 Neonatal Blood Stream Infection Rate (NQI #3)

- Questions about the specifications
- Concerns about having three separate measures on hospital acquired infections and requests that the measures be harmonized.

Developer response: The developer clarified the specifications.

**Steering Committee:** Measure 1731 was created by The Joint Commission (TJC) when it selected five NQF-endorsed measures, including measure 478, for its Perinatal Core Set. <u>Measures 478 and 1731 are fully harmonized measures</u> within the limits of their data sources and measure 1731 is also harmonized with the other four measures in TJC Perinatal Core Set (0469 Elective Delivery < 39 weeks; 0471 Cesarean section; 0476 Antenatal Steroids; and 0480 Exclusive Breast Milk Feeding) for use in TJC's performance measurement programs. Measures 478 and 1731 differ from related measure 304 in that they also capture larger babies who experience in-hospital death; operating room procedure; mechanical ventilation; or transfers in less than 2 days of age. Measure 478 is based on administrative data and is collected in the HCUP State Inpatient Databases that are widely used by states.

The Committee understands the concerns about multiple related measures, but in the absence of head-to-head comparisons of the measures the Committee cannot make any judgments as to differences in reliability and validity. All three measures are widely used and each is useful to different user groups. After reviewing and discussing the comments, the Committee did not change its recommendation of all three measures.

| 1721 Health Care Associated Bloodstream Infections in Newborns   |
|--|
| 1731 Health Care-Associated Bloodstream Infections in Newborns New Measure   |
| <b>Description:</b> This measure assesses the number of staphylococcal and gram negative septicemias or bacteremias in high-risk         |
| newborns. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-01: Elective Delivery, |
| PC-02: Cesarean Section, PC-03: Antenatal Steroids, PC-05: Exclusive Breast Milk Feeding).   |
|  |
| Numerator Statement: Newborns with septicemia or bacteremia with an ICD-9-CM Other Diagnosis Codes for septicemias as defined in         |
| in Appendix A, Table 11.10.1 OR one or more ICD-9-CM Other Diagnosis Codes for newborn septicemia or bacteremia as defined in            |
| Appendix A, Table 11.10 and one diagnosis code for newborn bacteremia from Table 11.11 available at:                                     |
| http://manual.jointcommission.org  |
| Denominator Statement: Liveborn newborns with an ICD-9-CM Other Diagnosis Codes for birth weight between 500 and 1499g as                |
| defined in Appendix A, Table 11.12, 11.13 or 11.14 OR Birth Weight between 500 and 1499g OR an ICD-9-CM Other Diagnosis Codes            |
| for birth weight = 1500g as defined in Appendix A, Table 11.15, 11.16 or 11.17 OR Birth Weight = 1500g who experienced one or more       |
| of the following:  |
| o Experienced death  |
| o ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for major surgery as defined in Appendix A, Table                  |
| 11.18  |
| o ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for mechanical ventilation as defined in Appendix                  |
| A, Table 11.19   |
| o Transferred in from another acute care hospital or health care setting within 2 days of birth.   |
| Exclusions:  |
| <ul> <li>ICD-9-CM Principal Diagnosis Code for sepsis as defined in Appendix A, Table 11.10.2</li> </ul>                                 |
| ICD-9-CM Principal Diagnosis Code for liveborn newborn as defined in Appendix A, Table 11.10.3 AND ICD-9-CM Other                        |
| Diagnosis Codes for newborn septicemia or bacteremia as defined in Appendix A, Table 11.10   |
| • ICD-9-CM Other Diagnosis Codes for birth weight < 500g as defined in Appendix A, Table 11.20 OR Birth Weight < 500g                    |
| Length of Stay < 2 days OR > 120 days  |
| Enrolled in clinical trials  |
| Adjustment/Stratification: Statistical risk model Logistic regression  |
| Model Risk Factors:  |
| Intercept Intercept  |
| Birth Weight 1250g to 2499g  |
| Birth Weight 1000 to 1249g   |
| Birth Weight 500 to 999g   |
| Modified DRG Newborn Transfers Out or Died   |
| Congenital Anomaly Gastrointestinal Anomaly  |
| Congenital Anomaly Cardiovascular Anomaly  |
| Congenital Anomaly Other Anomaly   |
| Out-born Birth Newborns Transfers In Not applicable, the measure is not stratified.  |
| Level of Analysis: Facility, Population : National   |
| Type of Measure: Outcome   |
| Data Source: Administrative claims, Electronic Clinical Data, Paper Records  |
| Measure Steward: The Joint Commission  |
|  |
| STEERING COMMITTEE MEETING 11/29-30/2011   |
| Importance to Measure and Report: Y-20; N-4  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)   |
| 1a. Impact: H-3; M-1; L-0; I-0; 1b. Performance Gap: H-3; M-1; L-0; I-0  |
| 1c. Evidence Quantity: H-1; M-2; L-0; I-0; Quality: H-2; M-1; L-0; I-0; Consistency: H-2; M-1; L-0; I-0                                  |
| Rationale:   |
| Significant problem especially for VLBW infants  |
| <ul> <li>Infections increase LOS and costs</li> </ul>  |
| <ul> <li>Variable rates reported: 6-33%</li> </ul>   |
| <ul> <li>Very similar to measure 478 – harmonized within limits of data sources</li> </ul>   |
| - vorg similar to medisure +/o marmonized within innits of data sources  |
| 2. Scientific Acceptability of Measure Properties: Y-21; N-0   |
| (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)   |
| 2a. Reliability: H-1; M-3; L-0; I-0 2b. Validity: H-0; M-3; L-0; I-0   |
| NQF REVIEW DRAFT—DO NOT CITE OR QUOTE  |
| NQF Member Votes Due by February 27, 2012 by 6:00 PM ET  |
|  |

| NATIONAL QUALITY FORUM   |
|--|
| 1731 Health Care-Associated Bloodstream Infections in Newborns   |
| <ul> <li><u>Rationale</u>:         <ul> <li>Risk-adjusted outcome measure – not statistically significant results - Committee noted that measure implementers could change the reporting strategy such as using a 90% confidence interval rather than 95%</li> <li>Moderate reliability and validity</li> <li>Some coding issues noted.</li> </ul> </li> </ul>   |
| <ul> <li>3. Usability: H-9; M-12; L-0; I-0<br/>(<i>Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement</i>)</li> <li>3a. Public Reporting: H-2; M-1; L-0; I-1</li> <li>3b. QI: H-3; M-0; L-0; I-1</li> <li><u>Rationale</u>: <ul> <li>Improvement seen with use of the measure.</li> <li>Several similar measures for healthcare-acquired infection in newborns. Measure is harmonized with claims-based measure 478.</li> </ul> </li> </ul>  |
| <ul> <li>4. Feasibility: H-7; M-14; L-0; I-0</li> <li>(<i>4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented</i>)</li> <li>4a. Byproduct of Care Processes: H-3; M-1; L-0; I-0</li> <li>4b. Electronic data sources: H-1; M-2; L-0; I-1</li> <li>4c. Suscep inaccuracies, consequences: H-1; M-3; L-0; I-0</li> <li>4d. Data collection strategy: H-4; M-0; L-0; I-0</li> <li>Requires some chart abstraction</li> </ul>  |
| Preliminary Assessment of Criteria Met/Suitable for Endorsement: Y-21; N-0         (All criteria met, but final recommendation pending further information and/or evaluation of related and competing measures) <u>Comments</u> :         • This is an important, adverse outcome measure.   |
| 5. Related and Competing Measures ( <i>5a. Harmonization; 5b. Superior to competing measures</i> )<br>478 Nosocomial blood stream infections in neonates (NQI #3) (AHRQ)<br>303 Late sepsis or meningitis in neonates (risk-adjusted) (VON)<br>304 Late sepsis or meningitis in VLBW neonates (risk-adjusted) (VON)  |
| <ul> <li><u>Comments</u>:</li> <li>Committee had some difficulty comparing 478 and 1731 particularly for the exclusion of infection at the time of birth but once clarified were comfortable that the measure captured "health-care acquired" infections</li> <li>The different data streams are important for different users: states, Medicaid, and purchasers do not have access to chart data and rely on administrative data; Registry measures provide more clinical detail for the feedback/quality improvement program. The combined coding and chart review of the Joint Commission is important for accreditation purposes.</li> </ul>   |
| Steering Committee Recommendation for Endorsement: Y-10; N-8 to recommend both 478 and 1731 due to harmonized measures with different data streams         Rationale:         Steering Committee members acknowledged the added burden of multiple measures on hospitals and struggled with evaluating competing measures for hospital-acquired infections. The Committee noted that the variety of users with different data capabilities justify multiple, harmonized measures at this time.         Public & Member Comment         Comments included:         • Questions about the specifications         • Concerns about having three separate measures on hospital acquired infections and requests that the measures be |
| harmonized.  Developer response: The developer responded to the questions about the specifications.  |
| NQF REVIEW DRAFT—DO NOT CITE OR QUOTE<br>NQF Member Votes Due by February 27, 2012 by 6:00 PM ET   |

#### 1731 Health Care-Associated Bloodstream Infections in Newborns

**Steering Committee:** Measure 1731 was created by The Joint Commission (TJC) when it selected five NQF-endorsed measures, including measure 478, for its Perinatal Core Set. <u>Measures 478 and 1731 are fully harmonized measures</u> within the limits of their data sources and measure 1731 is also harmonized with the other four measures in TJC Perinatal Core Set (0469 Elective Delivery < 39 weeks; 0471 Cesarean section; 0476 Antenatal Steroids; and 0480 Exclusive Breast Milk Feeding) for use in TJC's performance measurement programs. Measures 478 and 1731 differ from related measure 304 in that they also capture larger babies who experience in-hospital death; operating room procedure; mechanical ventilation; or transfers in less than 2 days of age. Measure 478 is based on administrative data and is collected in the HCUP State Inpatient Databases that are widely used by states.

The Committee understands the concerns about multiple related measures, but in the absence of head-to-head comparisons of the measures the Committee cannot make any judgments as to differences in reliability and validity. All three measures are widely used and each is useful to different user groups. After reviewing and discussing the comments, the Committee did not change its recommendation of all three measures.



• Current performance – 15% infection rate

| 0304 Late Sepsis or Meningitis in Very Low Birth Weight (VLBW) Neonates (risk-adjusted)   |
|---|
| <ul> <li>A different measure from 478 and 1731 because it focuses on the high-risk, VLBW babies who have higher infection rates.<br/>Measures 478 and 1731 address all newborns.</li> </ul> |
| 2. Scientific Acceptability of Measure Properties: Y-26; N-0  |
| (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)  |
| 2a. Reliability: H-2; M-3; L-0; I-0 2b. Validity: H-1; M-4; L-0; I-0  |
| Rationale:  |
| Risk model slightly different for this population compared to the overall population in measure 303.  |
| 3. Usability: H-13; M-11; L-1; I-0  |
| (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)  |
| 3a. Public Reporting: H-2; M-2; L-1; I-0  |
| 3b. QI: H-4; M-1; L-0; I-0  |
| Rationale:  |
| <ul> <li>80% of VLBW infants in US enrolled in VON</li> </ul>   |
| A number of states have focused on this VLBW measure  |
| 4. Feasibility: H-11; M-14; L-1; I-0  |
| (4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences   |
| identified 4d. Data collection strategy can be implemented)   |
| 4a. Byproduct of Care Processes: H-5; M-0; L-0; I-0   |
| 4b. Electronic data sources: H-1; M-3; L-1; I-0   |
| 4c. Suscep inaccuracies, consequences: H-3; M-1; L-0; I-1   |
| 4d. Data collection strategy: H-3; M-1; L-0; I-1  |
| Rationale:  |
| 80% of VLBW babies born in the US are currently reported to the VON registry. The data is already collected with benchmarking and   |
| feedback to the participants. VON data is not public reported.  |
| Preliminary Assessment of Criteria Met/Suitable for Endorsement: Y-25; N-1  |
| (All criteria met, but final recommendation pending further information and/or evaluation of related and competing measures)<br>Comments:   |
| VLBW infants are an important subgroup with very high risk of infection   |
| 5. Related and Competing Measures (5a. Harmonization; 5b. Superior to competing measures)   |
| 478 Nosocomial blood stream infections in neonates (NQI #3) (AHRQ)  |
| 1731 Healthcare-associated bloodstream infections in newborns (Joint Commission)  |
| 303 Late sepsis or meningitis in neonates (risk-adjusted) (VON)   |
|   |
| Comments:   |
| 80% of VLBW infants are in VON registry; hospitals will continue participation  |
| VLBW infants a special population not captured independently in 478 or 1371 with high infection rates around 15%  |
| Steering Committee Recommendation for Endorsement: Y-9; N-8   |
| Rationale: The Committee agreed that this measure is addresses a special population not captured independently in 478 or 1731 with  |
| high infections rates (15%) but Committee members also note that VON data is not publicly available even though 80% of VLBW infants   |
| are included in the network.  |
| Public & Member Comment   |
| Comments included:  |
| Questions about the specifications  |
| <ul> <li>Concerns about having three separate measures on hospital acquired infections and requests that the measures be</li> </ul>   |
| harmonized.   |
| Concerns about the ability of EHRs to handle the measure.   |
| Developer:  |
| <ul> <li>VON measures are based on specific data items that require adherence to a clear definition of that item to ensure consistency</li> </ul>   |
| NQF REVIEW DRAFT—DO NOT CITE OR QUOTE   |
| NQF Member Votes Due by February 27, 2012 by 6:00 PM ET   |
|   |

#### 0304 Late Sepsis or Meningitis in Very Low Birth Weight (VLBW) Neonates (risk-adjusted)

across reporting centers and the interpretability of the measure across centers. As you mention, we believe these are critical to ensure the appropriateness, accuracy, and importance of the individual measures. Standard codes do not directly align with the VON measure definitions, and are also subject to data quality and reliability concerns.

• VON has been in discussions with various EHR providers, including Epic, regarding the feasibility of obtaining measures from electronic records. We welcome further discussions and are committed to working with EHR vendors to reduce the data collection burden while maintaining the quality of the data measures.

**Steering Committee:** The Committee agreed that measure 304 was a related HAI measure but is quite distinct in that it 1) focuses on a very-high risk population—VLBW infants with a infection rate of 15% (VLBW represents only 1.5% of all births); 2) the measure only applies to hospitals with NICUs (approximately 800-900 hospitals in the US); and uses clinical data for the Vermont Oxford Network registry that captures 80% of VLBW infants in the US.

The Committee understands the concerns about multiple related measures, but in the absence of head-to-head comparisons of the measures the Committee cannot make any judgments as to differences in reliability and validity. All three measures are widely used and each is useful to different user groups. After reviewing and discussing the comments, the Committee did not change its recommendation of all three measures.

| NATIONAL QUALITY FORUM  |      |
|---|------|
| 0480 PC-05 Exclusive Breast Milk Feeding  |      |
| Maintenance Measure<br>Description: This measure assesses the number of newborns exclusively fed breast milk feeding during the newborn's entire<br>nospitalization. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-01: Electiv<br>Delivery, PC-02: Cesarean Section, PC-03: Antenatal Steroids, PC-04: Health Care-Associated Bloodstream Infections in Newborn<br>Numerator Statement: Newborns that were fed breast milk only since birth<br>Denominator Statement: Single term liveborn newborns discharged from the hospital with ICD-9-CM Principal Diagnosis Code or<br>P-CM Other Diagnosis Codes for single liveborn newborn as defined in Appendix A, Table 11.20.1available at: | าร). |
| Admitted to the Neonatal Intensive Care Unit (NICU) at this hospital during the hospitalization   |      |
| ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for galactosemia as defined in Appendix A, Ta<br>IL21<br>ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for parenteral infusion as defined in Appendix   |      |
| Table 11.22         Experienced death         Length of Stay >120 days         Enrolled in clinical trials  | ,    |
| Documented Reason for Not Exclusively Feeding Breast Milk<br>Patients transferred to another hospital<br>ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for premature newborns as defined in Appendi<br>Table 11.23  | x A, |
| Adjustment/Stratification: No risk adjustment or risk stratification Not Applicable<br>Level of Analysis: Facility, Population : National<br>Type of Measure: Process<br>Data Source: Administrative claims, Electronic Clinical Data, Paper Records<br>Measure Steward: The Joint Commission   |      |
| STEERING COMMITTEE MEETING 11/29-30/2011<br>mportance to Measure and Report: Y-21; N-3<br>(1a. High Impact: 1b. Performance Gap, 1c. Evidence)<br>Ia. Impact: H-4; M-1; L-0; I-0; Ib. Performance Gap: H-4; M-1; L-0; I-0<br>Ic. Evidence Quantity: H-4; M-1; L-0; I-0; Quality: H-5; M-0; L-0; I-0; Consistency: H-5; M-0; L-0; I-0<br>Rationale:  |      |
| <ul> <li>Documented medical benefits to baby; some issues with intent and implementation of "exclusive"</li> <li>Exclusive breastfeeding during hospitalization and at discharge increases longer term breastfeeding</li> <li>Current performance = 41%</li> <li>Data presented on racial and ethnic disparities- large disparities; very susceptible to values of the patient population</li> <li>Large nursing component – a systems issue of the hospital environment</li> </ul>   |      |
| <ul> <li>Goal is not 100% Joint CommissionHealthy People 2010 set a 75% target</li> <li>2. Scientific Acceptability of Measure Properties: Y-22; N-2<br/>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-3; M-2; L-0; I-0 2b. Validity: H-5; M-0; L-0; I-0<br/>Rationale: <ul> <li>A Committee member noted that if the measure is "risk-adjusted" for race and educational level, 40% of the variance is</li> </ul> </li> </ul>   |      |

- A Committee member noted that if the measure is "risk-adjusted" for race and educational level, 40% of the variance is removed
- Measure is not stratified for disparities developers note lack of reliability in the data element for race needed for stratification. Some Committee members argued that "rules now exist" to assign race.
- Exclusions for NICU, HIV, multiple births, transfers, mom taking drugs or medications
- Sampling is allowed

### 3. Usability: H-16; M-6; L-2; I-0

(*Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement*) **3a.** Public Reporting: H-5; M-0; L-0; I-0

### 0480 PC-05 Exclusive Breast Milk Feeding

3b. QI: H-4; M-1; L-0; I-0

Rationale:

- Would also be good as a population -level measure communities can facilitate change in attitudes and cultural values
- Health benefits for the child and the mother
- The bar may be too high for some users consider intermediate process measures to facilitate adoption

### 4. Feasibility: H-9; M-12; L-3; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-4; M-1; L-0; I-0

4b. Electronic data sources: H-5; M-0; L-0; I-0

4c. Suscep inaccuracies, consequences: H-2; M-2; L-0; I-0

4d. Data collection strategy: H-3; M-2; L-0; I-0

Rationale:

- Possible encroachment on patient autonomy overzealous insistence on breastfeeding can alienate mothers
- Labor intensive to collect data unless data collection (feeding) forms are designed well
- An important measure for Medicaid

### Steering Committee Recommendation for Endorsement: Y-20; N-4

**Rationale:** Breast milk feeding confers many health benefits to mother and child. Current rates of breast milk feeding are low with much room for improvement. Supporting breast milk feeding requires strong systems support and significant nursing involvement.

### Public & Member Comment

Comments included:

- Many comments noting the benefits of breastfeeding, but raising concerns about "mandated breastfeeding". Commenters were also concerned about a woman's right to choose whether or not to breastfeed, and whether the measure would prevent women who chose not to breastfeed from receiving proper education and information on alternatives.
- Measure also received lots of supportive comments, stating that the health reasons for breastfeeding are well documented, that the measure would not mandate breastfeeding for all babies, and that performance for this measure is not expected to be at 100%.

### Steering Committee:

The Committee underscored the significant health benefits for newborns (reduction in otitis media, respiratory tract infections, atopic dermatitis, gastroenteritis, type 2 diabetes, sudden infant death syndrome, and obesity) and mother (decreased risk for type 2 diabetes, ovarian cancer, and breast cancer) conferred by breastfeeding and support all efforts to optimize maternal education, encouragement, and support to enable women to make the healthiest choices for herself and her child. The Committee agreed that improving support for mothers who wish to breastfeed does not equal removing a choice. The Committee acknowledged that the target for this measure is not 100% and that the potential unintended consequences of "inappropriate coercion" should be monitored.

The Committee noted that current performance is quite low at 40% with much room for improvement. Both the Committee and the developer agreed that the purpose of the measure is to eliminate impediments to breastfeeding. According to the CDC, (<u>http://www.cdc.gov/breastfeeding/data/reportcard.htm</u>) "less than 5% of U.S. infants are born in Baby-Friendly hospitals, a global designation that indicates best practices in maternity care to support breastfeeding mothers. The hospital period is critical for mothers and babies to learn to breastfeed, and hospitals need to do more to support them. Birth facility policies and practices significantly impact whether a woman chooses to start breastfeeding and how long she continues to breastfeed." The Committee recommends additional process measures to assist facilities in improving support for breastfeeding.

The Committee also noted that public policies impact support of breastfeeding. The Committee pointed to external barriers to breast feeding include the Family Leave Act providing mothers only with up to 12 weeks of unpaid, job-protected leave; health insurers may not cover the costs of breast pumps, donor human milk for at risk preterm infants, or a follow up nursing visit at home to facilitate breast feeding success; and most mothers are out of the hospital before breastfeeding is well established. While the hospital maternity stay is such a short, but critical, window of time, and hospital routine and culture may undermine women's ability to breast feed, this is also a major social issue that has long-term health care implications. The Committee strongly encourages additional public policies to encourage and support women's ability to breast feed.

0480 PC-05 Exclusive Breast Milk Feeding The Committee agreed to maintain their recommendation of the measure.

| NATIONAL QUALITY FORUM  |
|---|
| 0483 Proportion of Infants 22 to 29 Weeks Gestation Screened for Retinopathy of Prematurity.  |
| Maintenance Measure<br>Description: Proportion of infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for<br>retinopathy of prematurity (ROP) screening by the American Academy of Pediatrics (AAP) and who received a retinal examination for<br>ROP prior to discharge.  |
| Numerator Statement: Number of infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for ROP screening by the AAP and who received a retinal exam for ROP prior to discharge.<br>Denominator Statement: All eligible infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for ROP screening by the AAP.  |
| <ul><li>Exclusions: 1. Infants outside the gestational age range of 22 to 29 weeks.</li><li>2. Outborn infants admitted to the reporting hospital more than 28 days after birth.</li></ul>  |
| <ol> <li>Outborn infants who have been home prior to admission.</li> <li>Infants who die in the delivery room or initial resuscitation area prior to<br/>admission to the neonatal intensive care unit.</li> </ol>  |
| <ol> <li>Infants not in the reporting hospital at the postnatal age recommended for<br/>ROP screening by the AAP.</li> <li>Adjustment/Stratification: Stratification by risk category/subgroup N/A Reports are stratified by gestational age, birth location and birth</li> </ol>   |
| weight category.<br>Level of Analysis: Facility<br>Type of Measure: Process   |
| Data Source: Administrative claims, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records   |
| Measure Steward: Vermont Oxford Network   |
| <ul> <li>STEERING COMMITTEE MEETING 11/29-30/2011</li> <li>Importance to Measure and Report: Y-21; N-4</li> <li>(1a. High Impact: 1b. Performance Gap, 1c. Evidence)</li> <li>1a. Impact: H-4; M-1; L-0; I-0; 1b. Performance Gap: H-0; M-4; L-1; I-0</li> <li>1c. Evidence Quantity: H-4; M-0; L-0; I-1; Quality: H-2; M-2; L-1; I-0; Consistency: H-3; M-2; L-0; I-0</li> <li>Rationale: <ul> <li>Screening recommended by AAP and AAO</li> <li>VON data – moderate opportunity for improvement (not published data); 79% performance at the 10<sup>th</sup> percentile.</li> <li>APP recommendation up to 30 6/7 weeks but VON eligibility criteria limits measure to 29 6/7 weeks</li> <li>Larger babies are often discharged or transferred prior to appropriate time of screening and may be lost to follow-up; &lt; 29 weeks targets babies who are still in hospital when screening should occur</li> <li>Risk is higher at lower gestational ages</li> </ul> </li> </ul> |
| <ul> <li>2. Scientific Acceptability of Measure Properties: Y-23; N-2</li> <li>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-4; M-1; L-0; I-0 2b. Validity: H-5; M-0; L-0; I-0</li> <li>Rationale:</li> </ul>  |
| <ul> <li>Exclusion rate 21-24%; unknown how big the 30-32 weeks group recommended for screening that is not captured</li> <li>There are a small number of babies that are too sick to be screened at the appropriate time</li> <li>Credit is given for screening at whatever gestational age – not necessarily when recommended by AAP</li> <li>Excludes outborn infants &gt;28 days due to VON eligibility criteria</li> </ul>   |
| <ul> <li>3. Usability: H-11; M-13; L-1; I-0</li> <li>(<i>Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement</i>)</li> <li>3a. Public Reporting: H-2; M-3; L-0; I-0</li> <li>3b. Ql: H-4; M-1; L-0; I-0</li> <li><u>Rationale</u>:</li> </ul>  |
| <ul> <li>Mainly used for internal QI. Hospital may share their VON data at their discretion.</li> <li>The measure is used in California Perinatal Quality Care Collaborative and is reported to the state.</li> <li>Questions regarding transition of this measure from registry to wider use – limited by registry criteria</li> </ul>   |

#### 0483 Proportion of Infants 22 to 29 Weeks Gestation Screened for Retinopathy of Prematurity.

- No public reporting known
- Does not address whether appropriate follow-up was done after screening.

### 4. Feasibility: H-15; M-9; L-1; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

4a. Byproduct of Care Processes: H-5; M-0; L-0; I-0

4b. Electronic data sources: H-4; M-1; L-0; I-0

4c. Suscep inaccuracies, consequences: H-3; M-2; L-0; I-0

4d. Data collection strategy: H-5; M-0; L-0; I-0

Rationale:

• Currently used by VON registry participants. Clinical data is submitted to the registry.

#### Steering Committee Recommendation for Endorsement: Y-23; N-2

**Rationale:** Appropriate screening for retinopathy allows intervention to optimize vision. Although the data is not publicly available, the majority of hospitals with Level 3 NICUs participate in the VON registry.

### Public & Member Comment

Comments included:

- A commenter raised concerns noting that their internal data (submitted for publication) does not support the added measurement burden.
- Another commenter requested clarification on the exclusion criteria, stating that the exclusions "Outborn infants admitted to the reporting hospital more than 28 days after birth" and "Outborn infants who have been home prior to admission" do not appear aligned

**Steering Committee:** The Committee agreed the data mentioned by the commenter should be reviewed after it is published, and that it should be taken into consideration during annual updates or maintenance review. The Committee also noted that some high-performing hospitals may have very little room for improvement but the Vermont Oxford Network (VON) data indicates that more than 23% percent of infants at 29 weeks gestation are not screened before hospital discharge. The developer clarified the exclusions, explaining that they pertain to VON's data collection criteria. The Committee did not change their recommendation of the measure.

### MEASURES NOT RECOMMENDED

| 0479 Birth Dose of Hepatitis B Vaccine and Hepatitis B Immune Globulin for Newborns of Hepatitis B Surface Antigen (HBsAg)<br>Positive Mothers  |
|---|
| Maintenance Measure (previously time-limited endorsement)         Description: Percentage of infants born to hepatitis B surface antigen (HBsAg)-positive mothers who receive a birth dose of hepatitis B virus (HBV) vaccine and hepatitis B immune globulin (HBIG)         Numerator Statement: Number of infants born to HBsAg positive mothers who receive a birth dose of HBV vaccine and HBIG upon delivery         Denominator Statement: Number of infants born to mothers who tested positive for HBsAg during prenatal screening or upon admission to the hospital for delivery         Exclusions: Pregnancies of HBsAg positive mothers which result in any one of the following: stillbirths, voluntary abortions, miscarriages         Adjustment/Stratification: No risk adjustment or risk stratification. Given a large enough population, this measure does not require stratification for calculation. Stratification is only applicable when calculating estimates for specific populations. At minimum, the facility where HBIG and HBV vaccine was administered to the infant would be a variable for stratification. 'Facility' is an appropriate stratification variable due to the policies specific to the facility (e.g., birth hospital) which would have specific policies and/or standing orders to the administration of the HBIG and HBV vaccine.         Level of Analysis: Facility       Type of Measure: Process         Data Source: Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Laboratory, |
| Electronic Clinical Data : Pharmacy, Electronic Clinical Data : Registry, Paper Records<br>Measure Steward: California Department of Public Health  |
| <ul> <li>STEERING COMMITTEE MEETING 11/29-30/2011</li> <li>Importance to Measure and Report: Y-6; N-20 <ul> <li>(1a. High Impact: 1b. Performance Gap, 1c. Evidence)</li> </ul> </li> <li>1a. Impact: H-2; M-1; L-1; 1b. Performance Gap: H-0; M-1; L-4; I-0</li> <li>1c. Evidence Quantity: H-3; M-0; L-0; I-2; Quality: H-3; M-1; L-0; I-1; Consistency: H-3; M-0; L-0; I-2</li> <li>Rationale: <ul> <li>In California &gt;97% newborns receive it – translates to about 60 missed per year; uncertain about generalizability for national use – California has large Asian population at higher risk</li> <li>Not 100% preventive for vertical transmission</li> <li>More or less useful depending on population – regional differences; differences in carriers of Hepatitis B e-antigen –more likely to transmit</li> <li>CDC priority – highly preventive action</li> <li>Small impact; small opportunity; already recommended measure 475 – this measure adds little additional benefit</li> </ul> </li> </ul>   |
| Steering Committee Recommendation for Endorsement: Did not pass Importance criteria<br>Rationale: The Committee noted a small impact and small opportunity for improvement. The immunization component is already<br>covered in measure 475. This measure adds little additional benefit.   |
| <ul> <li>Public &amp; Member Comment Comments included: <ul> <li>The measure developer and 30 other stakeholders requested reconsideration of 479.</li> <li>Commenters raised concerns about the disparities in care for babies born to HBsAg positive mothers; about the long-term implications of not measuring HBIG administration from a quality of care perspective; and the long-term implications of not measuring HBIG administration to prevent Hepatitis B infection (HBV).</li> <li>The Immunization Action Coalition submitted data noting that of the 24,000 born to mothers who are chronically infected, this measure could prevent an estimated 9,100 infants from developing chronic HBV, including preventing an estimated 2,300 from dying of liver failure or liver cancer as adults.</li> <li>Other commenters noted that the CDC estimates that 1000 newborns a year are infected with HBV.</li> <li>Multiple comments noted that this measure would help achieve one of the primary goals of the DHHS "Action Plan for the</li> </ul> </li> </ul>  |

# 0479 Birth Dose of Hepatitis B Vaccine and Hepatitis B Immune Globulin for Newborns of Hepatitis B Surface Antigen (HBsAg) Positive Mothers

#### Prevention, Care and Treatment of Viral Hepatitis".

**Steering Committee:** The Committee noted that this is a very regional issue, and with measure *0475: Hep B vaccine coverage among all live newborn infants prior to hospital or birthing facility discharge* in place, the additional impact of this measure would be small and highly variable among states. This measure addresses only babies born to HBsAg positive mothers. In 2009 in California, the state with the largest number of maternal cases 2077 of 2138 infants, (97.1%) received the first dose of the HBV vaccine and the HBIG within 24 hours of birth. The developer argued that since HBV is a preventable disease every effort should be made to reach 100% compliance. The Committee agreed with the importance of the issue but suggested that with a small gap in current performance a national quality measure may not be the right approach to capture the few babies that are being missed. The Committee pointed to CDC's funded state, local, and territorial <u>Perinatal Hepatitis B Prevention Coordinators</u> that focus on preventing perinatal transmission of HBV. After reviewing the comments and listening to the measure developer, the Committee voted not to change their recommendation against endorsement of the measure (Yes-5 No-17).

#### 0481 First Temperature Measured Within One Hour of Admission to the NICU.

#### Maintenance Measure

**Description:** Percent of NICU admissions with a birth weight of 501-1500g with a first temperature taken within 1 hour of NICU admission.

Numerator Statement: Infants 501 to 1500 grams with first temperature taken within 1 hr of NICU

admission

**Denominator Statement:** Infants whose birth weight is between 501 and 1500 grams who are admitted to a NICU in the reporting hospital.

Exclusions: 1. Infants outside the birth weight range 501 to 1500 grams.

2. Outborn infants admitted more than 28 days after birth.

3. Outborn infants who have been home prior to admission.

4. Infants not admitted to the NICU.

Adjustment/Stratification: No risk adjustment or risk stratification N/A The measure is separately determined by birth location (inborn, outborn), as well for all eligible infants. The measure is reported by birth weight category (four levels and 10 levels), by gestational age and gestational age category (five levels) and by birth location (inborn, outborn).

Level of Analysis: Facility

Type of Measure: Process

**Data Source:** Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records **Measure Steward:** Vermont Oxford Network

### STEERING COMMITTEE MEETING 11/29-30/2011

Importance to Measure and Report: Y-4; N-21

(1a. High Impact: 1b. Performance Gap, 1c. Evidence)

1a. Impact: H-3; M-2; L-0; I-0; 1b. Performance Gap: H-2; M-0; L-3; I-0

1c. Evidence Quantity: H-2; M-1; L-1; I-1; Quality: H-3; M-1; L-0; I-1; Consistency: H-3; M-1; L-0; I-1 Rationale:

- Little performance gap (98% performance) though should be 100%
- Standard of care to take vital signs
- Not a challenging performance measure

Steering Committee Recommendation for Endorsement: Did not pass importance criteria

Rationale: The Committee noted this basic assessment measure has little opportunity for improvement.

### Public & Member Comment

Comments included:

• No comments were received for this measure.

| 0400 First NICH Terresenture 24 demons Continuede  |
|--|
| 0482 First NICU Temperature < 36 degrees Centigrade  |
| Maintenance Measure  |
| Description: Proportion of infants with birth weights between 501 to 1500 grams with first temperature measured within one hour of                     |
| admission to the neonatal intensive care unit (NICU) below 36 degrees centigrade.  |
| Numerator Statement: Infants whose birth weight is between 501-1500 grams and whose temperature first measured within one hou                          |
| of admission to the NICU and is less than 36 degrees centigrade.   |
| Denominator Statement: Number of infants with birth weights between 501 and 1500 grams whose temperature was measured within                           |
| one hour of admission to the NICU.   |
| Exclusions: 1. Infants outside the birth weight range 501 to 1500 grams.   |
| 2. Outborn infants admitted more than 28 days after birth.   |
| 3. Outborn infants who have been home prior to admission.  |
| 4. Infants not admitted to the NICU.   |
| 5. Infants whose temperature is not measured within one hour of admission to the   |
| NICU.  |
| Adjustment/Stratification: No risk adjustment or risk stratification N/A The measure is separately determined by birth location (inbor                 |
| outborn), as well for all eligible infants. The measure is reported by birth weight category (four levels and 10 levels), by gestational ag            |
| and gestational age category (five levels) and by birth location (inborn, outborn).  |
| Level of Analysis: Facility  |
| Type of Measure: Outcome   |
| Data Source: Administrative claims, Electronic Clinical Data : Registry, Paper Records   |
| Measure Steward: Vermont Oxford Network  |
| STEERING COMMITTEE MEETING 11/29-30/2011   |
| Importance to Measure and Report: Y-19; N-7  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)   |
| 1a. Impact: H-5; M-0; L-0; I-0; 1b. Performance Gap: H-5; M-0; L-0; I-0  |
| 1c. Evidence Quantity: H-1; M-4; L-0; I-0; Quality: H-1; M-4; L-0; I-0; Consistency: H-3; M-2; L-0; I-0  |
| Rationale:   |
| <ul> <li>Intermediate outcome; scant literature on long-term outcomes – lower temps associated with increased late sepsis and<br/>mortality</li> </ul> |
| 5  |
| Target value questioned: WHO recommendations 36 vs. 36.5 degrees   |
| Action is prevention of heat loss  |
| 2. Scientific Acceptability of Measure Properties: Y-8; N-18 as written; Y-7; N-18 if threshold changed to <36.5                                       |
| (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)   |
| 2a. Reliability: H-4; M-1; L-0; I-0 2b. Validity: H-3; M-2; L-0; I-0   |
| Rationale:   |
| Target value dispute 36 vs. 36.5 degrees   |
| <ul> <li>Method of taking temperature not standardized – may be axillary, rectal or skin – not specified; variation in result depending</li> </ul>     |
| method of taking temperature; are different methods systematically different? Should different methods have different                                  |
| thresholds? Biggest concern for validity of the measure. No guidance from AAP or WHO on standard method.   |
| Staaring Committee Decommondation for Endercoment. Did not need Colontific Accontability, which is required for  |
| Steering Committee Recommendation for Endorsement: Did not pass Scientific Acceptability, which is required for  |
| endorsement  |
| Rationale:   |
| Dispute over temperature target  |
| Lack of standardization on method of taking temperature; different methods are known to give different results   |
| Public & Member Comment  |
| Comments included:   |
| No comments were received for this measure.  |
|  |

| 0000 Lata Canada an Manda                                | and the Manual of Alaba and and   |
|--|---|
|  | gitis in Neonates (risk-adjusted)   |
| Maintenance Measure                                      |   |
| weight infants, other infants                            | ate and standardized morbidity ratio for nosocomial bacterial infection after day 3 of life for very low birth<br>who are admitted to a neonatal intensive care unit within 28 days of birth and other infants who die in a |
| hospital within 28 days of bir                           |   |
|  | ible infants with one or more of the following criteria:  |
|  | en. A bacterial pathogen is recovered from a blood and/or cerebral spinal fluid culture obtained after Day 3  |
| of life.<br>OR   |   |
|  | tive Stephylococcus. The infant has all 2 of the following:   |
|  | tive Staphylococcus. The infant has all 3 of the following:<br>hylococcus is recovered from a blood culture   |
|  | ntral line, or peripheral blood sample and/or is  |
|  | pinal fluid obtained by lumbar puncture,  |
| ventricular tap or ventricu                              |   |
|  | neralized infection (such as apnea, temperature   |
|  | ance, worsening respiratory distress or   |
| hemodynamic instability).                                |   |
|  | days of intravenous antibiotics after the above   |
|  | the infant died, was discharged, or transferred   |
| prior to the completion of                               | 5 days of intravenous antibiotics, this   |
| condition would still be me                              | et if the intention were to treat for 5 or more   |
| days.  |   |
|  | ligible infants who are in the reporting hospital after day 3 of life.  |
|  | ts who do not meet eligibility criteria for birth weight, gestational age or NICU admission. Exclude infants  |
|  | ransferred or die prior to day 3 of life.   |
|  | Statistical risk model: The risk adjustment process begins by using logistic regression to model the  |
|  | several case mix variables: gestational age and its quadratic term, APGAR score at 1 minute, maternal race,   |
| gestational age (Yes/No).                                | (Yes/No), vaginal delivery (Yes/No), birth location (Inborn/Outborn), major birth defect (Yes/No) and small for   |
|  | systematic variation" associated with the hospital standardized morbidity ratios (SMRs) using the method  |
|  | Hills (Martuzzi M and Hills M, Estimating the degree of heterogeneity between event rates using likelihood,   |
|  | (1995). This method assumes that the SMRs are distributed gamma, and that deviations from the gamma   |
|  | ith random variation. The systematic variation is used to "shrink" center SMR values and their confidence   |
|  | of infants reported. The values for centers with a smaller number of infants shrink more toward the mean of   |
|  | vith more infants. The adjusted rate for the hospital is shrunken using the calculated measure of systematic  |
| variation.   | , , , , , , , , , , , , , , , , , , ,   |
| The shrinkage method descr                               | ibed above is the "gamma-Poisson" approach to filtering random variation associated with Nosocomial   |
|  | adjusted indicator of performance. This approach has been used in other settings for documenting hospital   |
|  | pson J et al, Analysing differences in clinical outcomes between hospitals, Qual Saf Health Care, 12, 257-  |
| 262 (2003). N/A  |   |
| Level of Analysis: Facility                              |   |
| Type of Measure: Outcome                                 |   |
| Data Source: Electronic Clir<br>Measure Steward: Vermont |   |
| weasure steward: vermont                                 |   |
| STEERING COMMITTEE M                                     | FFTING 11/29-30/2011  |
| Importance to Measure and                                |   |
| (1a. High Impact: 1b. Perfor                             |   |
|  | 0; 1b. Performance Gap: H-4; M-1; L-0; I-0  |
| 1c. Evidence Quantity: H-2;                              | M-1; L-0; I-1; Quality: H-2; M-2; L-0; I-0; Consistency: H-4; M-0; L-0; I-0   |
| Rationale:   |   |
|  | nt than AHRQ measure 478; includes meningitis   |
| <ul> <li>Different case findi</li> </ul>                 | ing criterio  |

- Different case finding criteria
- Current infection rate at 3%

| NATIONAL QUALITY FORUM  |       |
|---|-------|
| 0303 Late Sepsis or Meningitis in Neonates (risk-adjusted)  |       |
| <ul> <li>2. Scientific Acceptability of Measure Properties: Y-20; N-6 (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-2; M-3; L-0; I-0 2b. Validity: H-2; M-2; L-1; I-0 Rationale: <ul> <li>How important are the many bacteria?</li> <li>What is the data quality of the registry?</li> <li>Shrinkage effect in the risk model;</li> <li>Risk model includes race as a co-factor - will mask disparities; VON says race doesn't have much impact, they are considering removing</li> <li>Disparities are seen at hospital-level: hospitals in areas with large minority population do poorly for all patients</li> <li>VON has not systematically considered the impact of LOS on rates</li> <li>Back transfer from another hospital with low infection rates or hospitals with high mortality may do well on measure becaus there is less exposure/opportunity for infection.</li> </ul> </li> </ul> | 5e    |
| <ul> <li>3. Usability: H-9; M-14; L-3; I-0</li> <li>(<i>Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvem</i></li> <li>3a. Public Reporting: H-1; M-3; L-1; I-0</li> <li>3b. Ql: H-4; M-1; L-0; I-0</li> <li>Rationale: <ul> <li>Hospitals are over-burdened with infection measures</li> </ul> </li> </ul>   | nent) |
| <ul> <li>4. Feasibility: H-6; M-17; L-3; I-0 <ul> <li>(<i>4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c.Susceptibility to inaccuracies/ unintended consequence identified 4d. Data collection strategy can be implemented</i>)</li> <li>4a. Byproduct of Care Processes: H-4; M-1; L-0; I-0</li> <li>4b. Electronic data sources: H-2; M-2; L-1; I-0</li> <li>4c. Suscep inaccuracies, consequences: H-2; M-2; L-1; I-0</li> <li>4d. Data collection strategy: H-4; M-1; L-0; I-0</li> <li>Rationale: <ul> <li>Bacteria specifications require intense chart review</li> <li>Demonstrated feasibility for VON members; unclear for non-members</li> </ul> </li> </ul></li></ul>  | 5     |
| Preliminary Assessment of Criteria Met/Suitable for Endorsement: Y-23; N-3         (All criteria met, but final recommendation pending further information and/or evaluation of related and competing measures) <u>Comments</u> :         • Overlap with 478 and 1731 <b>5. Related and Competing Measures</b> ( <i>5a. Harmonization; 5b. Superior to competing measures</i> )         478 Nosocomial blood stream infections in neonates (NQI #3) (AHRQ)         1731 Healthcare-associated bloodstream infections in newborns (Joint Commission)         304 Late sepsis or meningitis in VLBW neonates (risk-adjusted) (VON)  |       |
| <ul> <li>Comments:</li> <li>Hospitals select which measure meets their needs: Level 3 centers generally use VON; Level 1 and 2 centers will use a different measure</li> <li>VON registry data is not publicly reported or used for accountability except if the hospital chooses to share the data</li> <li>Overlaps with 478 and 1371</li> </ul>  |       |
| <ul> <li>Steering Committee Recommendation for Endorsement: Y-3; N-14</li> <li>Rationale: <ul> <li>VON registry data are not publicly reported or used for accountability except if the hospital chooses to share the data</li> <li>Overlaps with 478 and 1371</li> </ul> </li> </ul>   |       |

0303 Late Sepsis or Meningitis in Neonates (risk-adjusted)

Public & Member Comment

- Comments included:
  - No comments were received for this measure.

| 0502 Pregnancy Test for Female Abdominal Pain Patients.  |
|--|
| Maintenance Measure (previously time-limited endorsement)<br>Description: Percentage of female patients aged 14 to 50 who present to the emergency department (ED) with a chief complaint of<br>abdominal pain for whom a pregnancy test ordered   |
| Numerator Statement: Number of patients in the denominator who have a pregnancy test (urine or serum) ordered in the ED Denominator Statement: All women, ages 14 – 50 years old, who present to the ED with a chief complaint of abdominal pain.<br>Exclusions: i. Females for whom pregnancy is already documented or reported (verbal report by patient is acceptable).<br>ii. Females with documented or reported hysterectomy (verbal report by patient is acceptable). |
| <ul> <li>iii. Females documented or reported to be post-menopausal (verbal report by patient is acceptable).</li> <li>iv. Patient refusal</li> </ul>   |
| <ul> <li>v. Patients who do not complete their ED evaluation (Left before completion, Left AMA, etc.)</li> <li>Adjustment/Stratification: No risk adjustment or risk stratification n/a n/a</li> <li>Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Facility</li> </ul>  |
| Type of Measure: Process   |
| Data Source: Administrative claims, Electronic Clinical Data : Electronic Health Record, Paper Records<br>Measure Steward: American College of Emergency Physicians  |
| STEERING COMMITTEE MEETING 11/29-30/2011<br>Importance to Measure and Report: Y-18; N-8  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)   |
| <ul> <li>1a. Impact: H-4; M-1; L-1; I-0; 1b. Performance Gap: H-2; M-2; L-2; I-0</li> <li>1c. Evidence Quantity: H-0; M-2; L-4; I-0 Quality: H-0; M-3; L-3; I-0; Consistency: H-1; M-3; L-2; I-0</li> <li>Rationale:</li> </ul>  |
| <ul> <li>Limited data on current performance; a Committee member reported her unpublished data for women aged 11-50 years in 8 hospitals (180,000 patients per year) – current performance about 45%</li> </ul>  |
| <ul> <li>The selection of "test ordered" rather than "test performed" was questioned. Developer reported that "ordered" is used<br/>because it is specified as such for PQRS program</li> </ul>  |
| <ul> <li>Incidence of ectopic in the literature about 1%; higher in some populations</li> <li>No data on relationship to outcomes; death from ectopic pregnancy is falling; also good to screen prior to CT imaging for abdominal pain, but no direct evidence</li> </ul>  |
| <ul> <li>2. Scientific Acceptability of Measure Properties: Y-17; N-9</li> <li>(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)</li> <li>2a. Reliability: H-1; M-5; L-0; I-0 2b. Validity: H-1; M-4; L-1; I-0</li> <li>Rationale:</li> </ul>   |
| <ul> <li>Unclear on reliability and validity; different rates from different data sources were presented by the develop (hospital chart review compared to electronic data);</li> </ul>  |
| 3. Usability: H-9; M-11; L-2; I-4<br>( <i>Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement</i> )<br>3a. Public Reporting: H-2; M-3; L-1; I-0<br>3b. QI: H-2; M-2; L-1; I-0<br><u>Rationale</u> :   |
| Easily captured in EHRs  |
| <ul> <li>4. Feasibility: H-1; M-14; L-8; I-3</li> <li>(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)</li> <li>4a. Byproduct of Care Processes: H-3; M-2; L-1; I-0</li> </ul>   |
| <ul> <li>4b. Electronic data sources: H-1; M-4; L-1; I-0;</li> <li>4c. Suscep inaccuracies, consequences: H-0; M-4; L-2; I-0</li> <li>4d. Data collection strategy: H-1; M-3; L-2; I-0</li> </ul>  |
| <ul> <li><u>Rationale</u>:</li> <li>Easier with EHR; burdensome chart review</li> </ul>  |
| Steering Committee Recommendation for Endorsement: Y-12; N-14  |

### 0502 Pregnancy Test for Female Abdominal Pain Patients.

### Rationale:

• Limited data on impact and relationship to outcomes - need more studies on benefit of measure

### Public & Member Comment

Comments included:

• The developer requested that the Committee review and reconsider its recommendation of this measure, as it passed all of the four NQF evaluation criteria.

**Steering Committee:** The Committee pointed to the number of medium to low ratings on the sub-criteria. The Committee agreed to reevaluate the measure after review of the transcript of the original Steering Committee and workgroup discussions.

Re-vote: Importance: Yes – 16 No-10 Reliability and Validity: High – 2 Moderate-14 Low-8 Insufficient – 1 Usability: High – 5 Moderate-15 Low-4 Insufficient – 0 Feasibility: High – 4 Moderate-15 Low-5 Insufficient – 0 Recommendation for endorsement: Yes – 10, No-16

On re-evaluation, the Committee again decided not to recommend the measure. Although the Committee determined the measure passed the Importance criteria by a small margin, members voiced concerns over lack of data on ectopic disease burden; little data on current performance and gap; and specifically, no data on how many ectopic pregnancies are identified by routine urine pregnancy testing in the ER and impact on outcomes. Committee members noted that the ratings on the other criteria again had substantial numbers of medium or low votes citing concerns with the conflicting information presented on reliability and validity, and burden of data collection particularly for the exclusions.

| NATIONAL QUALITY FORUM   |
|--|
| 0582 Diabetes and Pregnancy: Avoidance of Oral Hypoglycemic Agents   |
| Maintenance Measure  |
| <b>Description:</b> This measure identifies pregnant women with diabetes who are not taking an oral hypoglycemic agent.  |
| Numerator Statement: Patients in the denominator who are not taking an oral hypoglycemic agent.  |
| Denominator Statement: Pregnant women with a diagnosis of non-gestational diabetes prior to pregnancy.   |
| Exclusions: No claims for gestational diabetes anytime after pregnancy onset date, no diagnosis of miscarriage or abortion anytime after the prognancy apact date, no claims for polycyclic quarks when determining pro prognancy diabetes diagnosis         |
| after the pregnancy onset date, no claims for polycystic ovaries when determining pre-pregnancy diabetes diagnosis.<br>Adjustment/Stratification: No risk adjustment or risk stratification. We have developed a hierarchical logistic regression model with |
| expert biostatisticians at the Johns Hopkins School of Public Health that enables one to produce a probability distribution around a point   |
| estimate of the "quality score" for a given physician. The measure specifications do not require the results to be stratified.   |
| Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Health Plan, Integrated Delivery System, Population : Community,  |
| Population : County or City  |
| Type of Measure: Process   |
| Data Source: Administrative claims, Electronic Clinical Data : Pharmacy, Other   |
| Measure Steward: Resolution Health, Inc.   |
|  |
| STEERING COMMITTEE MEETING 11/29-30/2011   |
| Importance to Measure and Report: Y-1; N-24  |
| (1a. High Impact: 1b. Performance Gap, 1c. Evidence)   |
| 1a. Impact: H-3; M-0; L-1; I-1; 1b. Performance Gap: H-0; M-3; L-0; I-2  |
| 1c. Evidence (based on decision logic): NA IF a Health Outcome, rationale supports: Y-; N-   |
| Quantity: H-2; M-1; L-1; I-0; Quality: H-2; M-1; L-1; I-0; Consistency: H-3; M-0; L-1; I-0   |
| Rationale:   |
| Only captures women with diabetes before pregnancy: small impact   |
| • Evolving evidence that some oral hypoglycemics may be appropriate for some women (metformin and glyburide) – developer   |
| adjusted the measure after the preliminary Workgroup discussion and removed metformin and glyburide from the list of oral  |
| hypoglycemic agents that would trigger the measure   |
| <ul> <li>Not a large performance gap – 81–100% performance in health plans</li> </ul>  |
| <ul> <li>Does not address the appropriate use of insulin and glycemic control in pregnancy</li> </ul>  |
| Steering Committee Recommendation for Endorsement: Did not pass Importance criteria, which is required for endorsement   |

Steering Committee Recommendation for Endorsement: Did not pass Importance criteria, which is required for endorsement Rationale:

• Small impact, with changing evidence; need better measures on appropriate management of diabetes in pregnancy

#### Public & Member Comment Comments included:

• No comments were received for this measure.

#### 1769 Adverse Outcome Index

#### New Measure

Description: The rate and severity of adverse events in the obstetric population during their delivery hospitalization Numerator Statement: Any delivery with one or more of the adverse events. Denominator Statement: Total deliveries occurring during the time frame under review. Exclusions: None Adjustment/Stratification: No risk adjustment or risk stratification Level of Analysis: Clinician : Team, Facility Type of Measure: Composite Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records Measure Steward: Beth Israel Deaconess Medical Center STEERING COMMITTEE MEETING 11/29-30/2011 Importance to Measure and Report: Y-7; N-17 (1a. High Impact: 1b. Performance Gap, 1c. Evidence)

Rationale:

- Outcome measures are not risk-adjusted ٠
- Seven of ten component measures were not rated as meeting the endorsement criteria – see individual evaluations
- Six of the ten components provide incentives for use of Cesarean section •
- Not ready for public reporting and accountability purposes •
- Computed in three ways: the Adverse Outcome Index (AOI) is a simple rate: percent of deliveries complicated by one or more of the 10 adverse events described above. The Weighted Adverse Outcome Score (WAOS) is calculated by multiplying each event by its weight, summing all weights, and dividing by the number of deliveries. The Severity Index (SI) is calculated by multiplying all the events by its weight, summing all the weights, and dividing by the number of cases with an adverse event (numerator for the AOI).

#### Steering Committee Recommendation for Endorsement: Did not pass Importance criteria Rationale:

- Not ready for public reporting and accountability purposes •
- Concern about incentives to use Cesarean section to avoid adverse outcomes •
- Concern about subjective process for determining weighting of individual components •

## Public & Member Comment

Comments included:

No comments were received for this measure.

### 0741 Five Minute APGAR Less Than 7

Description: Inborns only, Birthweight >= 2500 grams and >= 37 weeks completed gestation and APGAR 5 < 7, excludes cases with congenital anomalies (DX codes 740-759.9) or fetal hydrops (DX code 778.0) or dwarfism (DX Code 259.4). Numerator Statement: All infants who meet above criteria. Denominator Statement: For the AOI composite: All deliveries occurring during the review period Exclusions: None Adjustment/Stratification: No risk adjustment or risk stratification N/A Level of Analysis: Clinician : Individual, Clinician : Team, Facility Type of Measure: Outcome Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record Measure Steward: Beth Israel Deaconess Medical Center

Composite Component Measure - Assessment of Criteria Met/Suitable for Endorsement: Y-10: N-14 Comments:

• Is low Apgar score a measure of substandard care?

#### 0741 Five Minute APGAR Less Than 7

- AAP Policy statement use caution when using Apgar score, particularly when diagnosing asphyxia
- Restricted to term babies without congenital anomalies
- Cord blood gases might be a better measure

### Public & Member Comment

#### Comments included:

• No comments were received for this measure.

#### 0742 Birth Trauma

Description: All inborn babies who suffer one of a specific set of injuries during delivery.

Numerator Statement: All newborns meeting diagnostic criteria

Denominator Statement: As part of the AOI, all deliveries

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification

Level of Analysis: Clinician : Team, Facility

Type of Measure: Outcome

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record

Measure Steward: Department of OB/Gyn. Beth Israel Deaconess Medical Center

#### Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-8; N-15 Comments:

- Similar to 474 except it includes brachial plexus injury or code 767.8 other specified trauma
- Not risk-adjusted.

### Public & Member Comment

Comments included:

• No comments were received for this measure.

### 0743 In-hospital Maternal Deaths

**Description:** All pregnant women who die during the same hospital admission as their delivery Numerator Statement: All women who fit the description **Denominator Statement:** All pregnant women who deliver during the specified timeframe Exclusions: None Adjustment/Stratification: No risk adjustment or risk stratification n/a N/A Level of Analysis: Clinician : Team, Facility Type of Measure: Outcome Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record Measure Steward: Beth Israel Deaconess Medical Center Composite Component -Assessment of Criteria Met/Suitable for Endorsement: Y-12; N-12 Comments: • Developer postulates 50% deaths are preventable Maternal death is a true sentinel event - all cases need to be reviewed -approximately 600 cases/year in US • Maternal death or serious injury associated with labor or delivery in a low-risk pregnancy while being cared for in a healthcare • setting is an NQF-endorsed Serious Reportable Event

Lack of risk-adjustment

#### Public & Member Comment Comments included:

• No comments were received for this measure.

#### 0744 Uterine Rupture During Labor

Description: Rupture of uterus during labor in the primary, first or second diagnosis code positions only Numerator Statement: Uterine rupture (outcome) occurring during labor Denominator Statement: All women who deliver during period of analysis Exclusions: None Adjustment/Stratification: No risk adjustment or risk stratification No Level of Analysis: Clinician : Team, Facility Type of Measure: Outcome Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record Measure Steward: Beth Israel Deaconess Medical Center Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-4; N-20 Comments: Rare event : 0.06-.55% • Can happen in spontaneous labor ٠ This measure could eliminate a VBAC option for patients • Seems too heavily weighted in the weighted adverse outcome score (WAOS) Public & Member Comment **Comments included:** No comments were received for this measure.

#### 0745 Unplanned maternal admission to the ICU

**Description:** Any admission to the ICU or transfer to another hospital for admission to ICU during hospitalization in which the woman delivered a baby.

Numerator Statement: All women meeting above criteria

Denominator Statement: All women who deliver an infant during period of evaluation

Exclusions: None. Specific cases can be excluded after review if post-partum ICU admission were planned due to underlying maternal medical conditions.

Adjustment/Stratification: No risk adjustment or risk stratification None Some women with significant comorbidities (e.g. placenta accreta) may have a planned ICU admission. This is excluded from the numerator data. In addition, any women who deliver while in the ICU are excluded.

Level of Analysis: Clinician : Team, Facility

Type of Measure: Outcome

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record Measure Steward: Department of OB/Gyn. Beth Israel Deaconess Medical Center

#### Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-8; N-16 Comments:

- Lack of risk adjustment
- A process, not an outcome
- Post-hoc removal of planned admissions
- Delay in going to the ICU is also a problem
- Does it represent bad care?

## Public & Member Comment

Comments included:

• No comments were received for this measure.

#### 0746 In-hospital -Neonatal Death

**Description:** Any inborn with discharge disposition of died within 7 days of birth (perinatal death), excluding birth weight < 2500 grams, gestational age < 37 weeks, cases with congenital anomalies (DX codes 740-759.9), fetal hydrops (778.0), or dwarfism (259.4) **Numerator Statement:** Any inborn with discharge disposition of died within 7 days of birth (perinatal death) who does not meet exclusion criteria **Denominator Statement:** All inborns with birth weight >= 2500 grams and >= 37 gestational age and without exclusion criteria

**Denominator Statement:** All inborns with birth weight >= 2500 grams and >= 37 gestational age and without exclusion criteria **Exclusions**: None

Adjustment/Stratification: No risk adjustment or risk stratification NA except for exclusions

Level of Analysis: Clinician : Team, Facility

Type of Measure: Outcome

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record **Measure Steward:** Beth Israel Deaconess Medical Center

Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-8; N-16 Comments:

• Neonatal death has only half the weighting of maternal death

- Includes intrapartum and neonatal deaths; 750/yr heterogeneous group: 1/5 due to hypoxia/asphyxia
- No risk-adjustment

### Public & Member Comment

- Comments included:
  - No comments were received for this measure.

#### 0747 Admission to Neonatal Intensive Care Unit at Term

**Description:** Admission to NICU of neonate birthweight = 2500 grams and = 37 weeks gestational age (GA) for >1 day Inborns only BW = 2500 grams, GA = 37 weeks, and NICU admission (day or charge) within one day of birth for greater than a day. Excludes cases with congenital anomalies (DX codes 740-759.9) fetal hydrops (778.0), dwarfism (259.4), or neonatal abstinence syndrome (779.5) OR

Inborns with BW = 2500 grams and GA = 37 weeks and transferred to another hospital (UB92/UB04 disp=02 or =05) within 1 day of birth and excluding cases with congenital anomalies (DX codes 740-759.9), fetal hydrops (778.0), dwarfism (259.4) or neonatal abstinence syndrome (779.5)

Numerator Statement: All live inborns who meet the criteria, excluding those with congenital anomalies or fetal hydrops, dwarfism or neonatal abstinence syndrome.

Denominator Statement: All deliveries during occurring during the period under review

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification None

Level of Analysis: Clinician : Team, Facility

Type of Measure: Outcome

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record Measure Steward: Beth Israel Deaconess Medical Center

Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-11; N-13 Comments:

- Baseline rate = 6-8%; higher than other components will overwhelm other components of AOI
- Variability in NICU admission some is quality, some is system inefficiency, overuse, staffing
- No risk-adjustment

Public & Member Comment Comments included:

#### 0747 Admission to Neonatal Intensive Care Unit at Term

Two comments were submitted suggesting that this component of the composite Adverse Outcomes Index measure is an important measure and that it be endorsed on its own as a measure. Supporters voiced concerns with potential overuse of NICU facilities and the need for a measure to monitor the quality and appropriateness of NICU admissions.

Developer response: The developer is willing to consider submitting this component measure as a stand-alone measure. The developer clarified that the measure captures only the highest NICU acuity, i.e., uniform billing code 174 Level IV, newborn intensive care.

Steering Committee: Committee members noted that staffing and utilization patterns for NICUs is highly variable and speculated that overuse might be more likely at lower levels of acuity, e.g., observation for possible sepsis or hypothermia or hypoglycemia. Committee members would want to review the literature and evidence for overutilization as part of the evaluation for a stand-alone measure. Committee members asked how an NICU admission measure would relate to endorsed measure 0716 Healthy Term Newborn and noted that it would need to be harmonized if it was not directly competing. The Committee agreed the developer should pursue further development and testing, and bring the measure back to NQF for review in the future.

0748 Third or Fourth Degree Perineal Laceration

Description: Number of women who suffer a 3rd or 4th degree laceration of the perineum during vaginal delivery. Numerator Statement: All women who meet above criteria Denominator Statement: As part of the AOI/WAOS/SI- all women who deliver. Exclusions: None Adjustment/Stratification: No risk adjustment or risk stratification None Level of Analysis: Clinician : Team, Facility Type of Measure: Outcome Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Patient Reported Data/Survey Measure Steward: Beth Israel Deaconess Medical Center Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-7; N-17 Comments: Occurs in 3.7% of operative deliveries • Variation in provider diagnosis and coding ٠ Needs risk-adjustment • Often drives the entire composite • Focus on laceration does not address episiotomy use, which is the sentinel event and it's easier to measure episiotomy

### **Public & Member Comment**

**Comments included:** 

No comments were received for this measure.

### 0749 Unanticipated Operative Procedure

Description: This is the rate of women who during their delivery hospitalization have an unanticipated operative procedure defined as DRG 370-375 or MS DRG 765-768 and 774-775 with one of the following procedure codes in first or second procedure field: 75.92 (evacuation of other hematoma of vulva or vagina) or 69.02 (D&C following delivery), 54.61 (re-closure of postoperative disruption of abdominal wall), 38.86 (other surgical occlusion of abdominal vessels), 39.98 (control of hemorrhage), 69.52 (aspiration curettage following delivery).

Numerator Statement: All women who deliver an inborn who meet the diagnostic criteria Denominator Statement: All women who deliver during period of evaluation Exclusions: none

0749 Unanticipated Operative Procedure

Adjustment/Stratification: No risk adjustment or risk stratification none none

Level of Analysis: Clinician : Team, Facility

Type of Measure: Outcome

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper Records Measure Steward: Beth Israel Deaconess Medical Center

Composite Component - Assessment of Criteria Met/Suitable for Endorsement: Y-15; N-9 Comments:

• Limited to hospitalization only, does not include readmissions

• Variation in exposure – hospitals with very short LOS will have lower exposure for this measure

### Public & Member Comment

Comments included:

• No comments were received for this measure.

0750 Maternal blood transfusion

 Description: Maternal Blood Transfusion – DRG 370-375 or MS DRG 765-768 and 774-775 with procedure code 99.03 (Other transfusion of whole blood), 99.04 (Transfusion of packed cells), 99.05 (Transfusion of platelets), 99.07 (Transfusion of other serum), 99.08 (Transfusion of blood expander) or Blood Transfusion Indicator = 1

 Numerator Statement: All women who have a transfusion during their delivery hospitalization

 Denominator Statement: All women who deliver an infant during period of evaluation

 Exclusions: none

 Adjustment/Stratification: No risk adjustment or risk stratification none none

 Level of Analysis: Clinician : Team, Facility

 Type of Measure: Outcome

 Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Pharmacy, Paper Records

 Measure Steward: Beth Israel Deaconess Medical Center

 Composite Component -Assessment of Criteria Met/Suitable for Endorsement: Y-17; N-7

 <u>Comments</u>:

 • Sometimes transfusion is the right thing to do

Comments included:

• No comments were received for this measure.

### MEASURES WITHDRAWN FROM CONSIDERATION

Nine measures previously endorsed by NQF have not been re-submitted or withdrawn from maintenance of endorsement. Two additional measures were withdrawn after initial submission. The following measures are being retired from endorsement:

| Measure   | Reason for retirement                                       |
|---|---|
| 0012: Prenatal Screening for Human Immunodeficiency Virus (HIV) (AMA/PCPI)  | Will be superseded by measures currently in development.    |
| 0014: Prenatal Anti-D Immune Globulin (AMA/PCPI)  | Will be superseded by measures currently in development.    |
| 0015: Prenatal Blood Groups (ABO), D (Rh) Type (AMA/PCPI)   | Will be superseded by measures currently in development.    |
| 0016: Prenatal Blood Group Antibody Testing (AMA/PCPI)  | Will be superseded by measures currently in development.    |
| 0333: Severity-Standardized ALOS - Deliveries (Leapfrog Group)  | Developer no longer maintains the measure.                  |
| 0474: Birth Trauma – Injury to Neonate (PSI 17) (AHRQ)  | Withdrawn during Steering Committee discussion.             |
| 0485: Neonatal Immunization (Child Health Corporation of America)   | Measure no longer aligns with APIC guidelines               |
| 0606: Pregnant women that had HIV testing (Ingenix)   | Developer elected not to pursue maintenance of endorsement. |
| 0607: Pregnant women that had syphilis screening (Ingenix)  | Developer elected not to pursue maintenance of endorsement. |
| 0608: Pregnant women that had HBsAg testing (Ingenix)   | Developer elected not to pursue maintenance of endorsement. |
| 0484: Proportion of infants 22-29 weeks gestation treated with surfactant who are treated within 2 hours of birth (VON) | Withdrawn due to changing evidence and practice.            |

### NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR PERINATAL AND REPRODUCTIVE HEALTHCARE: ENDORSEMENT MAINTENANCE 2011

### **APPENDIX A: MEASURE SPECIFICATIONS**

The following tables present the detailed specifications for the National Quality Forum (NQF)endorsed® *National Voluntary Consensus Standards Perinatal and Reproductive Healthcare: Endorsement Maintenance 2011.* All information presented has been derived directly from measure sources/developers without modification or alteration (except when the measure developed agreed to such modification during the NQF Consensus Development Process) and is current as of December 21, 2011. All NQF-endorsed voluntary consensus standards are open source, meaning they are fully accessible and disclosed. Measures stewards include Agency for Healthcare Research and Quality, California Maternal Quality Care Collaborative, Centers for Disease Control and Prevention, Christiana Care Health System, Hospital Corporation of America, Massachusetts General Hospital/Partners Health Care System, The Joint Commission, and the Vermont Oxford Network.

|                      | Measure 0304: Late sepsis or meningitis in Very Low Birth Weight (VLBW) neonates (risk-adjusted)<br>(Vermont Oxford Network)  |
|----------------------|---|
| Description          | Standardized rate and standardized morbidity ratio for nosocomial bacterial infection after day 3 of life for very low birth weight infants, including infants with birth weights between 401 and 1500 grams and infants whose gestational age is between 22 and 29 weeks.  |
| Numerator            | <ul> <li>Eligible infants with one or more of the following criteria:</li> <li>Criterion 1:</li> <li>Bacterial Pathogen. A bacterial pathogen is recovered from a blood and/or cerebral spinal fluid culture obtained after Day 3 of life.</li> <li>OR</li> <li>OR</li> <li>Criterion 2:</li> <li>Coagulase Negative Staphylococcus. The infant has all 3 of the following:</li> <li>1. Coagulase negative staphylococcus is recovered from a blood culture obtained from either a central line, or peripheral blood sample and/or is recovered from cerebrospinal fluid obtained by lumbar puncture, ventricular tap or ventricular drain.</li> <li>2. One or more signs of generalized infection (such as apnea, temperature instability, feeding intolerance, worsening respiratory distress or hemodynamic instability).</li> <li>3. Treatment with 5 or more days of intravenous antibiotics after the above cultures were obtained. If the infant died, was discharged, or transferred prior to the completion of 5 days of intravenous antibiotics, this condition would still be met if the intention were to treat for 5 or more days.</li> </ul>  |
| Numerator<br>Details | Infants whose birth weight is between 401 and 1500 grams or whose gestational age is between 22 weeks 0<br>days and 29 weeks 6 days are included if they have coagulase negative staphylococcus or one of the<br>bacterial pathogens listed below after day 3 of life, provided they meet one of the following criteria:<br>1. They are born at the reporting hospital.<br>OR<br>2. They are admitted to any location in the reporting hospital within 28 days of birth, without first having gone<br>home.<br>Bacterial Pathogens List:<br>1. Achromobacter species [including Achromobacter xylosoxidans (also known as<br>Alcaligenes xylosoxidans) and others]<br>2. Acinetobacter species<br>3. Aeromonas species<br>4. Alcaligenes species [Alcaligenes xylosoxidans and others]<br>5. Bacteroides species [Burkholderia capecia and others]<br>6. Burkholderia species [Campylobacter fetus, C. jejuni and others]<br>7. Campylobacter species<br>9. Citrobacter species<br>11. Enterobacter species<br>11. Enterobacter species [Enterobacter aerogenes, E. cloacae, and others]<br>12. Enterococcus species [Enterococcus faecalis (also known as Streptococcus<br>faecalis), E.faecium, and other Enterococcus species]<br>13. Escherichia coli |

|                  | 14. Flavobacterium species  |
|------------------|---|
|                  | 15. Haemophilus species [Haemophilus influenzae and others]   |
|                  | 16. Klebsiella species [Klebsiella oxytoca, K. pneumoniae and others]   |
|                  | 17. Listeria monocytogenes<br>18. Moraxella species [Moraxella catarrhalis (also known as Branhamella   |
|                  | catarrhalis) and others]  |
|                  | 19. Neisseria species [Neisseria meningitidis, N. gonorrhoeae and others]   |
|                  | 20. Pasteurella species   |
|                  | 21. Prevotella species  |
|                  | 22. Proteus species [Proteus mirabilis, P. vulgaris and others]   |
|                  | 23. Providencia species [Providencia rettgeri, and others]  |
|                  | 24. Pseudomonas species [Pseudomonas aeruginosa and others]   |
|                  | 25. Ralstonia species   |
|                  | 26. Salmonella species  |
|                  | 27. Serratia species [Serratia liquefaciens, S. marcescens and others]  |
|                  | 28. Staphylococcus coagulase positive [aureus]  |
|                  | 29. Stenotrophomonas maltophilia  |
|                  | 30. Streptococcus species [including Streptococcus Group A, Streptococcus Group   |
|                  | B, Streptococcus Group D, Streptococcus pneumoniae, Strep milleri and   |
|                  | others]   |
| Denominator      | Eligible infants who are in the reporting hospital after day 3 of life.   |
| Denominator      | Infants whose birth weight is between 401 and 1500 grams or whose gestational age is between 22 weeks 0   |
| Details          | days and 29 weeks 6 days are included if they are in the reporting hospital after day 3 of life, provided they  |
|                  | meet one of the following criteria:   |
|                  | 1. They are born at the reporting hospital.   |
|                  | OR  |
|                  | 2. They are admitted to any location in the reporting hospital within 28 days of birth, without first having gone   |
|                  | home.   |
| Exclusions       | Exclude patients who do not meet eligibility criteria for birth weight, gestational age or hospital admission, or if  |
|                  | the infant is discharged  |
|                  | home, is transferred or dies prior to day 3 of life.  |
| Exclusion        | 1. Any infant who meets neither of the following conditions is excluded:  |
| details          | - Birth weight between 401 and 1500 grams   |
|                  | - Gestational age between 22 and 29 weeks.  |
|                  | 2. Outborn infants who are admitted to the reporting hospital more than 28 days   |
|                  | after birth are excluded.   |
|                  | 3. Outborn infants who have been home prior to admission to the reporting   |
|                  | hospital are excluded.  |
|                  | 4. Infants discharged home on or before day 3 of life are excluded.   |
|                  | <ol> <li>Infants who die on or before day 3 of life are excluded.</li> <li>Infants who transfor to another bespital on or before day 3 of life and who</li> </ol> |
|                  | <ol><li>Infants who transfer to another hospital on or before day 3 of life and who<br/>are not readmitted to the reporting hospital.</li></ol>                   |
|                  | 7. Infants who transfer more than once prior to day 3 of life.  |
| Dick Adjustment  |   |
| TRISK ADDISTMENT |   |
|                  | Statistical risk model  |
| Stratification   | N/A<br>After day 3 of life and until death or discharge home or transfer from the reporting hospital. Infants readmitted  |

| window        | to the reporting hospital following transfer to another hospital are monitored following readmission.   |
|---------------|---|
| Туре          | Outcome   |
| Type of Score | Other Adjusted rate and standardized morbidity ratio (observed minus expected values are also provided) |
| Data Source   | Electronic Clinical Data : Registry   |
| Level         | Facility  |
| Setting       | Hospital/Acute Care Facility  |
|                        | Measure 0475: Hepatitis B Vaccine Coverage Among All Live Newborn Infants Prior to Hospital or<br>Birthing Facility Discharge (Centers for Disease Control and Prevention)   |
|------------------------|--|
| Description            | Percent of live newborn infants that receive hepatitis B vaccination before discharge at each single hospital/birthing facility during given time period (one year).   |
| Numerator              | The number of live newborn infants administered hepatitis B vaccine prior to discharge from the hospital/birthing facility ("birth dose" of hepatitis B vaccine).  |
| Numerator<br>Details   | <ul> <li>Per hospital/birthing facility, the number of live newborn infants, during a calendar year, who received a dose of hepatitis B vaccine prior to hospital/birthing facility discharge (or within 1 month of life, if the infant had an extended hospital stay). Acceptable data sources include: pharmacy records, vaccine consent forms, medication administration records, claims data, nurses notes, electronic medical records, or other available records.</li> <li>a. Suggested ICD-9 code V05.3 converts to ICD-10 code z23 (type of immunization given will be identified by the procedure code—effective October 1, 2013. Procedure code for viral hepatitis unknown. Suggest the use</li> </ul>  |
|                        | of ICD-10 code z23.9955 described as "prophylactic administration of vaccine against other diseases" or ICD-<br>10 code z23.9959 described as "other vaccination or inoculation"):<br>http://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z28/Z23-/Z23<br>b. CPT administration codes: 90744 (hepatitis B vaccine) and 90471 (immunization administration code)   |
| Denominator            | The number of live newborn infants born at the hospital/birthing facility during the reporting window (one calendar year)  |
| Denominator<br>Details | <ul> <li>a. The number of live births at the hospital during one calendar year can be determined from a variety of sources, including the paper or electronic patient records, claims data, nursery birth records, or other available records. ICD-10 codes can be used. Stillborn deliveries are not included in the definition of the MEASURE.</li> <li>i. ICD-10 codes to be used (link: http://www.icd10data/ICD10CM/Codes/Z00-Z99/Z30-Z39/Z37-/#Z37 and http://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z30-Z39/Z38-/#Z38) :</li> <li>1. Z37.0 Single live birth</li> <li>2. Z37.2 Twins, both live born</li> <li>3. Z37.3 Twins, one live born and one stillborn</li> <li>4. Z37.50 Multiple births, unspecified, all live born</li> <li>5. Z37.51 Triplets, all live born</li> </ul> |
|                        | <ul> <li>6. Z37.52 Quadruplets, all live born</li> <li>7. Z37.53 Quintuplets, all live born</li> <li>8. Z37.54 Sextuplets, all live born</li> <li>9. Z37.59 Other multiple births, all live born</li> <li>10. Z37.60 Multiple births, unspecified, some live born</li> <li>11. Z37.61 Triplets, some live born</li> <li>12. Z37.62 Quadruplets, some live born</li> <li>13. Z37.63 Quintuplets, some live born</li> <li>14. Z37.64 Sextuplets, some live born</li> <li>15. Z37.69 Other multiple births, some live born</li> <li>16. Z38.00 Single live born infant, delivered vaginally</li> <li>17. Z38.01 Single live born infant, born outside hospital</li> </ul>   |
|                        | <ol> <li>Z38.2 Single live born infant, unspecified as to place of birth</li> <li>Z38.30 Twin live born infant, delivered vaginally</li> <li>Z38.31 Twin live born infant, delivered by cesarean</li> <li>Z38.4 Twin live born infant, born outside hospital</li> </ol>  |

|                          | 23. Z38.5 Twin live born infant, unspecified as to place of birth  |
|--------------------------|--|
|                          | 24. Z38.61 Triplet live born infant, delivered vaginally   |
|                          | 25. Z38.62 Triplet live born infant, delivered by cesarean   |
|                          | 26. Z38.63 Quadruplet live born infant, delivered vaginally  |
|                          | 27. Z38.64 Quadruplet live born infant, delivered by cesarean  |
|                          | 28. Z38.65 Quintuplet live born infant, delivered vaginally  |
|                          | 29. Z38.66 Quintuplet live born infant, delivered by cesarean  |
|                          | 30. Z38.68 Other multiple live born infant, delivered vaginally  |
|                          | 31. Z38.69 Other multiple live born infant, delivered by cesarean  |
|                          | 32. Z38.7 Other multiple live born infant, born outside hospital   |
|                          | 33. Z38.8 Other multiple live born infant, unspecified as to place of birth  |
|                          | The results of this measure will identify that the coverage excludes infants whose parent(s)/guardian(s) refused hepatitis B vaccine for their infant before hospital or facility discharge (or by 1 month of age if during a prolonged stay).   |
| Exclusions               | a. Determine number of live newborn infants born at the hospital/birthing facility whose parent/guardian refused hepatitis B birth dose and exclude from the denominator. ICD-10 code for this information will include the following(link: <a href="http://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z28/Z28-l#Z28">http://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z28/Z28-l#Z28</a> ): |
|                          | i. Z28.03 Immunization not carried out because of immune compromised state of patient  |
|                          | ii. Z28.04 Immunization not carried out because of patient allergy to vaccine or component   |
|                          | iii. Z28.1 Immunization not carried out because of patient decision for reasons of belief or group pressure  |
|                          | iv. Z28.20 Immunization not carried out because of patient decision for unspecified reason   |
|                          | v. Z28.21 Immunization not carried out because of patient refusal  |
|                          | vi. Z28.29 Immunization not carried out because of patient decision for other reason   |
|                          | vii. Z28.82 Immunization not carried out because of caregiver refusal  |
| Exclusion                | Subtract from the number of infants discharged from the hospital/birthing facility, the number of infants born at  |
| details                  | the facility during one calendar year, whose parent/guardian refused administration of a birth dose of hepatitis   |
|                          | B vaccine before discharge from the hospital/birthing facility. Information on exclusions might come from a  |
|                          | variety of sources, including vaccine consent forms, clinical notes, and medication administration records. No   |
|                          | billing codes exist for vaccine refusal; therefore ICD-10 codes in the Z28 series should be used to document   |
|                          | vaccine refusal.   |
| Risk Adjustment          | No risk adjustment or risk stratification  |
| Stratification           | N/A  |
| Numerator Time<br>window | one calendar year  |
| Туре                     | Process  |
| Type of Score            | Rate/proportion  |
| Data Source              | Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Electronic Clinical Data : Registry   |
| Level                    | Clinician : Group/Practice, Clinician : Individual, Facility, Health Plan  |
| Setting                  | Hospital/Acute Care Facility   |
| L                        |  |

|             | Measure 0478: Neonatal Blood Stream Infection Rate (NQI #3) (Agency for Healthcare Research and Quality)  |
|-------------|---|
| Description | Percentage of high-risk newborn discharges with an ICD-9-CM diagnosis code of bloodstream infection   |
| Numerator   | Discharges among cases meeting the inclusion and exclusion rules for the denominator with an ICD-9-CM code for bloodstream infection in any secondary diagnosis field |
| Numerator   | Note: the specification reflects the harmonized measure with The Joint Commission, rather than the technical  |
| Details     | specification as currently posted.  |
|             | Any secondary diagnosis ICD-9-CM code for:  |
|             |   |
|             | STAPHYLCOCC SEPTICEM NOS<br>03811   |
|             | METH SUSC STAPH AUR SEPT  |
|             | 03812   |
|             | MRSA SEPTICEMIA   |
|             | 03819   |
|             | STAPHYLCOCC SEPTICEM NEC  |
|             | 03840   |
|             | GRAM-NEG SEPTICEMIA NOS   |
|             | 03842   |
|             | E COLI SEPTICEMIA   |
|             | 03843   |
|             | PSEUDOMONAS SEPTICEMIA  |
|             | 03844   |
|             | SERRATIA SEPTICEMIA   |
|             | 03849   |
|             | GRAM-NEG SEPTICEMIA NEC   |
|             | 1125  |
|             | DISSEMINATED CANDIDIASIS  |
|             | OR  |
|             | Any secondary diagnosis ICD-9-CM code for:  |
|             | 77181   |
|             | NB SEPTICEMIA [SEPSIS]  |
|             | 77183   |
|             | BACTEREMIA OF NEWBORN   |
|             | AND   |
|             | Any secondary diagnosis ICD-9-CM code for:  |
|             | 04104   |
|             | ENTEROCOCCUS GROUP D  |
|             | 04110   |
|             | STAPHYLOCOCCUS UNSPCFIED  |
|             |   |
|             | MTH SUS STPH AUR ELS/NOS  |

|             | OTHER STAPHYLOCOCCUS   |
|-------------|--|
|             | 0413   |
|             | KLEBSIELLA INFECT N  |
|             | 0414   |
|             | E. COLI INFECT NOS   |
|             | 04141  |
|             | SHIGA TXN-PRODUCE E.COLI   |
|             | 04142  |
|             |  |
|             | SHGA TXN PROD E.COLI NEC   |
|             | 04143  |
|             | SHGA TXN PROD E.COLI NOS   |
|             | 04149  |
|             | E.COLI INFECTION NEC/NOS   |
|             | 0417   |
|             | PSEUDOMONAS INFECT NOS   |
|             | 04185  |
|             | OTH GRAM NEGATV BACTERIA   |
|             |  |
| Denominator | All newborns and outborns with   |
|             | 1) Birth weight 500 to 1499g OR  |
|             | 2) Gestational age between 24 and 30 weeks OR  |
|             | 3) Birth weight greater than or equal to 1500g AND   |
|             | - in-hospital death OR   |
|             | - operating room procedure OR  |
|             | - mechanical ventilation OR  |
|             | - age in days less than 2 AND transferred from another health care facility                                  |
| Denselation |  |
| Denominator | Note: the specification reflects the harmonized measure with The Joint Commission, rather than the technical |
| Details     | specification as currently posted.   |
|             |  |
|             | In-hospital death (DISP=20)  |
|             |  |
|             | ICD-9-CM Diagnosis Codes for gestation age between 24 and 30 weeks:  |
|             | 76522  |
|             | 24 COMPLETED WEEKS OF GESTATION  |
|             | 76523  |
|             | 25-26 COMPLETED WEEKS OF GESTATION   |
|             |  |
|             |  |
|             | 27-28 COMPLETED WEEKS OF GESTATION   |
|             | 76525  |
|             | 29-30 COMPLETED WEEKS OF GESTATION   |
|             | ICD-9-CM Procedure Codes for Mechanical Ventilation:   |
|             |  |
|             |  |
|             | CONTINUOUS MECHANICAL VENTILATION OF UNSPEC DURATION   |
|             | 9671   |
|             | CONTINUOUS MECHANICAL VENTILATION FOR LESS THAN 96 CONSECUTIVE HRS   |
|             | 9672   |
| L           |  |

|                      | CONTINUOUS MECHANICAL VENTILATION FOR 96 CONSECUTIVE HOURS OR MORE   |
|----------------------|--|
|                      | See Pediatric Quality Indicators Appendices:<br>• Appendix A – Operating Room Procedure Codes<br>NOTE: THE FOLLOWING CODES SHOULD BE REMOVED FROM APPENDIX A:<br>70058 INS INTRA-ANSM PRES MNTR (begin 2008)<br>70059 INTRAVASC MSMNT COR ART (begin 2008)<br>70067 INTRAVAS MSMNT THORC ART (begin 2008)<br>70068 INTRAVAS MSMT PERIPH ART (begin 2008)<br>70069 INTRAVS MSMT VES NEC/NOS (begin 2008)<br>70069 INTRAVS MSMT VES NEC/NOS (begin 2008)<br>• Appendix I – Definitions of Neonate, Newborn, Normal Newborn, and Outborn<br>• Appendix J – Admission Codes for Transfers<br>• Appendix L – Low Birth Weight Categories<br>http://qualityindicators.ahrq.gov/Downloads/Software/SAS/V43/TechnicalSpecifications/PDI%20Appendices.pdf |
| Exclusions           | <ul> <li>Exclude cases:</li> <li>with principal diagnosis code of sepsis or secondary diagnosis code present on admission</li> <li>with birth weight less than 500 grams</li> <li>with length of stay less than 2 days</li> <li>with missing data for (SEX=missing), age (AGE=missing), quarter (DQTR=missing), year (YEAR=missing) or principal diagnosis (DX1=missing)</li> </ul>  |
|                      | See Pediatric Quality Indicators Appendices:<br>• Appendix L – Low Birth Weight Categories<br>http://qualityindicators.ahrq.gov/Downloads/Software/SAS/V43/TechnicalSpecifications/PDI%20Appendices.pdf  |
| Exclusion<br>details | Note: the specification reflects the harmonized measure with the Joint Commission, rather than the technical specification as currently posted.  |
|                      | ICD-9-CM Diagnosis Codes for Sepsis:<br>0380<br>STREPTOCOCCAL SEPTICEMIA<br>0381<br>STAPHYLOCOCCAL SEPTICEMIA<br>03810<br>STAPHYLOCOCCAL SEPTICEMIA, UNSPECIFIED<br>03811<br>METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS SEPTICEMIA (OCT08)<br>03812<br>METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS SEPTICEMIA (OCT08)   |
|                      | 03819<br>OTHER STAPHYLOCOCCAL SEPTICEMIA<br>0382<br>PNEUMOCOCCAL SEPTICEMIA (STREPTOCOCCUS PNEUMONIAE SEPTICEMIA)<br>0383<br>SEPTICEMIA DUE TO ANAEROBES<br>03840<br>GRAM-NEGATIVE ORGANISM, UNSPECIFIED<br>03841  |

|                          | HEMOPHILUS INFLUENZAE   |
|--------------------------|---|
|                          | 03842   |
|                          | ESCHERICHIA COLI  |
|                          | 03843   |
|                          | PSEUDOMONAS   |
|                          | 03844   |
|                          | SERRATIA  |
|                          |   |
|                          | SEPTICEMIA DUE TO OTHER GRAM-NEGATIVE ORGANISMS<br>0388                             |
|                          | OTHER SPECIFIED SEPTICEMIAS   |
|                          | 0389  |
|                          | UNSPECIFIED SEPTICEMIA  |
|                          | 1125  |
|                          | DISSEMINATED CANDIDIASIS  |
|                          | 77181   |
|                          | NB SEPTICEMIA [SEPSIS]  |
|                          |   |
|                          | BACTEREMIA OF NEWBORN<br>78552  |
|                          | SEPTIC SHOCK  |
|                          | 78559*  |
|                          | SHOCK WITHOUT MENTION OF TRAUMA, OTHER  |
|                          | 7907  |
|                          | BACTEREMIA  |
|                          | 99591   |
|                          | SYSTEMIC INFLAMMATORY RESPONSE SYNDROME DUE TO INFECTIOUS PROCESS W/O ORGAN         |
|                          | DYSFUNCTION   |
|                          | 99592<br>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME DUE TO INFECTIOUS PROCESS W/ ORGAN |
|                          | DYSFUNCTION   |
|                          | 9980  |
|                          | POSTOPERATIVE SHOCK   |
|                          | 99800   |
|                          | POSTOPERATIVE SHOCK, NOS  |
|                          | 99802   |
|                          | POSTOP SHOCK, SEPTIC  |
|                          | *Not valid for discharges effective October 1, 2004                                 |
| Risk                     | Statistical risk model  |
| Adjustment               | Not every Parala  |
| Stratification           | Not applicable  |
| Numerator<br>Time window | Users may select the time window, but generally one calendar year                   |
|                          | Outcome   |
| Type                     | Outcome   |
| Type of Score            | Rate/proportion   |
| Data Source              | Administrative claims   |

| Level   | Facility                     |
|---------|------------------------------|
| Setting | Hospital/Acute Care Facility |

|                        | Measure 0471: PC-02 Cesarean Section (The Joint Commission)  |
|------------------------|--|
| Description            | This measure assesses the number of nulliparous women with a term, singleton baby in a vertex position delivered by cesarean section. This measure is part of a set of five nationally implemented measures that address perinatal care (PC-01: Elective Delivery, PC-03: Antenatal Steroids, PC-04: Health Care-Associated Bloodstream Infections in Newborns, PC-05: Exclusive Breast Milk Feeding).   |
| Numerator              | Patients with cesarean sections with ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for cesarean section as defined in Appendix A, Table 11.06 available at:<br>http://manual.jointcommission.org   |
| Numerator<br>Details   | <ul> <li>Two data elements are used to calculate the numerator:</li> <li>I. ICD-9-CM Other Procedure Codes - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies significant procedures performed other than the principal procedure during this hospitalization.</li> <li>ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization.</li> <li>ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization. The principal procedure is the procedure performed for definitive treatment rather than diagnostic or exploratory purposes, or which is necessary to take care of a complication.</li> <li>Patients are eligible for the numerator population with ICD-9-CM Other Procedure Codes or ICD-9-CM Principal Procedure Code for cesarean section. If none of these codes is present, patients are in the</li> </ul>   |
| Denominator            | denominator population only.<br>Nulliparous patients delivered of a live term singleton newborn in vertex presentation   |
| Denominator<br>Details | <ul> <li>Ten data elements are used to calculate the denominator:</li> <li>1. Admission Date – The month, day and year of admission to acute inpatient care.</li> <li>2. Birthdate - The month, day and year the patient was born.</li> <li>3. Clinical Trial - Documentation that during this hospital stay the patient was enrolled in a clinical trial in which patients with pregnancy were being studied. Allowable values: Yes or No/UTD</li> <li>4. Discharge Date – The month day and year the patient was discharged from acute care, left against medical advice or expired during the stay.</li> <li>5. Gestational Age – Documentation of the weeks of gestation completed at the time of delivery. Allowable Values: 1-50 or UTD.</li> <li>6. ICD-9-CM Other Diagnosis Codes - The International Classification of Diseases, Ninth Revision, and Clinical Modification (ICD-9-CM) codes associated with the secondary diagnoses for this hospitalization.</li> <li>7. ICD-9-CM Other Procedure Codes - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies significant procedures performed other than the principal procedure during this hospitalization.</li> <li>8. ICD-9-CM Principal Diagnosis Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code associated with the diagnosis established after study to be chiefly responsible for occasioning the admission of the patient for this hospitalization.</li> <li>9. ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization.</li> <li>9. ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization. The principal procedure is the procedure performed for definitive treatment rather than diagnostic o</li></ul> |

| Exclusions<br>Exclusion  | <ul> <li>ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for contraindications to vaginal delivery as defined in Appendix A, Table 11.09</li> <li>Less than 8 years of age</li> <li>Greater than or equal to 65 years of age</li> <li>Length of Stay &gt;120 days</li> <li>Enrolled in clinical trials</li> <li>Patients with ICD-9-CM Principal Diagnosis Code or Other Diagnosis Codes for contraindications to patient delivery and delivery</li></ul> |
|--------------------------|--|
| details                  | <ul> <li>vaginal delivery are excluded.</li> <li>The patient age in years is equal to the Admission Date minus the Birthdate. Patients less than 8 years of age or greater or equal to 65 years of age are excluded.</li> <li>Length of stay (LOS) in days is equal to the Discharge Date minus the Admission Date. If the LOS is greater than 120 days, the patient is excluded.</li> <li>Patients are excluded if "Yes" is selected for Clinical Trial.</li> </ul>   |
| •                        | Other Direct rate standardization to the distribution of the 2006 US population of nulliparous births. See attached spreadsheet for age bands used in the direct standardization.  |
| Stratification           | The Stratification Table used for direct standardization includes the Set Number, Stratified By, and the Age Stratum (Allowable Value). The Age Stratum refers to Patient Age which is calculated by the data element Admission Date minus the data element Birthdate. Each case will be stratified according to the patient age, after the Category Assignments (e.g., numerator, denominator, not in measure population) are completed and the overall rate is calculated.   |
|                          | Set Number       Stratified By       Age Stratum         PC-02a       Overall Rate       No allowable value exists for the overall rate. It includes all patients greater than or equal to 8 years and less than 65 years.         PC-02b       Age 8 years through 14 years A Patient Age (Admission Date minus Birthdate) greater than or equal to 9 years and less than 15 years.   |
|                          | to 8 years and less than 15 years.<br>PC-02c Age 15 years through 19 years A Patient Age (Admission Date minus Birthdate) greater<br>than or equal to 15 years and less than 20 years.   |
|                          | PC-02dAge 20 years through 24 yearsA Patient Age (Admission Date minus Birthdate) greaterthan or equal to 20 years and less than 25 years.PC-02eAge 25 years through 29 yearsA Patient Age (Admission Date minus Birthdate) greater  |
|                          | than or equal to 25 years and less than 30 years.<br>PC-02f Age 30 years through 34 years A Patient Age (Admission Date minus Birthdate) greater   |
|                          | than or equal to 30 years and less than 35 years.PC-02gAge 35 years through 40 yearsA Patient Age (Admission Date minus Birthdate) greaterthan or equal to 35 years and less than 40 years.  |
|                          | PC-02hAge 40 years through 44 yearsA Patient Age (Admission Date minus Birthdate) greaterthan or equal to 40 years and less than 45 years.PC-02iAge 45 years through 64 yearsA Patient Age (Admission Date minus Birthdate) greaterthan or equal to 45 years and less than 65 years.   |
| Numerator Time<br>window | Episode of care  |
| Туре                     | Outcome  |
| Type of Score            | Rate/proportion  |
| Data Source              | Administrative claims, Paper Records   |
| Level                    | Facility, Population : National  |

|                        | Measure 0472: Appropriate Prophylactic Antibiotic Received Within One Hour Prior to Surgical<br>Incision – Cesarean section. (Massachusetts General Hospital/Partners Health Care System)   |
|------------------------|---|
| Description            | Percentage of patients undergoing cesarean section who receive appropriate prophylactic antibiotics within 60 minutes of the start of the cesarean delivery, unless the patient is already receiving appropriate antibiotics  |
| Numerator              | Percentage of women who receive recommended antibiotics within one hour before the start of cesarean section. This requires that (a) the antibiotic selection is consistent with current evidence and practice guidelines, and (b) that the antibiotics are given within an hour before delivery.   |
|                        | If the patient is already receiving appropriate antibiotics, for example for chorioamnionitis, additional dosing is not necessary.  |
| Numerator<br>Details   | Patients receiving antibiotics within an hour before incision as recommended in major guidelines, specifically of the American College of Obstetricians and Gynecologists (ACOG). The ACOG guidelines currently call for a first-generation cephalosporin such as cefazolin as first-line therapy, and the combination of gentamicin and clindamycin for women with relevant allergies.   |
|                        | For the purposes of reporting, there may be one numerator of patients whose antibiotic selection is appropriate, and a second numerator of patients who receive antibiotics within one hour. While both components are necessary in the overall quality of care measure, separate reporting may help identify opportunities for improvement.  |
| Denominator            | All patients undergoing cesarean section without evidence of prior infection or already receiving prophylactic antibiotics for other reasons. Patients with significant allergies to penicillin and/or cephalosporins AND allergies to gentamicin and/or clindamycin are also excluded.   |
| Denominator<br>Details | All patients undergoing cesarean section without evidence of prior infection or already receiving prophylactic antibiotics for other reasons; or with multiple significant drug allergies.  |
|                        | There may be various operational systems for identification of cesarean section, which is an unambiguous event. Most commonly hospital quality measurement systems rely on ICD-9 procedure codes (pending implementation of ICD-10). These may be found in Appendix A, Table 4.07 of the specifications for the National Hospital Quality Measures. Currently, they include   |
|                        | <ul> <li>o 74.0 Classical cesarean section</li> <li>o 74.1 Low cervical cesarean section</li> <li>o 74.2 Extraperitoneal cesarean section</li> <li>o 74.4 Cesarean section of other specified type</li> <li>o 74.99 Other cesarean section of unspecified type</li> </ul>   |
| Exclusions             | Women with evidence of prior infection or already receiving prophylactic antibiotics for other reasons; or with significant allergies to penicillin and/or cephalosporins AND allergies to gentamicin and/or clindamycin.   |
|                        | We do not exclude patients having emergency cesarean deliveries. We recognize that while in the case of most urgent and emergent cesarean deliveries administering timely antibiotic prophylaxis will be possible, very rarely clinical circumstances may not permit administration of antibiotic prophylaxis before skin incisions. Specifying these unusual circumstances, especially from readily abstracted medical record data, is not possible/feasible. Allowing a self-defined exclusion risks inappropriate definition. Instead we recognize that ideal performance on this measure may not be 100% given the small number of unusual emergencies and/or other circumstances. Providers/facilities should however target a 100% goal by, among other efforts, considering how antibiotic prophylaxis will be appropriately delivered even in the case of emergencies |

| Exclusion                | Patients who had a principal ICD-9 diagnosis code suggestive of preoperative infectious disease (as defined  |
|--------------------------|--|
| details                  | in Appendix A, Table 5.09 of the Specification Manual for National Hospital Quality Measures, Version 2.2, and future updates)   |
|                          | <ul> <li>Patients who were already receiving antibiotics within 24 hours prior to surgery except that prophylaxis with penicillin or ampicillin for Group B Streptococcus (GBS) is not a reason for exclusion.</li> <li>Patients with physician/advanced practice nurse/physician assistant/certified nurse midwife documented infection or prophylaxis for infection, except that prophylaxis for GBS is not a reason for exclusion.</li> <li>Patients who undergo other surgeries within 3 days before or after the cesarean section.</li> </ul> |
| Risk Adjustment          | No risk adjustment or risk stratification  |
| Stratification           | The measure may electively be stratified by race, ethnicity, or other variables of interest. These additional variables would be identified and supplied by users according to local needs and interests.  |
| Numerator Time<br>window | One hour before incision time.   |
| Туре                     | Process  |
| Type of Score            | Rate/proportion  |
| Data Source              | Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper Records  |
| Level                    | Facility, Population : State   |
| Setting                  | Hospital/Acute Care Facility   |

|                          | Measure 0473: Appropriate DVT prophylaxis in women undergoing cesarean delivery (Hospital Corporation of America)   |
|--------------------------|---|
| Description              | Measure adherence to current ACOG, SMFM recommendations for use of DVT prophylaxis in women<br>undergoing cesarean delivery. Current ACOG and SMFM recommendations call for the use of pneumatic<br>compression devices in all women undergoing cesarean delivery who are not already receiving medical VTE<br>prophylaxis. Numerator: Number of women undergoing cesarean delivery receiving either pneumatic<br>compression device or medical prophylaxis prior to cesarean delivery. Denominator: All women undergoing<br>cesarean delivery. |
| Numerator                | Number of women undergoing cesarean delivery who receive either fractionated or unfractionated heparin or heparinoid, or pneumatic compression devices prior to surgery   |
| Numerator<br>Details     | Patients with DRG: 740,741,742,744,7491,7499 who had pneumatic compression devices placed pre-<br>operatively   |
| Denominator              | All women undergoing cesarean delivery.   |
| Denominator<br>Details   | DRG 740,741,742,744,7491,7499   |
| Exclusions               | Not receiving medical anticoagulation   |
| Exclusion<br>details     | one of the following HCPCS codes: J1644, J1650, J1645, J1655  |
| Risk Adjustment          | No risk adjustment or risk stratification   |
| Stratification           | N/A   |
| Numerator Time<br>window | Hospital admission for delivery   |
| Туре                     | Process   |
| Type of Score            | Rate/proportion   |
| Data Source              | Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Records   |
| Level                    | Facility  |
| Setting                  | Hospital/Acute Care Facility  |

|                        | Measure 0469: PC-01 Elective Delivery (The Joint Commission)   |
|------------------------|--|
| Description            | This measure assesses patients with elective vaginal deliveries or elective cesarean sections at >= 37 and < 39 weeks of gestation completed. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-02: Cesarean Section, PC-03: Antenatal Steroids, PC-04: Health Care-Associated Bloodstream Infections in Newborns, PC-05: Exclusive Breast Milk Feeding)   |
| Numerator              | <ul> <li>Patients with elective deliveries with ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for one or more of the following:</li> <li>Medical induction of labor as defined in Appendix A, Table 11.05 available at:<br/>http://manual.jointcommission.org</li> <li>Cesarean section as defined in Appendix A, Table 11.06 while not in Active Labor or experiencing Spontaneous Rupture of Membranes available at:<br/>http://manual.jointcommission.org</li> </ul>  |
| Numerator<br>Details   | Four data elements are used to calculate the numerator:  |
|                        | <ol> <li>Active Labor- Documentation that the patient was in active labor or presented with regular uterine contractions with cervical change before medical induction and/or cesarean section. Allowable values: Yes or No/UTD.</li> <li>ICD-9-CM Other Procedure Codes - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies significant procedures performed other than the principal procedure during this hospitalization.</li> <li>ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed other than the principal procedure during this hospitalization.</li> <li>ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization. The principal procedure is the procedure performed for definitive treatment rather than diagnostic or exploratory purposes, or which is necessary to take care of a complication.</li> <li>Spontaneous Rupture of Membranes-Documentation that the patient had spontaneous rupture of membranes (SROM) before medical induction and/or cesarean section. Allowable values: Yes or No/UTD. Patients are eligible for the numerator population with ICD-9-CM Other Procedure Codes or ICD-9-CM Principal Procedure Code for cesarean section when the allowable value equals "no" for the data elements Active Labor and Spontaneous Rupture of Membranes.</li> </ol> |
| Denominator            | Patients delivering newborns with >= 37 and < 39 weeks of gestation completed  |
| Denominator<br>Details | <ul> <li>Seven data elements are used to calculate the denominator:</li> <li>1. Admission Date – The month, day and year of admission to acute inpatient care.</li> <li>2. Birthdate - The month, day and year the patient was born.</li> </ul>  |
|                        | <ol> <li>Clinical Trial - Documentation that during this hospital stay the patient was enrolled in a clinical trial in which patients with pregnancy were being studied. Allowable values: Yes or No/UTD</li> <li>Discharge Date – The month day and year the patient was discharged from acute care, left against medical advice or expired during the stay.</li> <li>Gestational Age – Documentation of the weeks of gestation completed at the time of delivery. Allowable Values: 1-50 or UTD.</li> <li>ICD-9-CM Other Diagnosis Codes - The International Classification of Diseases, Ninth Revision, and Clinical Modification (ICD-9-CM) codes associated with the secondary diagnoses for this hospitalization.</li> <li>ICD-9-CM Principal Diagnosis Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code associated with the diagnosis established after study to be chiefly responsible for occasioning the admission of the patient for this hospitalization.</li> </ol>   |
| Exclusions             | ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for conditions possibly  |

|                 | justifying elective delivery prior to 39 weeks gestation as defined in Appendix A, Table 11.07      |
|-----------------|---|
|                 | Less than 8 years of age  |
|                 | Greater than or equal to 65 years of age  |
|                 | Length of Stay >120 days  |
|                 | Enrolled in clinical trials   |
| Exclusion       | Patients with ICD-9-CM Principal Diagnosis Code or Other Diagnosis Codes for conditions for         |
| details         | possibly justifying elective delivery are excluded.   |
|                 | The patient age in years is equal to the Admission Date minus the Birthdate. Patients less than 8   |
|                 | years of age or greater or equal to 65 years of age are excluded.                                   |
|                 | Length of stay (LOS) in days is equal to the Discharge Date minus the Admission Date. If the LOS is |
|                 | greater than 120 days, the patient is excluded.   |
|                 | Patients are excluded if "Yes" is selected for Clinical Trial.                                      |
| Risk Adjustment | No risk adjustment or risk stratification   |
| Stratification  | Not Applicable  |
| Numerator Time  | Episode of care   |
| window          |   |
| Туре            | Process   |
| Type of Score   | Rate/proportion   |
| Data Source     | Administrative claims, Electronic Clinical Data, Paper Records                                      |
| Level           | Facility, Population : National   |
| Setting         | Hospital/Acute Care Facility  |

|                          | Measure 0470: Incidence of Episiotomy (Christiana Care Health System)   |
|--------------------------|---|
| Description              | Percentage of vaginal deliveries (excluding those coded with shoulder dystocia) during which an episiotomy is performed.  |
| Numerator                | Number of episiotomy procedures (ICD-9 code 72.1, 72.21, 72.31, 72.71, 73.6; ICD-10<br>PCS:0W8NXZZ,0WQNXZZ,10D07Z3,10D07Z4,10D07Z5,10D07Z6) performed on women undergoing a<br>vaginal delivery (excluding those with shoulder dystocia) during the analytic period- monthly, quarterly, yearly<br>etc. |
| Numerator                | Any vaginal delivery with one of the ICD-9 codes for episiotomy- 72.1, 72.21, 72.31, 72.71, and 73.6 (ICD-10  |
| Details                  | PCS:see 2a.   |
| Denominator              | All vaginal deliveries during the analytic period- monthly, quarterly, yearly etc. excluding those coded with a shoulder dystocia.  |
| Denominator<br>Details   | Any woman with a vaginal delivery calculated by either MS DRG 774,775,767,768   |
| Exclusions               | Women who have a coded complication of shoulder dystocia. In the case of shoulder dystocia, an episiotomy   |
|                          | is performed to free the shoulder and prevent/mitigate birth injury to the infant.  |
| Exclusion<br>details     | Vaginal deliveries coded with shoulder dystocia, ICD-9 code 660.41, 660.42( ICD-10 CM : 066.0)  |
| Risk Adjustment          | No risk adjustment or risk stratification   |
| Stratification           | NA  |
| Numerator Time<br>window | Inpatient delivery stay.  |
| Туре                     | Outcome, Process  |
| Type of Score            |   |
| Data Source              | Administrative claims, Paper Records  |
| Level                    | Facility  |
| Setting                  | Hospital/Acute Care Facility  |

| Measure 0476: PC-03 Antenatal Steroids (The Joint Commission)  |
|--|
| This measure assesses patients at risk of preterm delivery at 24 0/7-32 0/7 weeks gestation receiving antenatal steroids prior to delivering preterm newborns. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-01: Elective Delivery, PC-02: Cesarean Section, PC-04: Health Care-Associated Bloodstream Infections in Newborns, PC-05: Exclusive Breast Milk Feeding).  |
| Patients with a full course of antenatal steroids completed prior to delivering preterm newborns (refer to Appendix B, Table 11.0, antenatal steroid medications available at: <a href="http://manual.jointcommission.org">http://manual.jointcommission.org</a> )   |
| One data element is used to calculate the numerator:   |
| 1. Antenatal Steroids Administered- Documentation that a full course of antenatal steroids was administered before delivery. A full course of antenatal steroids consists of two doses of 12 mg betamethasone IM 24 hours apart OR four doses of 6 mg dexamethasone IM every 12 hours. Allowable values: Yes or No/UTD. Cases are eligible for the numerator population when allowable value = Yes is selected.  |
| Patients delivering live preterm newborns with 24 0/7-32 0/7 weeks gestation completed   |
| <ul> <li>Eight data elements are used to calculate the denominator:</li> <li>1. Admission Date – The month, day and year of admission to acute inpatient care.</li> <li>2. Birthdate - The month, day and year the patient was born.</li> <li>3. Clinical Trial - Documentation that during this hospital stay the patient was enrolled in a clinical trial in which patients with pregnancy were being studied. Allowable values: Yes or No/UTD</li> <li>4. Discharge Date – The month day and year the patient was discharged from acute care, left against medical advice or expired during the stay.</li> <li>5. Gestational Age – Documentation of the weeks of gestation completed at the time of delivery. Allowable Values: 1-50 or UTD.</li> <li>6. ICD-9-CM Other Diagnosis Codes - The International Classification of Diseases, Ninth Revision, and Clinical Modification (ICD-9-CM) codes associated with the secondary diagnoses for this hospitalization.</li> <li>7. ICD-9-CM Principal Diagnosis Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code associated with the diagnosis established after study to be chiefly responsible for occasioning the admission of the patient for this hospitalization.</li> <li>8. Reason for Not Administering Antenatal Steroid - Reasons for not administering a full course of antenatal steroids before delivery are clearly documented in the medical record. Reasons for not administering a full course of antenatal steroids may include fetal distress, imminent delivery or other reasons documented by physician/APN/PA/CNM. Allowable Values: Yes or No/UTD</li> </ul> |
| <ul> <li>Less than 8 years of age</li> <li>Greater than or equal to 65 years of age</li> <li>Length of Stay &gt;120 days</li> <li>Enrolled in clinical trials</li> <li>Documented Reason for Not Administering Antenatal Steroid</li> <li>ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for fetal demise as defined in Appendix A, Table 11.09.1 available at: <a href="http://manual.jointcommission.org">http://manual.jointcommission.org</a></li> </ul>  |
| <ul> <li>The patient age in years is equal to the Admission Date minus the Birthdate. Patients less than 8 years of age or greater or equal to 65 years of age are excluded.</li> <li>Length of stay (LOS) in days is equal to the Discharge Date minus the Admission Date. If the LOS is greater than 120 days, the patient is excluded.</li> <li>Patients are excluded if "Yes" is selected for Clinical Trial.</li> </ul>   |
|  |

|                 | <ul> <li>The data element Reason for Not Administering Antenatal Steroid is used to determine if the patient had a documented reason for not receiving the antenatal steroid.</li> <li>Patients with ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for fetal demise are excluded.</li> </ul> |
|-----------------|--|
| Risk Adjustment | No risk adjustment or risk stratification  |
| Stratification  | Not applicable, the measure is not stratified.   |
| Numerator Time  | Episode of care  |
| window          |  |
| Туре            | Process  |
| Type of Score   | Rate/proportion  |
| Data Source     | Electronic Clinical Data, Electronic Clinical Data : Registry, Paper Records   |
| Level           | Facility, Population : National  |
| Setting         | Hospital/Acute Care Facility   |

|                        | Measure 0480: PC-05 Exclusive Breast Milk Feeding (The Joint Commission)  |
|------------------------|---|
| Description            | This measure assesses the number of newborns exclusively fed breast milk feeding during the newborn's entire hospitalization. This measure is a part of a set of five nationally implemented measures that address perinatal care (PC-01: Elective Delivery, PC-02: Cesarean Section, PC-03: Antenatal Steroids, PC-04: Health Care-Associated Bloodstream Infections in Newborns).   |
| Numerator              | Newborns that were fed breast milk only since birth   |
| Numerator<br>Details   | One data element is used to calculate the numerator:  |
|                        | 1. Exclusive Breast Milk Feeding - Documentation that the newborn was exclusively fed breast milk during the entire hospitalization. Allowable Values: Yes or No/UTD. Cases are eligible for the numerator when allowable value = yes.  |
| Denominator            | Single term liveborn newborns discharged from the hospital with ICD-9-CM Principal Diagnosis Code or ICD-<br>9-CM Other Diagnosis Codes for single liveborn newborn as defined in Appendix A, Table 11.20.1available at:<br>http://manual.jointcommission.org   |
| Denominator<br>Details | Thirteen data elements are used to calculate the denominator:   |
|                        | <ol> <li>Admission Date – The month, day and year of admission to acute inpatient care.</li> <li>Admission Type- The code indicating priority/type of admission.</li> <li>Admission to NICU - Documentation that the newborn was admitted to the Neonatal Intensive Care Unit<br/>(NICU) at this hospital any time during the hospitalization. Allowable values: Yes or No/UTD</li> <li>Birthdate - The month, day and year the patient was born.</li> <li>Clinical Trial - Documentation that during this hospital stay the patient was enrolled in a clinical trial in which<br/>patients who are newborns were being studied. Allowable values: Yes or No/UTD</li> <li>Discharge Date – The month day and year the patient was discharged from acute care, left against medical<br/>advice or expired during the stay.</li> <li>Discharge Status - The place or setting to which the patient was discharged.</li> <li>ICD-9-CM Other Diagnosis Codes - The International Classification of Diseases, Ninth Revision, and<br/>Clinical Modification (ICD-9-CM) codes associated with the secondary diagnoses for this hospitalization.</li> <li>ICD-9-CM Other Procedure Codes - The International Classification of Diseases, Ninth Revision, Clinical<br/>Modification (ICD-9-CM) code that identifies significant procedures performed other than the principal<br/>procedure during this hospitalization.</li> <li>ICD-9-CM Principal Diagnosis Code - The International Classification of Diseases, Ninth Revision, Clinical<br/>Modification (ICD-9-CM) code associated with the diagnosis established after study to be chiefly responsible</li> </ol> |
|                        | <ul> <li>for occasioning the admission of the patient for this hospitalization.</li> <li>11. ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization. The principal procedure is the procedure performed for definitive treatment rather than diagnostic or exploratory purposes, or which is necessary to take care of a complication.</li> <li>12. Point of Origin for Admission or Visit- The code indicating the point of patient origin for this admission.</li> <li>13. Reason for Not Exclusively Feeding Breast Milk - Reasons for not exclusively feeding breast milk during the entire hospitalization are clearly documented in the medical record. These reasons are due to a maternal medical condition for which feeding breast milk should be avoided. Allowable Values: Yes or No/UTD.</li> </ul>   |
| Exclusions             | <ul> <li>Admitted to the Neonatal Intensive Care Unit (NICU) at this hospital during the hospitalization</li> <li>ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for galactosemia as defined in Appendix A, Table 11.21</li> <li>ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for parenteral infusion as</li> </ul>   |

|                | defined in Appendix A, Table 11.22  |
|----------------|---|
| •              | Experienced death   |
| •              | Length of Stay >120 days  |
| •              | Enrolled in clinical trials   |
| •              | Documented Reason for Not Exclusively Feeding Breast Milk   |
| •              | Patients transferred to another hospital  |
| •              | ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for premature newborns                |
| ć              | as defined in Appendix A, Table 11.23   |
| Exclusion •    | The data element Admission to NICU is used to determine if the patient was admitted to the NICU.          |
| details •      | <ul> <li>Patients with ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for</li> </ul> |
| Q              | galactosemia are excluded.  |
| •              | • Patients with ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for                   |
| F              | parenteral infusion are excluded.   |
| •              | • The data element Discharge Status is used to determine if the patient experienced death.                |
|                | • Length of stay (LOS) in days is equal to the Discharge Date minus the Admission Date. If the LOS is     |
| 0              | greater than 120 days the patient is excluded.  |
| •              | • Patients are excluded if "Yes" is selected for Clinical Trial.  |
|                | The data element Reason for Not Exclusively Feeding Breast Milk is used to determine if the patient       |
| ł              | had a documented reason for not being exclusively fed breast milk.  |
| •              | • The data element Discharge Status is used to determine if the patient the patient was transferred to    |
|                | another hospital.   |
|                | Patients with ICD-9-CM Principal Diagnosis Code or ICD-9-CM Other Diagnosis Codes for                     |
| r.             | premature newborns are excluded.  |
|                | No risk adjustment or risk stratification   |
| -              | Not Applicable  |
| Numerator Time |   |
| window         |   |
|                |   |
| 51             | Process   |
| 51             | Rate/proportion   |
|                | Administrative claims, Electronic Clinical Data, Paper Records  |
| _evel          | Facility, Population : National   |
| Setting        | Hospital/Acute Care Facility  |

|                          | Measure 0477: Under 1500g infant Not Delivered at Appropriate Level of Care (California Maternal<br>Quality Care Collaborative)  |
|--------------------------|--|
| Description              | The number per 1,000 livebirths of <1500g infants delivered at hospitals not appropriate for that size infant.   |
| Numerator                | Liveborn infants (<1500gms but over 24 weeks gestation) born at the given birth hospital   |
| Numerator<br>Details     | Birthweight: <1500gms; Gestational Age >=24.0 weeks; livebirth (not stillbirth)  |
| Denominator              | All live births over 24 weeks gestation at the given birth hospital. NICU Level III status is defined by the State Department of Health or similar body typically using American Academy of Pediatrics Criteria. |
| Denominator<br>Details   | All live births at the hospital>=24weeks gestation. This is easily calculated from Vital Stats data. The field used is typically the Best Obstetric Estimate of Gestational Age.                                 |
| Exclusions               | Stillbirths and livebirths <24weeks gestation.   |
| Exclusion<br>details     | Vital Stats data clearly identify stillbirths and Best Obstetric Gestational Age.  |
| Risk Adjustment          | No risk adjustment or risk stratification  |
| Stratification           | none   |
| Numerator Time<br>window | one year   |
| Туре                     | Outcome  |
| Type of Score            | Rate/proportion  |
| Data Source              | Electronic Clinical Data : Registry, Other   |
| Level                    | Facility, Health Plan, Population : County or City, Population : National, Population : Regional, Population : State   |
| Setting                  | Hospital/Acute Care Facility   |

|                          | Measure 0483: Proportion of infants 22 to 29 weeks gestation screened for retinopathy of prematurity.<br>(Vermont Oxford Network)  |
|--------------------------|--|
| Description              | Proportion of infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for retinopathy of prematurity (ROP) screening by the American Academy of Pediatrics (AAP) and who received a retinal examination for ROP prior to discharge.   |
| Numerator                | Number of infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for ROP screening by the AAP and who received a retinal exam for ROP prior to discharge.  |
| Numerator<br>Details     | All eligible infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for ROP screening by the AAP)and who had a retinal examination for Retinopathy of Prematurity prior to discharge.  |
| Denominator              | All eligible infants 22 to 29 weeks gestation who were in the reporting hospital at the postnatal age recommended for ROP screening by the AAP.  |
| Denominator<br>Details   | Any infant who is born at the reporting hospital and whose gestational age is<br>between 22 weeks, 0 days and 29 weeks, 6 days should be included if they are in the reporting hospital at the<br>postnatal age recommended for ROP screening by the AAP.<br>Any outborn infant who is admitted to any location in the reporting hospital within 28 days of birth, without first<br>having gone home, and whose gestational age is between 22 weeks, 0 days and 29 weeks, 6 days should be<br>included if they are in the reporting hospital at the postnatal age recommended for ROP screening by the<br>AAP. |
| Exclusions               | <ol> <li>Infants outside the gestational age range of 22 to 29 weeks.</li> <li>Outborn infants admitted to the reporting hospital more than 28 days after<br/>birth.</li> <li>Outborn infants who have been home prior to admission.</li> <li>Infants who die in the delivery room or initial resuscitation area prior to<br/>admission to the neonatal intensive care unit.</li> <li>Infants not in the reporting hospital at the postnatal age recommended for<br/>ROP screening by the AAP.</li> </ol>  |
| Exclusion<br>details     | See 2a1.8 above.   |
| Risk Adjustment          | Stratification by risk category/subgroup   |
| Stratification           | Reports are stratified by gestational age, birth location and birth weight category.   |
| Numerator Time<br>window | From birth until retinal exam for ROP.   |
| Туре                     | Process  |
| Type of Score            | Rate/proportion  |
| Data Source              | Administrative claims, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records   |
| Level                    | Facility   |
| Setting                  | Hospital/Acute Care Facility   |

|                        | Measure 1731: Health Care-Associated Bloodstream Infections in Newborns (The Joint Commission)   |
|------------------------|--|
| Description            | This measure assesses the number of staphylococcal and gram negative septicemias or bacteremias in high-<br>risk newborns. This measure is a part of a set of five nationally implemented measures that address perinatal<br>care (PC-01: Elective Delivery, PC-02: Cesarean Section, PC-03: Antenatal Steroids, PC-05: Exclusive Breast<br>Milk Feeding).   |
| Numerator              | Newborns with septicemia or bacteremia with an ICD-9-CM Other Diagnosis Codes for septicemias as defined<br>in Appendix A, Table 11.10.1 OR one or more ICD-9-CM Other Diagnosis Codes for newborn septicemia or<br>bacteremia as defined in Appendix A, Table 11.10 and one diagnosis code for newborn bacteremia from<br>Table 11.11 available at: <u>http://manual.jointcommission.org</u>  |
| Numerator<br>Details   | One data element is used to calculate the numerator:   |
|                        | <ol> <li>ICD-9-CM Other Diagnosis Codes- The International Classification of Diseases, Ninth Revision,<br/>Clinical Modification (ICD-9-CM) codes associated with the secondary diagnoses for this hospitalization.<br/>Cases are eligible for the numerator population with ICD-9-CM Other Diagnosis Code for septicemias OR one<br/>or more ICD-9-CM Other Diagnosis Codes for newborn septicemia or bacteremia and one diagnosis code for<br/>newborn bacteremia.</li> </ol>  |
| Denominator            | Liveborn newborns with an ICD-9-CM Other Diagnosis Codes for birth weight between 500 and 1499g as<br>defined in Appendix A, Table 11.12, 11.13 or 11.14 OR Birth Weight between 500 and 1499g OR an ICD-9-<br>CM Other Diagnosis Codes for birth weight = 1500g as defined in Appendix A, Table 11.15, 11.16 or 11.17<br>OR Birth Weight = 1500g who experienced one or more of the following:<br>o Experienced death   |
|                        | o ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for major surgery as defined in Appendix A, Table 11.18  |
|                        | o ICD-9-CM Principal Procedure Code or ICD-9-CM Other Procedure Codes for mechanical ventilation as defined in Appendix A, Table 11.19   |
|                        | o Transferred in from another acute care hospital or health care setting within 2 days of birth.   |
| Denominator<br>Details | Twelve data elements are used to calculate the denominator:  |
|                        | 1. Admission Date – The month, day and year of admission to acute inpatient care.  |
|                        | <ol> <li>Admission Type- The code indicating priority/type of admission.</li> <li>Bidly Maintha Theorem and the time of delivery of the line of delivery.</li> </ol>   |
|                        | <ol> <li>Birth Weight- The weight (in grams) of a newborn at the time of delivery.</li> <li>Birthdate - The month, day and year the patient was born.</li> </ol>   |
|                        | <ol> <li>5. Clinical Trial - Documentation that during this hospital stay the patient was enrolled in a clinical trial in which patients who are newborns were being studied. Allowable values: Yes or No/UTD</li> </ol>   |
|                        | 6. Discharge Date – The month day and year the patient was discharged from acute care, left against medical advice or expired during the stay.   |
|                        | <ol> <li>Discharge Status - The place or setting to which the patient was discharged.</li> <li>ICD-9-CM Other Diagnosis Codes - The International Classification of Diseases, Ninth Revision, and<br/>Clinical Modification (ICD-9-CM) codes associated with the secondary diagnoses for this hospitalization.</li> <li>ICD-9-CM Other Procedure Codes - The International Classification of Diseases, Ninth Revision, Clinical<br/>Modification (ICD-9-CM) code that identifies significant procedures performed other than the principal<br/>procedure during this hospitalization.</li> </ol> |
|                        | <ol> <li>ICD-9-CM Principal Diagnosis Code - The International Classification of Diseases, Ninth Revision, Clinical<br/>Modification (ICD-9-CM) code associated with the diagnosis established after study to be chiefly responsible<br/>for occasioning the admission of the patient for this hospitalization.</li> <li>ICD-9-CM Principal Procedure Code - The International Classification of Diseases, Ninth Revision, Clinical</li> </ol>   |

| Exclusions               | <ul> <li>Modification (ICD-9-CM) code that identifies the principal procedure performed during this hospitalization. The principal procedure is the procedure performed for definitive treatment rather than diagnostic or exploratory purposes, or which is necessary to take care of a complication.</li> <li>12. Point of Origin for Admission or Visit- The code indicating the point of patient origin for this admission.</li> <li>ICD-9-CM Principal Diagnosis Code for sepsis as defined in Appendix A, Table 11.10.2</li> <li>ICD-9-CM Principal Diagnosis Code for liveborn newborn as defined in Appendix A, Table 11.10.3</li> <li>AND ICD-9-CM Other Diagnosis Codes for newborn septicemia or bacteremia as defined in Appendix A, Table 11.10</li> </ul> |
|--------------------------|---|
|                          | <ul> <li>ICD-9-CM Other Diagnosis Codes for birth weight &lt; 500g as defined in Appendix A, Table 11.20 OR<br/>Birth Weight &lt; 500g</li> <li>Length of Stay &lt; 2 days OR &gt; 120 days</li> <li>Enrolled in clinical trials</li> </ul>   |
| Exclusion<br>details     | <ul> <li>Patients with ICD-9-CM Principal Diagnosis Code for sepsis are excluded.</li> <li>Patients with ICD-9-CM Principal Diagnosis Code for liveborn newborn and ICD-9-CM Other<br/>Diagnosis Codes for newborn septicemia are excluded.</li> <li>Patients with ICD-9-CM Other Diagnosis Codes for birth weight &lt;500 grams OR a birth weight<br/>&lt;500 grams are excluded.</li> <li>Length of stay (LOS) in days is equal to the Discharge Date minus the Admission Date. If the LOS is<br/>greater than 120 days or equal to or less than 2 days, the patient is excluded.</li> <li>Patients are excluded if "Yes" is selected for Clinical Trial.</li> </ul>  |
| Risk Adjustment          | Statistical risk model  |
| Stratification           | Not applicable, the measure is not stratified.  |
| Numerator Time<br>window | Episode of care   |
| Туре                     | Outcome   |
| Type of Score            | Rate/proportion   |
| Data Source              | Administrative claims, Electronic Clinical Data, Paper Records  |
| Level                    | Facility, Population : National   |
| Setting                  | Hospital/Acute Care Facility  |

|                        | Measure 1746: Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (GBS) (Massachusetts General Hospital)   |  |  |
|------------------------|---|--|--|
| Description            | Percentage of pregnant women who are eligible for and receive appropriate intrapartum antibiotic prophylaxis (IAP) for Group B Streptococcus (GBS)  |  |  |
| Numerator              | All eligible patients who receive intrapartum antibiotic prophylaxis for GBS.   |  |  |
| Numerator<br>Details   | Patients who receive antibiotics as recommended under current CDC guidelines. The 2010 guidelines recommend penicillin as the agent of choice, with ampicillin as an acceptable alternative. Penicillin-allergic women who do not have a history of anaphylaxis, angioedema, respiratory distress or urticaria following administration of penicillin or a cephalosporin should antimicrobial susceptibility testing. If the culture is susceptible to clindamycin, clindamycin should be given. If the culture is resistant to clindamycin, vancomycin should be given.  |  |  |
| Denominator            | All women delivering live infants, except certain classes (described in response to 2a1.9 below) who are specifically deemed not to be at risk of vertical transmission of GBS.   |  |  |
| Denominator<br>Details | The population may be identified in two stages. The first stage identified all women delivering live infants. The second stage further restricts the eligible population on the basis of specific clinical criteria.  |  |  |
|                        | Identification of women giving birth to live infants is generally a straightforward task that may be accomplished in various ways. Commonly, it is done using ICD-9 principal and secondary diagnosis codes for live births as defined in the Appendices of the National Hospital Quality Measures, as they may be modified from time to time. In 2011, codes for live births are listed in Appendix A Tables 4.01, 4.02, 4.03, or 4.04 of the Specifications Manual.   |  |  |
|                        | <ul> <li>This population must be further restricted on the basis of the following criteria.</li> <li>Previous infant with invasive GBS disease, or</li> <li>GBS bacteriuria during current pregnancy, or</li> <li>Positive GBS screening culture during current pregnancy* (unless a planned cesarean delivery, in the absence of labor or amniotic membrane rupture, is performed), or</li> <li>Unknown GBS status (culture not done, incomplete or results unknown) and any of the following:</li> <li>Delivery at &lt; 37 weeks gestation**</li> <li>Amniotic membrane rupture greater than or equal to 18 hours, or</li> <li>Intrapartum temperature greater than or equal to 100.4° F (38.0° C)</li> </ul> |  |  |
|                        | <ul> <li>*Optimal timing for prenatal GBS screening is 35-37 weeks of gestation. In the absence of culture results for this period, other available results from the 5 weeks preceding delivery should be reviewed.</li> <li>**Recommendations for prophylaxis in the setting of threatened preterm delivery are presented separately by the CDC in Figures 5 and 6 of the most recent guidelines (Centers for Disease Control and Prevention. Prevention of perinatal Group B Streptococcal disease: revised guidelines from CDC, 2010. MMWR 2010;59(RR-10):1-36.) Those interested in detailed criteria and assessment of compliance for the preterm population are referred there for specifics.</li> </ul>  |  |  |
| Exclusions             | Women not included in the denominator defined above, with specific exclusions as described below.   |  |  |
| Exclusion<br>details   | <ul> <li>Excluded populations:</li> <li>Patient screened negative for GBS at 35-37 weeks of delivery.</li> <li>Patients delivering via planned cesarean sections (in the absence of labor or amniotic membrane rupture).</li> </ul>   |  |  |

|  | Patients already on antibiotics for a pre-natal maternal infection or other                                   |  |  |
|--|---|--|--|
|  | prophylaxis.  |  |  |
| Deliveries resulting in stillbirths identified by ICD-9-CM principal and secondary diagnosis codes |   |  |  |
|  | position) of V.27.1, V27.3, V27.4, V27.6, or V27.7.   |  |  |
|  |   |  |  |
|  | *Optimal timing for prenatal GBS screening is 35-37 weeks of gestation. In the absence of culture results for |  |  |
|  | this period, other available results from the 5 weeks preceding delivery should be reviewed.                  |  |  |
| Risk Adjustment  | No risk adjustment or risk stratification   |  |  |
| Stratification   |   |  |  |
| Numerator Time   | At the time of labor or rupture of membranes, in the absence of complicating circumstances (listed as         |  |  |
| window   | exclusions).  |  |  |
| Туре   | Process   |  |  |
| Type of Score  | Rate/proportion   |  |  |
| Data Source  | Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Paper   |  |  |
|  | Records   |  |  |
| Level  | Facility, Integrated Delivery System, Population : State  |  |  |
| Setting  | Hospital/Acute Care Facility  |  |  |

#### **APPENDIX B: STEERING COMMITTEE and NQF STAFF**

#### **STEERING COMMITTEE**

Laura Riley, MD (Co-Chair) Massachusetts General Hospital Boston, MA

**Carol Sakala, PhD, MSPH (Co-Chair)** Childbirth Connection New York, NY

Joanne Armstrong, MD, MPH Aetna Sugarland, TX

**Jennifer Bailit, MD, MPH** Case Western Reserve University and MetroHealth Medical Center Cleveland, OH

**Scott Berns, MD, MPH, FAAP** March of Dimes Foundation and Warren Alpert Medical School of Brown University White Plains, NY

**Jennifer Brandenburg, RN, MSN** Decatur Memorial Hospital Cerro Gordo, IL

Sarah Brown, MSPH National Campaign to Prevent Teen and Unplanned Pregnancy Washington, DC

**William Callaghan, MD, MPH** Division of Reproductive Health, Centers for Disease Control and Prevention Atlanta, GA

Kate Chenok, MBA Pacific Business Group on Health San Francisco, CA

**Charles Denk, PhD** New Jersey Department of Health Trenton, NJ

Elizabeth Drye, MD, SM Yale/Yale-New Haven Hospital Center for Outcomes Research and Evaluation (CORE) and Yale School of Medicine New Haven, CT

#### Rebekah Gee, MD, MPH, MS

Louisiana State University (LSU) and Louisiana Department of Health and Hospitals New Orleans, LA

Andrea Gelzer, MD, MS, FACP The AmeriHealth Mercy Family of Companies Philadelphia, PA

**Craig Gilliam, BSMT, MT (ASCP), CIC** Arkansas Children's Hospital Little Rock, AR

**Kimberly D. Gregory, MD, MPH** Cedars-Sinai Medical Center and University of California Los Angeles Los Angeles, CA

William A. Grobman, MD, MBA Northwestern Memorial Hospital Chicago, IL

Mambarambath Jaleel, MD University of Texas Southwestern Medical Center, and Parkland Memorial Hospital Dallas, TX

**Barbara Kelly, MD** AF Williams Family Medicine Center Denver, CO

**Teri Kiehn, MS, RNC** Intermountain Healthcare Salt Lake City, UT

Mayri Sagady Leslie, CNM, MSN, EdD(c) Coalition for Improving Maternity Services Raleigh, NC

Nancy K. Lowe, CNM, PhD, FACNM, FAAN University of Colorado College of Nursing Aurora, CO

Lee Partridge National Partnership for Women & Families Washington, DC

Jochen Profit, MD, MPH Texas Children's Hospital Houston, Texas

**Kathleen Rice Simpson, PhD, RNC, FAAN** St John's Mercy Medical Center and Saint Louis University

St. Louis, MO

Sharon Sutherland, MD Cleveland Clinic Cleveland, OH

**Robert K. Watson, MD, MMM, CPE** Andrews Women's Hospital, Baylor All Saints Medical Center Dallas, TX

Janet Young, MD Department of Emergency Medicine, Virginia Tech Carilion School of Medicine Roanoke, VA

#### NATIONAL QUALITY FORUM STAFF

Helen Burstin, MD, MPH Senior Vice President, Performance Measures

**Reva Winkler, MD, MPH** Senior Program Director, Performance Measures

**Heidi Bossley, MSN, MBA** Vice President, Performance Measures

Suzanne Theberge, MPH Project Manager, Performance Measures

Gene Cunningham, MS Project Analyst, Performance Measures

# APPENDIX C: NQF-ENDORSED REPRODUCTIVE AND PERINATAL HEALTHCARE MEASURES

| Measure Number           | Title   | Description  | Steward  |
|--------------------------|---|--|--|
| <b>REPRODUCTIVE HEAI</b> |   |  |  |
| 0502                     | Pregnancy test for female abdominal pain patients.  | Pregnancy test for female abdominal pain patients.   | American College<br>of Emergency<br>Physicians |
| 0651                     | Ultrasound determination<br>of pregnancy location for<br>pregnant patients with<br>abdominal pain | Percentage of pregnant<br>patients who present to the ED<br>with a chief complaint of<br>abdominal pain and or vaginal<br>bleeding who receive a trans-<br>abdominal or trans-vaginal<br>ultrasound. | American College<br>of Emergency<br>Physicians |
| PREGNANCY CARE           | 1   |  |  |
| 0012*                    | Prenatal Screening for<br>Human Immunodeficiency<br>Virus (HIV)                                   | Percentage of patients who<br>gave birth during a 12-month<br>period who were screened for<br>HIV infection during the first or<br>second prenatal care visit.                                       | AMA-PCPI                                       |
| 0014*                    | Prenatal Anti-D Immune<br>Globulin  | Percentage of D-negative,<br>unsensitized patients who gave<br>birth during a 12-month period<br>who received anti-D immune<br>globulin at 26-30 weeks<br>gestation.                                 | AMA-PCPI                                       |
| 0015*                    | Prenatal Blood Groups<br>(ABO), D (Rh) Type   | Percentage of patients who<br>gave birth during a 12-month<br>period who had a determination<br>of blood group (ABO) and D<br>(Rh) type by the second<br>prenatal care visit.                        | AMA-PCPI                                       |
| 0016*                    | Prenatal Blood Group<br>Antibody Testing  | Percentage of patients who<br>gave birth during a 12-month<br>period who were screened for<br>blood group antibodies during<br>the first or second prenatal<br>care visit.                           | AMA-PCPI                                       |
| 0476                     | Appropriate Use of<br>Antenatal Steroids  | Mothers receiving antenatal<br>steroids during pregnancy at<br>any time prior to delivery of a<br>preterm infant   | Providence St.<br>Vincent Medical<br>Center    |
| 0582                     | Diabetes and Pregnancy:<br>Avoidance of Oral<br>Hypoglycemic Agents                               | This measure identifies<br>pregnant women with diabetes<br>who are not taking an oral<br>hypoglycemic agent.   | Resolution<br>Health, Inc.                     |
| 0606*                    | Pregnant women that had HIV testing.  | This measure identifies<br>pregnant women who had an<br>HIV test during their<br>pregnancy.  | Ingenix  |
| 0607*                    | Pregnant women that had syphilis screening.   | This measure identifies<br>pregnant women who had a<br>syphilis test during their  | Ingenix  |

\*Measures have not been resubmitted for endorsement; endorsement will be retired at the completion of the Perinatal and Reproductive Healthcare Project.

|                     |  | pregnancy.  |  |
|---------------------|--|---|--|
| 0608*               | Pregnant women that had HBsAg testing.   | This measure identifies<br>pregnant women who had a<br>HBsAg (hepatitis B) test during<br>their pregnancy.  | Ingenix  |
| 0652                | RH Immunoglobulin<br>(rhogam) for RH negative<br>pregnant women at risk of<br>fetal blood exposure | Percent of RH negative<br>pregnant women at risk of fetal<br>blood exposure who receive<br>Rhogam the ED.   | American College<br>of Emergency<br>Physicians |
| 1391                | Frequency of Ongoing<br>Prenatal Care (FPC)  | The percentage of Medicaid<br>deliveries between November 6<br>of the year prior to the<br>measurement year and<br>November 5 of the<br>measurement year that<br>received the following number<br>of expected prenatal visits.<br>•>21 percent of expected visits<br>•21 percent-40 percent of<br>expected visits<br>•41 percent-60 percent of<br>expected visits<br>•61 percent-80 percent of<br>expected visits<br>•=81 percent of expected visits  | NCQA   |
| 1517                | Prenatal and Postpartum<br>Care  | The percentage of deliveries of<br>live births between November 6<br>of the year prior to the<br>measurement year and<br>November 5 of the<br>measurement year. For these<br>women, the measure assesses<br>the following facets of prenatal<br>and postpartum care.<br>• Rate 1: Timeliness of Prenatal<br>Care. The percentage of<br>deliveries that received a<br>prenatal care visit as a member<br>of the organization in the first<br>trimester or within 42 days of<br>enrollment in the organization.<br>• Rate 2: Postpartum Care. The<br>percentage of deliveries that<br>had a postpartum visit on or<br>between 21 and 56 days after<br>delivery. | NCQA   |
| CHILDBIRTH<br>0333* | Soverity Standardized  | Standardized ALOS for   | Loopfrog Croup                                 |
|                     | Severity-Standardized<br>ALOS - Deliveries   | Standardized ALOS for<br>deliveries   | Leapfrog Group                                 |
| 0278                | Low birth weight (PQI 9)   | This measure is used to assess<br>the number of low birth weight<br>infants per 100 births. See<br>Notes.   | AHRQ   |
| 0469                | Elective delivery prior to 39<br>completed weeks<br>gestation                                      | Percentage of babies electively<br>delivered prior to 39 completed<br>weeks gestation   | Hospital<br>Corporation of<br>America          |
| 0470                | Incidence of Episiotomy  | Percentage of vaginal   | Christiana Care                                |

\*Measures have not been resubmitted for endorsement; endorsement will be retired at the completion of the Perinatal and Reproductive Healthcare Project.

|              |  | deliveries during which an episiotomy is performed   | Health System  |
|--------------|--|--|--|
| 0471         | Cesarean Rate for low-risk<br>first birth women (aka<br>NTSV CS rate)  | Percentage of low-risk first birth<br>women (aka NTSV CS rate:<br>nulliparous, term, singleton,<br>vertex) with a Cesarean rate<br>that has the most variation<br>among practitioners, hospitals,<br>regions and states. Unlike<br>other cesarean measures, it<br>focuses attention on the<br>proportion of cesarean births<br>that is affected by elective<br>medical practices such as<br>induction and early labor<br>admission. Furthermore, the<br>success (or lack thereof) of<br>management of the first labor<br>directly impacts the remainder<br>of the woman's reproductive life<br>(especially given the current<br>high rate of repeat cesarean<br>births). | California<br>Maternal Quality<br>Care<br>Collaborative                |
| 0472         | Prophylactic Antibiotic<br>Received Within One Hour<br>Prior to Surgical Incision or<br>at the Time of Delivery –<br>Cesarean section. | Percentage of patients<br>undergoing cesarean section<br>who receive prophylactic<br>antibiotics within one hour prior<br>to surgical incision or at the<br>time of delivery.  | Massachusetts<br>General<br>Hospital/Partners<br>Health Care<br>System |
| 0473         | Appropriate DVT<br>prophylaxis in women<br>undergoing cesarean<br>delivery   | Measure adherence to current<br>ACOG, ACCP<br>recommendations for use of<br>DVT prophylaxis in women<br>undergoing cesarean delivery   | Hospital<br>Corporation of<br>America                                  |
| 0474         | Birth Trauma Rate: Injury<br>to Neonates (PSI #17)   | Percentage of neonates with<br>specific birth trauma per 1000<br>births. Exclude infants with<br>injury to skeleton and<br>osteogenesis imperfecta,<br>subdural or cerebral<br>hemorrhage in preterm infant.   | AHRQ, National<br>Perinatal<br>Information<br>Center                   |
| 0477         | Under 1500g infant Not<br>Delivered at Appropriate<br>Level of Care  | The number per 1,000<br>livebirths of <1500g infants<br>delivered at hospitals not<br>appropriate for that size infant.  | California<br>Maternal Quality<br>Care<br>Collaborative                |
| NEWBORN CARE |  |  |  |
| 0303         | Late sepsis or meningitis<br>in neonates (risk-adjusted)   | Percentage of infants born at<br>the hospital, whose birth weight<br>is between 401 and 1500<br>grams OR whose gestational<br>age is between 22 weeks 0<br>days and 29 weeks 6 days with<br>late sepsis or meningitis with<br>one or more of the following<br>criteria: Bacterial Pathogen,<br>Coagulase Negative<br>Staphylococcus, Fungal  | Vermont Oxford<br>Network  |

\*Measures have not been resubmitted for endorsement; endorsement will be retired at the completion of the Perinatal and Reproductive Healthcare Project.

|      |  | Infection  |   |
|------|--|--|---|
| 0304 | Late sepsis or meningitis<br>in Very Low Birth Weight<br>(VLBW) neonates (risk-<br>adjusted)                                   | Percentage of infants born at<br>the hospital, whose birth weight<br>is between 401 and 1500<br>grams OR whose gestational<br>age is between 22 weeks 0<br>days and 29 weeks 6 days,<br>who have late sepsis or<br>meningitis, with one or more of<br>the following criteria: Bacterial<br>Pathogen, Coagulase Negative<br>Staphylococcus, Fungal<br>Infection   | Vermont Oxford<br>Network                               |
| 0475 | Measurement of Hepatitis<br>B Vaccine Administration<br>to All Newborns Prior to<br>Hospital or Birthing Facility<br>Discharge | Percentage of newborns<br>administered hepatitis B<br>vaccine prior to discharge from<br>the birthing facility or hospital,<br>subtract the number of<br>newborns who died prior to<br>discharge, and divide this<br>number by the number of live<br>newborns discharged from the<br>birthing facility or hospital<br>during a given time period<br>(perhaps annually) to identify<br>the hepatitis B vaccine<br>coverage rate for newborns at<br>a single birthing facility or<br>hospital. | CDC   |
| 0478 | Nosocomial Blood Stream<br>Infections in Neonates<br>(NQI #3)  | Percentage of qualifying<br>neonates with selected<br>bacterial blood stream<br>infections   | AHRQ  |
| 0479 | Birth dose of hepatitis B<br>vaccine and hepatitis<br>immune globulin for<br>newborns of mothers with<br>chronic hepatitis B   | Percentage of newborns to<br>hepatitis B surface antigen<br>(HBsAg)-positive mothers who<br>receive a birth dose of hepatitis<br>B virus (HBV) vaccine and<br>hepatitis B immune globulin<br>(HBIG)  | Asian Liver<br>Center at<br>Stanford<br>University      |
| 0480 | Exclusive Breastfeeding<br>during Birth Hospitalization  | Exclusive Breastfeeding (BF)<br>for the first 6 mos of neonatal<br>life has long been the<br>expressed goal of WHO,<br>DHHS, APA, and ACOG.<br>Holding perinatal and<br>intrapartum providers<br>accountable is an important<br>way to incent greater efforts<br>during the critical prenatal and<br>immediate postpartum periods<br>where BF attitudes are<br>solidified.   | California<br>Maternal Quality<br>Care<br>Collaborative |
| 0481 | First temperature<br>measured within one hour<br>of admission to the NICU.   | Percent of NICU admissions<br>with a birth weight of 501-<br>1500g with a first temperature<br>taken within 1 hour of NICU   | Vermont Oxford<br>Network                               |

\*Measures have not been resubmitted for endorsement; endorsement will be retired at the completion of the Perinatal and Reproductive Healthcare Project.

|       |   | admission.  |   |
|-------|---|---|---|
| 0482  | First NICU Temperature < 36 degrees C   | Percent of all NICU admissions<br>with a birth weight of 501-<br>1500g whose first temperature<br>was measured within one hour<br>of admission to the NICU and<br>was below 36 degrees<br>Centigrade. | Vermont Oxford<br>Network   |
| 0483  | Proportion of infants 22 to<br>29 weeks gestation<br>screened for retinopathy of<br>prematurity.                            | Proportion of infants 22 to 29<br>weeks screened for retinopathy<br>of prematurity using the<br>guidelines from the American<br>Academy of Pediatrics   | Vermont Oxford<br>Network   |
| 0484  | Proportion of infants 22 to<br>29 weeks gestation treated<br>with surfactant who are<br>treated within 2 hours of<br>birth. | Number of infants 22 to 29<br>weeks gestation treated with<br>surfactant within 2 hours of<br>birth   | Vermont Oxford<br>Network   |
| 0485* | Neonatal Immunization   | Percent of neonates with a<br>length of stay greater than 60<br>days receiving DPT, Hepatitis<br>B, Polio, Hib, and PCV<br>immunizations in adherence<br>with current guidelines.                     | Child Health<br>Corporation of<br>America                                     |
| 0716  | Healthy term newborn  | Percent of term singleton<br>livebirths (excluding those with<br>diagnoses originating in the<br>fetal period) who DO NOT have<br>significant complications during<br>birth or the nursery care.      | California<br>Maternal<br>Quality Care<br>Collaborative                       |
| 1354  | Hearing screening prior to<br>hospital discharge (EHDI-<br>1a)  | This measure assesses the<br>proportion of births that have<br>been screened for hearing loss<br>before hospital discharge.   | CDC   |
| 1351  | Proportion of infants<br>covered by Newborn<br>Bloodspot Screening<br>(NBS)   | What percentage of infants had<br>bloodspot newborn screening<br>performed as mandated by<br>state of birth?  | HRSA-MCHB   |
| 714   | Standardized mortality<br>ratio for neonates<br>undergoing non-cardiac<br>surgery   | Ratio of observed to expected<br>rate of in-hospital mortality<br>following non-cardiac surgery<br>among infants less than or<br>equal to 30 days of age, risk-<br>adjusted.                          | Children's<br>Hospital Boston -<br>Program for<br>Patient Safety &<br>Quality |

\*Measures have not been resubmitted for endorsement; endorsement will be retired at the completion of the Perinatal and Reproductive Healthcare Project.